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PREFACE 
 
This dissertation is being submitted to the Faculty of the Graduate School of Vanderbilt University in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy. The research contained 
within—involving a genomic investigation into Inflammatory Myobribroblastic Tumor and biochemical 
assessments of anaplastic lymphoma kinase (ALK) fusion proteins—was conducted by Merrida 
Childress, under the supervision of Dr. Christine M. Lovly, M.D., Ph.D. between 2014 and 2018. This 
written work is original, except where acknowledgements and references are made to previously 
published work. For example, chapter 3 has already been published: 
 
Merrida A. Childress, Stephen M. Himmelberg, Huiqin Chen, Wanleng Deng, Michael A. Davies, 
Christine M. Lovly, ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on 
Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res. 2018 
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Chapter I 
INTRODUCTION 
1.1 Overview 
This introductory chapter will provide background information necessary to understand the original 
research contained in this dissertation. The chapter is divided into three sections: the first is focused 
on Inflammatory Myofibroblastic Tumor (IMT), a sarcoma primarily driven by oncogenic kinase 
fusions; the second is focused on oncogenic kinase fusion biology with an emphasis on Anaplastic 
Lymphoma Kinase (ALK) fusions, and the third is reserved for concluding remarks. The first section 
will concentrate on our current knowledge of IMT including pathological and genetic descriptions. The 
second section will detail our current understanding of the biology of ALK fusions in cancer, including 
the signaling pathways that are activated downstream of ALK, the role of the 5’ partner proteins in 
mediating ALK fusion oligomerization, subcellular localization, and kinase activation, and the clinical 
implications for targeting ALK fusions.  
 
1.2 Inflammatory Myofibroblastic Tumor 
 
Clinical Features 
Inflammatory myofibroblastic tumor (IMT) is a rare, mesenchymal neoplasm that has a tendency for 
local recurrence.  While it can occur at any age and in multiple anatomic locations, it arises primarily 
in the soft tissue and viscera of children, adolescents, and young to middle-aged adults.  Tumors 
average 6 cm in size, but can range from 1 cm to >20 cm in diameter5,6. IMTs in the abdomen or 
retroperitoneum, often present as multiple discrete masses in the same region1,5-7. Surgical resection 
is the current standard of care for IMT. There is no systemic standard of care therapy for patients 
whose tumors cannot be resected. Although, regression and response to anti-tumor necrosis factor-a 
binding antibody, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and chemotherapy 
have been reported in a few cases8-11. A subset of patients experience an inflammatory clinical 
syndrome of fever, weight loss, growth failure, anemia, thrombocytosis, polyclonal hyperglobulinemia, 
and an elevated erythrocyte sedimentation rate12,13.  This syndrome relaxes following tumor 
resection, and a return of these clinical and laboratory abnormalities may indicate disease 
recurrence5,13,14.  
 
Recurrence rate appears to differ based on anatomical site. Primary tumors confined to the lung recur 
at a rate of <2%1,15,16 compared to 25% for extra-pulmonary disease5. Recurrence is most frequently 
seen in patients presenting with multi-focal intra-abdominal tumors and those in anatomical locations 
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where complete surgical resection is difficult. Distant metastasis of IMT is rare, striking <5% of 
patients5,17. The most common sites of metastasis are lung and brain, followed by liver and bone18.  
 
IMT is diagnosed by its pathology using a set of criteria set by the World Health Organization (WHO). 
The WHO defines IMT as “a lesion composed of a proliferation of myofibroblastic spindle and stellate 
cells with abundant eosinophilic cytoplasm mixed with infiltrative plasma, inflammatory cells, 
lymphocytes and eosinophils”19,20. More recently a distinct subtype of IMT, known as epitheliod 
Inflammatory Myofibroblastic Sarcoma (eIMS), has been described. This subtype is characterized by 
a dominance of large epitheliod cells with only minor spindle cell components, noticeable nuclear 
atypia, and positive anaplastic lymphoma kinase (ALK) immunohistochemistry in a perinuclear 
pattern21, and it demonstrates a more clinically aggressive phenotype and dismal prognosis22,23. 
Additionally, eIMS is almost exclusively found in the abdominal cavity and has a strong predominance 
in males24. 
 
Pathology 
Three types of histological patterns are described; combinations of which are frequently seen within 
the same tumor: 1.) a myxoid/vascular type, characterized by loosely arranged, plump spindle tumor 
cells within in a myxoid, edematous, and vascular stroma, appearing like nodular fasciitis or 
granulation tissue; 2.) a compact, spindle cell pattern, characterized by tight proliferation of the 
spindle tumor cells with fascicle architecture and a collagen stroma; and 3.) a hypocellular fibrous 
pattern, characterized by the proliferation of elongated, plump spindle tumor cells within a dense 
collagenous stroma5. All histological patterns contain distinct infiltration of inflammatory cells. The 
inflammatory infiltrate in the myxoid regions often consists of greater neutrophils and eosinophils and 
fewer plasma cells than the other two patterns. The foci of compact, spindle cells typically have 
abundant plasma cells and lymphocytes closely mixed with the spindle cells; however, isolated 
lymphoid follicles and plasma cells are also commonly seen. The fibromatosis-like pattern contains 
scattered lymphocytes, plasma cells and eosinophils18. 
 
Approximately 50% of IMTs contain dispersed “ganglion-like” cells- larger, polygonal shaped cells 
with copious amphophilic or eosinophilic cytoplasm with large, vesicular nuclei and obvious 
nucleoli6,25. Foamy histiocytes are found in a minority of cases14,26. Mitotic counts are typically low (0–
2 mitoses per 10 HPF), and atypical mitoses are rare5,17,25,26. While necrosis and vascular invasion 
have been reported in typical IMTs, they are also very rare5,27,28. While the conventional IMT is 
considered low grade, IMTs may evolve into an atypical, higher grade, exhibiting increased cellularity, 
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numerous mitoses, atypical mitotic figures, distinct nuclear atypia, and necrosis5,17,29,30, especially 
upon recurrence. The cellular morphologies of the higher grade tumors include hypercellular, spindle 
cell, epithelioid/histiocytoid, or round cell morphology5,17,29.  
 
Histologically, eIMS exhibits different cell types compared to classic IMT. eIMS is composed 
predominantly of large, epithelioid tumor cells and an inflammatory infiltrate dominated by neutrophils, 
in contrast to the spindled tumor cells with lymphocyte and plasma cell infiltration observed in the 
classic IMT24. As this subtype of IMT tends to exhibit a more mixoid background and increased 
vasculature, it is most similar to first histological pattern described above. 
 
Molecular Features 
There are many fundamental aspects about IMT that remain unknown including the cell type that 
gives rise to IMT. However, distinct molecular markers that distinguish IMT from other tumor types 
have been established. Due to the myofibroblastic presentation, 80-90% of IMTs are positive for 
smooth muscle actin, 60-70% express desmin and calponin, and approximately 33% are reactive to 
keratin by immunohistochemistry (IHC). Given the often focal histology of these tumors, reactivity for 
these markers is can also be focal5,26,29,31. Variable CD30 expression has been reported for eIMS23. 
 
Kinase Fusions in IMT 
Rearrangements of the ALK gene on chromosome 2p23 have been reported in 50-60% of IMTs2,32,33. 
Several ALK fusion partners have been identified in IMT, including TPM-3/-4, ATIC, CLTC, CARS, 
FN1, PRKAR1A, EML4, RANBP2, and many others2,34,35. Unlike some other diseases, studies 
suggest that ALK rearranged IMT (except eIMS) generally exhibit a low risk toward metastasis; 
however, there does not appear to be a correlation with ALK reactivity and recurrence17,36,37.  
 
Importantly, ALK fusions have been validated as a therapeutic target in IMT. Results from the 
Children’s Oncology Group study for crizotinib in ALK positive IMT reported an impressive overall 
response rate of 85%. A complete response was observed in 36% of patients and a partial response 
was observed in 50% of patients38. This study demonstrates the importance of identifying ALK fusions 
in IMT and also highlights the importance of finding novel therapeutic targets in ALK negative IMT. 
Recently ROS1, PDGFRβ, NTRK3, and RET gene alterations have also been reported, bringing 
kinase fusion detection in IMT to approximately 85%2,28,39.  
 
EIMS are also distinct in their specific expression of kinase fusions. 100% of eIMS cases reported to 
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date harbor either RANBP2-ALK or RRBP1-ALK fusions with distinctive nuclear membranous ALK 
IHC or cytoplasmic combined with intense nuclear membranous ALK IHC respectively40.   
 
Kinase fusion negative IMTs typically occur in older patients and have a more aggressive histological 
appearance2,17,28. In addition, the frequency of metastasis appears to be greater in ALK negative IMT 
compared to ALK positive IMT, with the exception of eIMS. Little is known about the genomic 
landscape of IMT outside of the presence or absence of oncogenic kinase fusions, and as such, there 
are no currently available targeted therapies for kinase fusion negative patients.  
 
One recent study of 25 distinct IMTs reported no difference in rate of PD-L1 expression between ALK 
positive and ALK negative patients, but that patients experiencing metastasis/recurrence (all ALK 
negative) exhibited greater PD-L1 expression compared to those that did not experience 
metastasis/recurrence. Additionally ALK fusion negative IMTs had greater CD8+ TILs, compared 
to ALK fusion positive tumors41. This early data suggests that ALK fusion negative IMTs may be good 
candidates for immune checkpoint blockade therapies, but further studies are needed to gain 
conclusive answers.   
 
1.3 ALK Fusions 
 
The study of oncogenic tyrosine kinase fusions began with the discovery of the t(9:22) translocation in 
chronic myelogenous leukemia and its chimeric protein product, BCR-ABL42. Since then, other liquid 
and solid tumors have been found to harbor chromosomal rearrangements that result in activated 
tyrosine kinase fusions. Notably, rearrangements involving anaplastic lymphoma kinase (ALK) have 
been found across all cell lineages, arising in hematologic, neural, epithelial, and mesenchymal 
malignancies43. While these cancers can differ in the specific ALK kinase fusion they harbor, they 
share two features that underlie the importance of this class of oncogenes. First, no other known 
genetic drivers are found in concurrence with the ALK kinase fusion. This is likely attributed to the 
strength of the kinase to drive proliferative and anti-apoptotic pathways. Second, they all exhibit a 
dependency on the activated kinase for proliferation and survival. This dependency, or ‘oncogene 
addiction’, makes the cancer highly sensitive to small molecule tyrosine kinase inhibitors (TKIs) and 
has resulted in the development of several ALK TKIs, including crizotinib, alectinib, ensartinib, 
lorlatinib, and many others in clinical development44-50. 
 
In this section, I will focus on the current knowledge of the functional and structural biology of ALK 
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fusion proteins and the therapeutic strategies aimed at targeting these oncogenic kinase fusions. I will 
discuss the functional domains present in the different ALK fusions, the signaling pathways activated 
downstream of the fusion, and the role of the 5’ fusion partner in mediating fusion activation, 
subcellular localization, and oligomerization. Additionally, I will address the clinical features of ALK 
fusion positive (ALK+) malignancies including the types of patients in which they occur and the 
current therapeutic approaches to target these fusions. 
 
ALK Biology 
ALK was originally discovered as part of the characteristic t(2,5) chromosomal translocation found in 
anaplastic large cell lymphoma, which results in the NPM-ALK translocation. Since its discovery, 
many other ALK fusions have been found in several cancers, which initiated investigations into the 
function of wild-type ALK. Located on chromosome 2p23, wild-type ALK is a receptor tyrosine kinase 
that belongs to the insulin receptor superfamily. Midkine, pleiotrophin, and many others are proposed 
ALK ligands that have roles in cell survival, neural development, and tumorigenesis51-54. However, the 
subject of activating ALK ligands is controversial as many of the studies are contradictory55-58.  
Expression and functional studies show ALK transcripts in the developing nervous system, which 
subside by 3 weeks of age59,60. ALK(-/-) knockout mice only exhibit slight behavioral changes with no 
identifiable developmental, anatomical or locomotive insufficiencies, leaving the exact function of the 
ALK receptor unclear61-63. 
 
Investigations into the signaling networks of the ALK receptor have revealed downstream activation of 
pathways controlling cell proliferation and survival such as JAK-STAT, PI3K-AKT, mTOR, SHH, 
JUNB, and MAPK64-67. ALK may also interact with several adaptor proteins including: FRS2/3, IRS1, 
SHC, and GRB2 and affects proteins such as BIM, p27, and cyclinD264-67. Less understood ALK 
interactions include Nuclear Interacting Partner of ALK (NIPA), RAC1, CD42, BCAR1, SHP1/2, SRC, 
and phosphatidylinositol-3-phosphate 5-kinase type III (PINKFYVE)68-76. Notably, to date, ALK 
signaling has predominantly been studied in the setting of cancer activating mutations fusions, and 
amplifications and therefore, these results must be interpreted and applied with care. 
 
ALK Rearranged Cancers 
ALK rearrangements have been detected in hematologic, mesenchymal, neural, and epithelial 
cancers including anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), 
inflammatory myofibroblastic tumor (IMT), ependymoma-like glioma, non-small cell lung cancer 
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 (NSCLC), renal cell carcinoma (RCC), colorectal cancer (CRC), breast cancer, ovarian cancer, and 
esophageal cancer (Figure 1.1)3,43. Though each malignancy has a particular 5’ fusion partner that 
occurs most frequently, multiple different ALK fusions have been detected within the same disease. 
For example, NPM-ALK occurs in 80% of reported cases of ALCL77,78), but TFG-ALK, ATIC-ALK, CLTC-
ALK, TPM3-ALK, MYH9-ALK, MSN-ALK, and ALO17-ALK have also been reported43(Figure 1.1). 
Interestingly, in all diseases, ALK positive patients tend to be younger than their ALK negative 
counterparts. However, the correlation between ALK positivity and prognostic outcome is disease 
dependent. ALK positive DLBCL and NSCLC tend to be more aggressive79-83. In ALCL and IMT, 
however, the ALK positive populations tend to have a better prognosis32,37. 
 
 
TFG 
PRK- 
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STRN 
PTPN1 
C2orf- 
44 
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TPM4 
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RAN- 
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-like glioma OC 
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88A 
Figure 1.1: The Diversity of ALK fusions in Cancer. This diagram depicts the different tissues in which 
ALK   rearranged cancers have been detected, the specific cancers within each tissue type, and the 
different ALK fusion partners that have been reported within each cancer type1-4. Note: This diagram is not a 
comprehensive list of all ALK fusions or ALK fusion cancers.  
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Disease Response to ALK Targeted Therapy 
Non-Small Cell Lung Cancer + (Phase 3 trial, FDA approved)48,50 
Anaplastic Large Cell Lymphoma + (Phase 2/3 trial)38,86 
Diffuse Large B Cell Lymphoma + (Case reports)87 
Inflammatory Myofibroblastic Tumor + (Phase 1/2 trial)38,86,88 
Spitz ND 
Renal Cell Carcinoma +(phase 1 trial ongoing)89 
Colorectal Cancer +(phase 1 trial ongoing)89 
Breast Cancer ND  
Ovarian Cancer ND  
Esophageal Cancer ND 
Papillary Thyroid Cancer ND 
Glioma ND 
 
 
 
 
ALK TKIs have demonstrated great success in the clinic in certain ALK positive cancers, as 
discussed below84,85. Unfortunately, however, the efficacy of ALK targeted therapy is still unknown for 
some tumor types harboring ALK fusions (Table 1.1). As better diagnostic tools enter the clinic, the 
identification of ALK positive cancers will likely continue to grow. Importantly, to better predict efficacy  
of ALK inhibition across diseases, we must improve our understanding of the biology of ALK fusions 
within each disease. 
 
ALK Fusion Biology 
Structure and Biological Function 
In membrane spanning tyrosine kinases, the kinase domain is located toward the C-terminus while 
the N-terminus contains the inhibitory and trans-membrane domains. One shared feature of ALK 
kinase fusions is a largely conserved breakpoint within the C terminus of the receptor67,90,91, just 
upstream of the kinase domain, resulting in the loss of the inhibitory juxtamembrane domain and 
ligand independent activation4. For ALK fusions, the genomic breakpoints have been found in the 
introns preceding exons 19 or 20, making exon 19 or 20 is the first exon of the ALK kinase domain2,4. 
 
Another characteristic of kinase fusions is the occurrence of multiple fusion partners within the same 
disease2. Although these partners can vary, they share three features. First, the regulatory unit of the 
5’ fusion partner dictates the expression of the fusion, which may contribute to the level of active 
kinase92,93. Secondly, most fusion partners contribute an oligomerization domain, which can aid in 
auto-activation of the kinase94; although, this has not been verified for all fusion partners. The most 
Table 1.1: Response to ALK tyrosine kinase inhibitor therapy in ALK-rearranged tumors.  This 
table summarizes the current clinical information known for patients with ALK-rearranged 
malignancies treated with ALK targeted therapies. + = a positive response. ND = not determined. 
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common oligomerization domains found in the fusion partners are coiled-coil domains (Figure 1.2)95. 
For example, EML4-ALK, the most common ALK fusion detected in NSCLC, homodimerizes by virtue 
of a coiled-coil domain in EML4. Disruption of the coiled-coil domain abrogates the ability of EML4-
ALK to transform cells94. Furthermore, the extent of oligomerization may be important to 
transformation; other kinase fusions have been found to dimerize96, trimerize97,98, form tetramers99, or 
require polymeric binding for transformation100. Lastly, the 5’ fusion partner also determines 
subcellular localization of the fusion, and this may have profound effects on the protein interactions 
that the fusion encounters, affecting activation, signaling, function, and degradation of the fusion. For 
example, a thorough analysis of each EML4-ALK variant revealed differences in their function and 
localization and implicated these properties in the variable sensitivity to Hsp90 inhibitors seen 
clinically98. Additionally, for some fusions, subcellular localization controls fusion activation, as is the 
case for CLTC-ALK and MSN-ALK which congregate in clathrin coated vesicles and the plasma 
membrane respectively101,102. While most ALK fusions appear pan-cytoplasmic, others like RANBP2-
ALK and NPM-ALK have different localization, the effects of which have yet to be investigated 
(Figure 1.2)67. 
 
Some cancers may also exhibit effects from the loss of one wild-type allele of the partner gene. For 
example, PRKAR1A and TPM3 are tumor suppressors, and as has been demonstrated for KANK1 
and ETV6, the remaining wild-type allele may be lost as a result of additional genetic or epigenetic 
alterations, resulting in no normal expression of the protein103-105. This has yet to be investigated for 
PRKAR1A. Additionally, if the remaining wild-type allele of the partner gene inhibits the fusion 
function, loss of the normal allele may exacerbate the disease as demonstrated for TPM-ALK106,107. 
These kinds of interactions between the fusion and the WT partner protein have best been 
investigated in the case of NPM-ALK where studies have shown this interaction to affect nuclear 
translocation, activation, and response to ALK tyrosine kinase inhibitors108-110.   
 
Signaling 
How different ALK fusions signal based on tissue of origin is only beginning to be elucidated. Of all 
known ALK fusions, NPM-ALK is the most investigated, since this was the first ALK fusion identified. 
Countless protein interactions involving NPM-ALK have been identified including those critical for 
transformation and migration, like activation of PLCγ, SRC, PI3K-AKT, STAT3, and SHH 
pathways67,111-114, and less important interactions such as IRS-1 and SHC, which do not seem to be 
required for transformation59. While NPM-ALK in has been found to activate PLCγ, PI3K-AKT, and  
STAT3 pathways, STAT3 activation seems to be the primary oncogenic mechanism in ALCL112,115-117. 
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Additionally, characterization of CLTC-ALK, the most commonly found ALK fusion in DLBCL, 
displayed increased STAT3 activity81. Further studies into EML4-ALK, the most commonly found ALK 
fusion in NSCLC, show similarities to NPM-ALK. In lung cancer cell lines and patient tumor samples, 
the MAP kinase, JAK-STAT, and PI3K-AKT pathways are all downstream of the EML4-ALK fusion 
proteins118. These studies, however, are investigating different ALK fusions. Whether or not the 
signaling networks of one particular ALK fusion changes with tissue type is a question yet to be 
explored. 
 
Properties that may affect signaling between the various ALK fusions within the same disease are 
also not clear. For example, in IMT, it is unknown if the difference in cellular localization of RANBP2-
ALK, which is at the periphery of the nucleus, compared to TFG-ALK, which is pan-cytoplasmic, has 
an effect on downstream signaling. Fusion partners found in ALCL are structurally and functionally 
different, yet their ALK protein interactions are similar90,119,120. Signaling studies of ALCL fusions, 
however, reveal differences in pathway dependencies106. Most studies focused on these questions, 
however, fail to study or validate the fusions in the corresponding cellular context making it difficult to 
draw clear conclusions or know the clinical relevance. 
 
Therapeutic Targeting of ALK Fusions 
ALK fusions have become the paradigm for development of targeted therapies since the time from 
discovery of the fusion in NSCLC, in 2007, to the initial FDA approval of the first ALK TKI, crizotinib, 
in 2011, showed the remarkable pace of bringing scientific discovery to the clinic. The phase I study 
of crizotinib in NSCLC was one of the first studies in which the biomarker, the ALK rearrangement, 
was identified prospectively before patients were enrolled onto the trial. In this study, the response 
rate to crizotinib in patients with heavily pre-treated ALK+ NSCLC was 60%; compared to only ~5% 
with traditional second- or third-line cytotoxic chemotherapy84. After these initial Phase I results, a 
subsequent trial compared crizotinib in the first-line setting to standard chemotherapy for advanced 
NSCLC and showed a remarkable 55% increase in progression free survival over chemotherapy121. 
Thereafter, similar results have been published for patients with ALK+ ALCL and ALK+ IMT treated 
with crizotinib, overall demonstrating that ALK is an important therapeutic target in these 
Figure 1.2.  Structural and Biological Characteristics of ALK Fusions. This figure presents the 
majority of ALK fusions reported to date including the oligomerization domains present in the 5’ 
fusion partner, the cellular localization of the fusion, and the cancers in which they have been 
detected to date. *Note that not all oligomerization domains have been experimentally validated. 
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malignancies38,88.  Since the approval of crizotinib, four additional ALK TKIs (ceritinib, alectinib, 
brigatinib, and lorlatinib) with greater potency toward ALK have been granted FDA approval for use in 
ALK positive NSCLC45,48-50.  
 
Despite these promising results, we are still faced with difficulties in ALK detection and acquired drug 
resistance. The most widely used tools to detect ALK fusions in a patient’s tumor are 
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). All diagnostic tools have 
limitations; consequently, other forms of identifying ALK fusions in tumors, such as next generation 
sequencing methods, are increasingly being implemented122. Therapeutic drug resistance is another 
major barrier to overcome to improve outcomes for patients with ALK positive tumors123. Mechanisms 
of acquired resistance to crizotinib are only beginning to be uncovered. These resistance 
mechanisms include: amplification of the ALK fusion, acquired mutations in the ALK kinase domain, 
up-regulation of ‘bypass’ signaling pathways to evade the drug-inhibited ALK fusion, and epithelial-to-
mesenchymal transition. The most promising strategy to overcome crizotinib resistance to date 
involves the use of ‘second or third-generation’ ALK TKIs, such as ceritinib, alectinib, ensartinib, 
brigatinib, and lorlatinib, all more potent and more specific for the target (ALK).  These drugs have 
proven to be effective against many ALK mutations that mediate crizotinib resistance124. Strategies to 
combat ALK TKI resistance mediated by ‘bypass’ signaling pathways must include the use of 
combination therapies. We can also learn from the treatment of Acute Promyelocytic Leukemia, 
APML, and investigate targeting the fusion partner as another way to combat resistance125. Further 
studies like Richards et al. 2015, are needed to clarify and predict drug action as well as reveal 
avenues to block ALK activation by way of inhibiting the fusion partner. 
 
1.4 Concluding Remarks 
The cause of chromosomal rearrangements is a subject that has been investigated by many. The 
direct link between environmental factors such as ionizing radiation and chromosomal breaks in 
thyroid cancer has been well established while causes of other rearrangements remain less well 
known125-127. Interestingly, younger age may be a risk factor for some TK fusions such as ALK, 
ROS1, and RET, which occur more frequently in younger patients35,128-131. Though the exact 
molecular mechanisms are unknown, the recurrence of similar fusions across many different cancers 
suggests a shared molecular deficiency. Along that line, some hypothesize that breaks are occurring 
at fragile DNA locus132,133. Additionally, the occurrence and oncogenic potential of a particular kinase 
fusion seems to be tissue and cell-type dependent. In the case of CCDC6-RET, found in higher 
frequency in thyroid cancer than in breast cancer, CCDC6 and RET were shown to be adjacent in the 
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nucleus of normal thyroid cells considerably more than in normal breast cells. Therefore, proximity 
may explain the higher frequency in thyroid cancer. However, while CCDC6 and RET are juxtaposed 
in the nucleus of lymphoid cells just as frequently as in thyroid cells, CCDC6-RET is not seen in any 
lymphoid malignancies, and CCDC6-RET transgenic mice develop thyroid rather than lymphoid 
tumors134,135.  Cell-type dependencies are also seen for the fusion BCR-ABL where CML only occurs 
if the fusion is expressed in hematopoietic stem cells136,137. These findings highlight the importance of 
the cellular context in which fusions occur. In-depth contextual studies are lacking for ALK fusions, 
and further investigation into the setting in which they display oncogenic activity is warranted. 
Understanding the background in which these fusions are oncogenic will allow us to more effectively 
inhibit the cancer and understand potential resistance mechanisms. 
 
1.5 Purpose of These Studies 
Beyond the presence or absence of a kinase fusion, nothing else is known about IMT on the genomic 
and transcriptomic level. The aim of these studies is to further reveal the genomic and transcriptomic 
landscape of IMTs and combine the data with the current histologic knowledge of the disease to gain 
insight into the pathogenesis or potential new therapies for patients with kinase fusion negative 
tumors or kinase fusion positive tumors which progress on targeted therapy. 
 
While ALK fusions are validated targets for cancer therapy, our understanding of how to most 
effectively target these fusions clinically is lacking in comparison to other oncogenic drivers like 
mutant EGFR or RARα fusions, where we know that different variants dictate drug sensitivity124, 125, 
138-141. For example, in EGFR-mutant NSCLC, we know that different EGFR alterations confer varying 
degrees of sensitivity or resistance to EGFR directed therapies139-142. In addition, for other oncogenic 
fusions, such as the retinoic acid receptor alpha (RARα) fusions found in APML, it is known that the 
particular gene fused to RARα not only affects response to RARα directed therapy but also can be a 
therapeutic target itself125. Although many different 5’ partner genes have been reported for ALK, 
even within the same disease, currently, there is very little data to address the question of how a 
different fusion partner may affect pretreatment clinical characteristics, disease responsiveness to 
targeted therapies, or acquired resistance. There are limited cell line models in which to study the 
various ALK fusions that occur in one particular disease; consequently, the role of the 5’ fusion 
partners has not been systematically investigated. As more sophisticated next-generation sequencing 
technologies come to the forefront of clinical diagnostics, clinicians will know both the 5’ partner and 
the 3’ kinase involved in the fusion. Therefore, it is imperative that we determine the therapeutic 
implications of the various ALK fusions. The goal of these studies is to provide the specific pre-clinical 
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data needed to more precisely direct clinical treatment as well as potential innovative treatment 
strategies for ALK positive cancers such as IMT. In addition, these studies may have potential 
implications for other kinase fusion-driven malignancies. 
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Chapter 2 
INFLAMMATORY MYOFIBROBLASTIC TUMOR: A GENOMIC AND TRANSCRIPTOMIC 
ANALYSIS 
2.1 Abstract 
Inflammatory myofibroblastic tumor (IMT) is a rare, mesenchymal neoplasm occurring primarily in the 
soft tissue and viscera of children, adolescents, and young adults. Surgical resection is the current 
standard of care for IMT. There is no systemic standard of care therapy for patients whose tumors 
cannot be resected. ALK kinase fusions have been reported in 50-60% of IMT, and ROS1, PDGFRB, 
RET, and NTRK3 fusions have also recently been detected in the ALK fusion negative cohort. 
Importantly, ALK fusions are validated as a therapeutic target in IMT, and there have also been 
reports of ROS1 rearranged IMT responding to ROS1 targeted therapy, demonstrating the 
importance of identifying kinase fusions in IMT. The genomic and transcriptomic landscape of IMT, 
outside of the presence or absence of oncogenic kinase fusions, remains largely unexplored; 
therefore, there is currently no rational to direct therapy, in particular, the use of targeted therapies for 
kinase fusion negative patients or kinase fusion positive patients who have progressed on targeted 
therapies. We hypothesized that further knowledge of the IMT transcriptome coupled with 
clinicopathologic data would provide insight into the pathogenesis of the disease and potential 
effective therapies. We performed targeted next generation sequencing (NGS) on 69 total samples 
and whole transcriptome RNA sequencing on 18 of the 69 samples. We identified kinase fusions in 
84% of IMTs. Specific kinase fusions were not associated with  anatomical location, age, or gender.  
Analysis of cancer associated SNVs revealed a set of 30 commonly shared variants involved in the 
VEGF pathway and chromatin remodeling. Three of four fusion negative tumors shared a mutation in 
PIK3R1 previously reported in other cancers. These findings support the use of NGS diagnostics to 
select effective targeted therapeutic options for patients with IMT and reveal common pathway 
disruptions that could potentially be therapeutically targeted. 
 
2.2  Introduction 
 
Inflammatory myofibroblastic tumor (IMT) is a rare, mesenchymal neoplasm, with approximately 200 
cases per year in the U.S.  While it can occur at any age and in multiple anatomic locations, tumors 
arise primarily in the soft tissue and viscera of children, adolescents, and young adults1-4. Surgical 
resection is the current standard of care for IMT. There is no systemic standard of care therapy for 
patients whose tumors cannot be resected. IMT has a tendency for local recurrence, most frequently 
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seen in patients presenting with multi-focal intra-abdominal tumors and those in anatomical locations 
where complete surgical resection is difficult. Distant metastasis of IMT is rare, affecting <5% of 
patients1,5.  
 
IMT is diagnosed by its pathology using a set of criteria set by the World Health Organization (WHO). 
The WHO defines IMT as “a lesion composed of a proliferation of myofibroblastic spindle and stellate 
cells with abundant eosinophilic cytoplasm mixed with infiltrative plasma, inflammatory cells, 
lymphocytes and eosinophils”6,7. More recently a distinct subtype of IMT, known as epithelioid 
Inflammatory Myofibroblastic Sarcoma (eIMS), has been described. This subtype is characterized by 
a dominance of large epithelioid cells with only minor spindle cell components, noticeable nuclear 
atypia, and positive anaplastic lymphoma kinase (ALK) immunohistochemistry (IHC) in a perinuclear 
pattern8. eIMS has been shown to have a more clinically aggressive phenotype and dismal 
prognosis9,10. Additionally, eIMS is almost exclusively found in the abdominal cavity and has a strong 
predominance in males11.  
 
Rearrangements involving ALK on chromosome 2p23 result in oncogenic fusion proteins and have 
been reported in 50-60% of IMTs12-14. Several ALK translocation partners have been identified in IMT, 
including TPM-3/-4, ATIC, CLTC, CARS, FN1, PRKAR1A, EML4, RANBP2, and many others14-16. 
EIMS are divergent in their specific expression of kinase fusions. 100% of eIMS cases reported to 
date harbor either RANBP2-ALK or RRBP1-ALK fusions with distinctive nuclear membranous ALK 
IHC or cytoplasmic combined with intense nuclear membranous ALK IHC respectively17.  Recently 
ROS1, PDGFRβ, NTRK3, and RET gene alterations have also been reported, bringing kinase fusion 
detection in IMT to approximately 85%14,18-20. Importantly, ALK fusions are validated as a therapeutic 
target in IMT21,22. There have also been reports of ROS1 rearranged IMT responding to ROS1 
targeted therapy14, demonstrating the importance of identifying kinase fusions in ALK negative IMT. 
ALK fusion negative IMTs typically occur in older patients and have a more aggressive histological 
appearance5,19. In addition, the frequency of metastasis appears to be greater in ALK negative IMT 
compared to ALK positive IMT, with the exception of eIMS.  
 
The genomic and transcriptomic landscape of IMT, outside of the presence or absence of oncogenic 
kinase fusions, remains largely unexplored; therefore, there is currently no rational to direct therapy, 
in particular, the use of targeted therapies for kinase fusion negative patients or kinase fusion positive 
patients who have progressed on targeted therapies. The goal of this study is to further reveal the 
genomic and transcriptomic landscape of IMTs to gain insight into the pathogenesis of the disease 
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and potentially offer new therapeutic opportunities. 
 
2.3  Materials and Methods 
 
Patient Tumor Samples: IMT samples and associated patient characteristics were obtained and 
analyzed with an Institutional Review Board (IRB)-approved protocol (#090572). All clinical data was 
obtained and maintained according to HIPAA standards. All unique identifiers have been removed 
prior to publication. 
 
Targeted NGS for Fusion Identification 
IMT cases are described in Table 2.1.  
 
IMT case  numbers 6-12,15,17-25, 39, 61-63, 65, and 66: Following the manufacturer’s protocol, RNA 
was extracted from formalin-fixed and paraffin embedded (FFPE) and fresh frozen (FF) samples 
using the Maxwell 16 LEV RNA FFPE Kit (Promega) and Maxwell RNA Kit (Promega) respectively. 
Fusions were identified using ArcherDx FusionPlex: Research Oncology Panel (ArcherDx) per 
manufacturer’s protocol. 
 
IMT case numbers 26-57: Fusions were identified using FoundationOne® assay, as previously 
reported14. 
 
IMT case numbers 58-60, 62, 63: Fusions were identified using the Impact Assay23 at Memorial Sloan 
Kettering Cancer Center. 
 
IMT cases numbers 61 and 64: Fusions were identified using FoundationOne® assay24. 
 
RNA sequencing and Data Analysis  
IMT case numbers 1-12, 66-69: RNA was extracted from FF samples. Libraries were prepared for 
whole transcriptome sequencing using Tru-Seq Stranded RNA library preparation. Sequencing was 
performed on the HiSeq2500 instrument (Illumina) with 100bp paired-end reads to an average 
sequencing depth of 50 million reads. Library preparation and sequencing was performed at the 
Broad Institute. 
 
IMT case numbers 13, 14, 16, and 65: RNA was extracted from FF samples. Libraries were prepared 
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for whole transcriptome sequencing using ribo-reduction library preparation. Sequencing was 
performed on the HiSeq2500 instrument (Illumina) with 100bp paired-end reads to an average 
sequencing depth of 50 million reads. Library preparation and sequencing was performed at 
HudsonAlpha Research Institute. 
 
Fusion Analysis 
RNA sequencing fusion detection was performed using JAFFA25 (version 1.09) and STAR-fusion 
(version 1.3.1) (reference genome hg19).  
 
Differential Analysis 
Illumina paired-end RNA sequencing data was aligned to the human genome assembly (reference 
genome hg38) using STAR26 (version 2.5) with quantMode parameters set to TranscriptomeSAM for 
alignments translated into transcript coordinates. The transcriptomic alignments were run through 
RSEM27 (version 1.2.31) command rsem-calculate-expression to calculate gene raw counts, TPM, 
FPKM and isoform expression. Differentially expressed genes were identified with R statistical 
software using the edgeR28 package from Bioconductor. KEGG Pathway and Gene ontology 
enrichment analysis was conducted on those genes with a p-value <0.05 and an absolute Fold 
Change greater than 2. Identification of activated and inhibited pathway analysis was conducted 
using SPIA29 (Signalling Pathway Impact Analysis). 
 
SNV Analysis 
Illumina paired-end RNA sequencing data was aligned to the human genome assembly (reference 
genome hg38) using STAR (version 2.5) 2-pass method. Alignments are sorted with SAMtools30 (v. 
1.3.1), duplicates marked with Picard Tools (version 2.4.1), reads are split and trimmed and mapping 
qualities reassigned with Genome Analysis Toolkit31 (version 3.6) using methods SplitNCigarReads 
and ReassignOneMappingQuality respectively. Variants are called with Haplotype Caller and 
annotated with ANNOVAR32. 
 
Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained 
if they were exonic, had a damaging function, previously reported in COSMIC and were considered 
pathogenic in the ClinVar Database. Variants were further filtered and excluded if they had a variant 
allele frequency less than 0.05, depth less than 10, a prevalence of greater than 10% in the 1000 
Genomes Project or if no annotations were present. 
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2.4  Results 
 
Kinase Fusions Identified 
In previous work, we identified ROS1 and PDGFRB rearrangements that had never been reported 
before in IMT14. In total, approximately 85% of the IMTs assessed harbored actionable kinase 
fusions. More recently, others have reported NTRK3 and RET fusions in IMT as well18-20. Using 
established NGS platforms, we sought to identify fusions in an additional 38 distinct samples 
including, but not limited to, a cohort from the Children’s Oncology Group and samples that were 
fusion negative by previous analyses. We identified ALK, ROS1, or PDGFRB rearrangements in 23 of 
the 38 samples (61%)(Figure 2.1A). ALK rearrangements were identified in 18 cases (47%). Both 
known and novel ALK fusion gene partners were detected. For example, EEF1G-ALK (detected in 
case 65) results in a novel fusion between EEF1G, a subunit in the complex responsible for 
aminoacyl t-RNA transport to the ribosome33, on chromosome 11 and ALK. In addition, KIF5B-ALK 
(detected in case 18) results from a rearrangement between KIF5B on chromosome 10 and ALK.  
KIF5B-ALK has been previously detected in non-small cell lung cancer (NSCLC) but not IMT. ROS1 
rearrangements were detected in in 4 cases (11% of the entire cohort). Interestingly, we detected a 
novel PDGFRB rearrangement, NOTCH1-PDGFRB, in one case (3% of the entire cohort). This fusion 
results from a chromosomal rearrangement between NOTCH1 on chromosome 9 and PDGFRB on 
chromosome 5 and contains not only the entire PDGFRB tyrosine kinase domain but also all 34 
exons of NOTCH1.  
 
In 6/38 cases (cases numbers 16, 20-22, 59, and 60), ALK IHC was positive, but no ALK 
rearrangement was identified. We sought to understand the correlation between detection of ALK 
protein, through ALK IHC, and ALK rearrangements through genomic analysis. Of 22 cases that were 
positive for ALK expression by IHC, 16 had verified ALK rearrangements detected by NGS. For 2 of 
the 22 ALK IHC+ cases, there was insufficient tissue for NGS analysis. For 4 of the 22 ALK IHC+ 
cases (cases numbers 16, 21, 59, 60), no ALK rearrangement was detected through deep 
sequencing analysis (Figure 2.1B). One of these cases (#16) was from FF material and underwent 
RNA sequencing analysis. The other three cases were from FFPE and underwent targeted NGS via 
the FusionPlex platform (case #21) or MSKCC’s Impact platform (case numbers 59 and 60). It is 
possible that an ALK rearrangement was not detected in these samples due to technical factors of the 
assay, low tumor content, or low expression of the fusion. By converse, there were 2 cases that were 
ALK IHC negative (case numbers 17 and 18) in which NGS analysis detected an ALK rearrangement.   
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This discrepancy is likely a result of low protein expression of the fusion or low tumor content on the 
analyzed tissue slide.  
We acknowledge that ALK expression detected by IHC does not explicitly tell us that there is an ALK 
fusion present but rather only that ALK is expressed. However, for the purposes of clarity in this 
study, from this point on, we will make the assumption that ALK expression detected by IHC would 
also mean the tumor is ALK fusion positive, a reasonable assumption based on previous studies14. In 
total, considering NGS analyses and ALK IHC status, a total of 29/38 tumors (76%) harbored a 
kinase fusion (Figure 2.1B,C). In 5 of the 38 samples assessed by NGS, ALK IHC was negative and 
no rearrangement was identified by NGS (case numbers 6,12, 25, 61, 66). Three of the five samples 
underwent analysis by both RNA sequencing and the FusionPlex platform (case numbers 6,12, 66), 
Figure 2.1: Inflammatory Myofibroblastic Tumor is a Kinase Fusion Driven Disease.  
A. Representation of the fusions identified in the newly analyzed cohort of 38 IMT cases by NGS technologies 
(FoundationOne®, FusionPlex, IMPACT, and/or RNA sequencing). If the tumor was positive for an ALK fusion by ALK IHC, but 
no fusion was found using NGS or the tumor did not undergo NGS due to quality or quantity, the case was considered ‘unknown’ 
for fusion status. ALK Fusions N=18; ROS1 Fusions N=4; PDGFRB Fusions N=1; unknown N=15 total N=38 B. Diagram 
depicting the study flow for kinase detection (including categorization by ALK IHC status and number of cases) and results. ALK 
IHC+ = ALK IHC positive. ALK IHC- = ALK IHC negative. C. Representation of the fusions identified in newly analyzed cohort of 
38 IMT cases by all molecular analyses (FoundationOne®, FusionPlex, IMPACT, RNA sequencing, and/or ALK IHC). . If the 
tumor was positive for an ALK fusion by ALK IHC, but no fusion was found using NGS or the tumor did not undergo NGS due to 
quality or quantity, the case was counted as positive for an ALK fusion. ALK Fusions N=24; ROS1 Fusion N=4; PDGFRB 
Fusions N=1; unknown N=9 (ALK IHC negative and NGS negative N=5; ALK IHC negative and no NGS testing N=4); total N =38  
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and one of the five by FusionPlex and FoundationOne (case 61). Four separate ALK IHC negative 
cases (case numbers 15, 23, 24, 68) either failed quality control (QC) or exhibited insufficient material 
and were unable to be evaluated by NGS.  
 
Of those samples that were analyzed by multiple NGS methods, 6 samples displayed discordant 
results. In one case (case 7), no rearrangement was detected by the FusionPlex platform, but a 
ROS1 fusion was detected by RNAseq. In the other case (Case #8), an ALK fusion was detected by 
the FusionPlex 
platform, but the 
RNA sequencing 
data was of too 
poor quality to 
analyze. In case 
#39, no fusion 
was reported by 
FoundationOne14, 
but the FN1-ALK 
fusion harboring 
a non-canonical 
ALK breakpoint in 
intron 18 was 
identified using 
the FusionPlex 
platform. It is 
important to note that the FoundationOne assay used in the previous study did not contain probes in 
intron 18 of ALK, but rather intron 19. This could be the reason it was not detected. Probes within 
intron 18 of ALK have now been added to the new FoundationOne assay to enable detection of ALK 
rearrangements with non-canonical breakpoints. The last two cases (#62 and 63) were negative for a 
fusion using MSKCC’s Impact assay, but ALK fusions were identified using the FusionPlex assay 
(Table 2.1).  
 
Regarding the frequency of the various fusion partner genes, previous studies have postulated that 
TPM3 and TPM4 are the most common ALK fusion partners in IMT34. When combining our entire 
cohort of IMT samples, including those previously published in 2014 (total N=69), we indeed verify  
Figure 2.2: Kinase Fusions in IMT are Heterogeneous.  
Representation of the specific fusions detected in all (N=69) IMT cases by all molecular analyses 
(including those that only underwent ALK IHC testing). Fusion occurrence is represented as a 
percentage of all IMT cases. 
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 that TPM3/4-ALK are the most common fusions, totaling 11 cases when combining both TPM3-ALK 
 (5 cases) and TPM4-ALK (6 cases) (Figure 2.2). The next most common fusion partners in our study 
were CLTC (6 cases), TFG-ROS1 (6 cases), and FN1-ALK (5 cases). Of note, 4 cases in our total 
cohort harbored RANBP2-ALK indicating that these are likely eIMS since the RANBP2-ALK fusion, 
has thus far been detected exclusively in the eIMS subtype11,17.  
 
Starting with the genomic breakpoints obtained through our NGS analyses, we translated each 
transcript and subsequently constructed schematic representations for each putative fusion protein  
(Figure 2.3, Table 2.1). All transcripts resulted in an in frame predicted fusion protein. Putative 
oligimerization domains and the tyrosine kinase domains were mapped for each case. We made 
several interesting observations with this analysis. First, we noted that a given fusion partner may 
have multiple distinct breakpoints, resulting in variable lengths of the partner gene fused to the 
kinase. For example, we detected four different FN1-ALK variants that differ by the breakpoint in FN1 
as well as ALK. Importantly, they all retain the transmembrane domain of ALK, and one also retained 
an extra-cellular region of ALK, exon 18 (case 17). Next, we noted overlap of the 5’ partner between 
multiple kinases, such as TFG-ALK and TFG-ROS1. Interestingly, although TFG was identified here 
as a 5’ fusion partner for both ALK and ROS1; the breakpoints in TFG differed between the ALK 
fusion and the ROS1 fusions. Additionally, the breakpoint in ROS1 differed between the TFG-ROS1 
fusions identified, resulting in two different TFG-ROS1 variants. 
 
Patient and Tumor Characterization  
Consistent with current literature, we did not find a gender predilection for IMT in our study. Of the 69 
distinct patient samples that we have evaluated to date, 49% were from male patients, and 51% were 
from female patients (Table 2.2). In addition, we found that the proportion of tumors harboring a 
kinase fusion was similar between male and female patients with kinase fusions being found in 88% 
of tumors from male patients and 77% of female patient’s tumors.  When considering all NGS 
analyses as well as ALK IHC, 84% of the 69 distinct tumors were positive for a kinase fusion. ALK 
Table 2.1: Annotation of 69 IMT cases that underwent genomic analyses as part of this study.  
This table details the method(s) through which each case was analyzed. Y = Yes, meaning that the sample underwent the noted 
type of analysis, as defined in the column heading. N= No, meaning that the sample did not undergo the noted type of analysis, as 
defined in the column heading. FF = fresh frozen. FFPE = formalin fixed and paraffin embedded. FM1 = Foundation Medicine 
FoundationOne® assay. NA = not available. ALK- = ALK IHC negative. ALK+ = ALK IHC positive. IM = insufficient material 
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fusions occurred in 70% of all tumors (52% male, 48% female); ROS1 fusions occurred in 10% of 
tumors (57% male, 43% female), and PDGFRB fusions occurred in 3% (50% male, 50% female) 
(Table 2.2).  Studies to date have reported age/fusion associations considering only the ALK kinase 
and with detection methodologies less sensitive than NGS, such as ALK IHC5,19.  Consistent with 
many other cancer types, these studies report a greater prevalence of ALK fusions in younger 
patients. In our study we did not find such associations. The average age of our overall patient cohort 
was 11 years. Those harboring ALK fusions exhibited a mean age of 11 years, as did both kinase 
fusion positive and kinase fusion negative cohorts. The average age of those harboring ROS1 
fusions. was 10 years. Patients with PDGFRB tumors averaged 7 years of age. There was also no 
	
	
	
Figure 2.3: Schematic Representation of Kinase Fusion Proteins Identified in This Study. 
Depicted are the structures of each kinase fusion variant in this study (scaled relative to each other, N=69). The kinase portion of 
the protein is represented in dark purple for ALK, dark gray for PDGFRB, and dark blue for ROS1. The 5' partner proteins are 
represented in steel blue, orange, light gray, light green, teal, light blue, lilac, red, maroon, light pink, royal blue, yellow, dark 
pink, gray, olive green, and bright green. Putative oligomerization domains within the 5’ partner protein are also represented. 
Note that the shape of the oligomerization domain in this figure does not necessarily represent the true shape of the protein 
domain.  
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relationship between age, sex, 
and fusion status identified. 
 
While IMTs can occur at any 
anatomic location, the lungs 
and the abdomen are the most 
commonly reported disease 
sites1,35,36. Surgical resection is 
the standard of care for all 
IMTs. However, surgical 
resection may present 
significant clinical challenges 
depending on the size and 
location of the tumor in the 
context of other vital anatomic 
structures. As a result, 
physicians may sometimes be 
faced with the decision to give 
neo-adjuvant therapy to 
facilitate resection. Therefore, we wanted to know if intra-thoracic or intra-abdominal tumors 
specifically showed a tendency for kinase fusions, and if so which ones. We chose to focus on intra-
thoracic tumors since, in our study, 23% of tumors originated in the lungs (Table 2.3). Similar to IMTs 
overall, we found that 82% of pulmonary IMTs were positive for expression of a potential kinase 
fusion (by NGS or IHC). 63% of which harbored ALK fusions as determined by NGS or were positive 
by ALK IHC, and 19% harbored ROS1 fusions (Table 2.2). Since crizotinib targets both ALK and 
ROS1, 82% of patients with pulmonary IMT may experience a positive response to crizotinib 
treatment. 
 
We also sought to evaluate the specific fusion reported in relation to the anatomical location. While 
there does appear to be some anatomical preference for certain fusions, such as FN1-ALK which was 
reported in the bladder in 4/5 cases, we did not find that any particular fusion strictly adhered to one 
organ site or that any one organ harbored only one type of fusion (Figure 2.4, Table 2.3). In 
agreement with current literature, however, RANBP2-ALK positive tumors were all reported in the 
abdomen11,17, excluding this fusion from the lungs. 
Figure 2.4: Anatomical Locations of Primary IMTs Represented by Kinase Type 
and 5’ Partner 
Anatomical map depicting the location of each primary IMT case with fusion positive 
status as determined by NGS. ALK fusions are depicted as circles, ROS1 fusions as 
squares, and PDGFRB fusions as triangles. Each 5’ partner is represented by a 
different color. 
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Pulmonary vs. Extra-pulmonary IMT Expression Analysis 
Rate of local recurrence, but not metastasis, appears to differ based on anatomical site. Primary 
tumors confined to the lung recur at a rate of <2%4,36,37 compared to 25% for extra-pulmonary 
disease1.  Given this documented difference in pulmonary vs. extra-pulmonary IMT, we interrogated 
our RNAseq data for differences in gene expression between these cohorts. We performed a 
differential expression analysis on 15 samples (case numbers 1-7, 9-12, 66-69), 5 of which were 
pulmonary, and 10 were extra-pulmonary. We identified a cohort of 74 significant differentially 
expressed genes (DEGs) (FC=>|2|, p=<0.05) (Figure 2.5A,B). (No genes were exhibited significantly 
different expression when adjusting the analysis for multiple comparisons (FDR<=0.05), likely due to 
small sample size.) KEGG Pathway and Gene Ontology (GO) term enrichment analyses revealed up-
regulation of pathways in protein processing in the endoplasmic reticulum (ER) and negative 
regulators of ER stressed-induced apoptosis and down-regulation of inflammatory responses (Table 
S2.1). Signaling Pathway Impact Analysis (SPIA) of the 74 genes revealed inhibition of the cell cycle 
and activation of neuroactive ligand-receptor interactions in pulmonary samples compared to extra-
pulmonary samples (Table S2.4). 
 
ALK 
N=48 
ROS1 
N=7 
PDGFRB 
N=2 
Fusion neg 
N=12 
Fusion pos 
N=57 
Total 
IMTs 
N=69 
Clinicopathological Parameters 
      
age (years, mean) 11 10 6.5 11 11 11 
age (years, mean) of males 10 10 1.5 8 10 9 
age (years, mean) of females 12 10 12 13 12 12 
       
sex (male)% of total IMTs 36 6 1 6 43 49 
pulmonary (% of total IMTs) 10 (14) 3 (4) 0 3 (4) 13(19) 16(23) 
       
sex (male)% of fusion 52 57 50 33 53 49 
pulmonary (% of fusion) 10 (21) 3 (43) 0 3 (25) 13(23) 16 
       
sex (male)% of male 74 12 3 12 88 100 
pulmonary (% of pulmonary) 10 (63) 3 (19) 0 3 (19) 13(81) 16 
Table 2.2: Clinicopathological Features of Inflammatory Myofibroblastic Tumors According to Fusion Status. All 69 IMT 
cases analyzed to date are represented. Cases positive by ALK IHC were considered ALK positive and fusion positive regardless of 
fusion status determined by NGS. Neg= negative. Pos = positive.  
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Expression Analysis of RANBP2-ALK Tumors 
The recently described subtype of IMT, eIMS, differentiates itself from conventional IMT histologically 
and clinically. These tumors have been known to exhibit a more aggressive clinical behavior including 
the prevalence for 
metastasis8-11 and 
resistance to ALK TKI 
therapy10,38,39. Therefore 
RNAseq data was 
interrogated to identify 
DEGs when comparing 
cases harboring the 
RANBP2-ALK fusion 
described in eIMS and 
other IMTs. Differential 
expression analysis was 
performed on a cohort of 
15 samples (case 
numbers 1-7, 9-12, 66-
69), of which 3 harbored 
RANBP2-ALK. We 
identified 235 DEGs 
(FC=>|2|, p=<0.05) 
(Figure 2.6A, B). (No 
genes were exhibited significantly different expression when adjusting the analysis for multiple 
comparisons (FDR<=0.05), likely due to small sample size.) KEGG Pathway and GO term enrichment 
analyses showed up-regulation of lysosomal and phagocytic pathways and processes in the 
inflammatory response and leukocyte migration and down-regulation of complement cascades, 
extracellular matrix organization, and cell adhesion (Table S2.2). SPIA revealed several impacted 
pathways including inhibition of Neuroactive ligand-receptor interactions and ECM-receptor 
interactions and activation of Fc gamma R-mediated phagocytosis, Fc epsilon RI signaling, and 
chemokine signaling (Table S2.5). 
 
 
Figure 2.5: Differential Expression Analysis of Pulmonary vs. Extra-pulmonary IMTs 
A. Heat map depicting the significant differentially expressed genes in pulmonary cases (cases 
7,9,10,12,67) vs. extra-pulmonary cases (cases 1-6,11,66,69). Extra-pulmonary cases are 
marked with a dark gray bar, and pulmonary cases are marked with a light gray bar. Red 
indicates increased expression, and blue indicates decreased expression relative to the mean.  
B. Volcano plot depicting the overall spread of l differential expression of each gene for 
pulmonary cases (cases 7, 9, 10,12, 67) vs. extra-pulmonary cases (cases 1-6,11, 66, 69). 
Black= Fold change <|2|; Blue = Fold change >=|2|; Red is FDR<0.05; Green is Fold 
Change>=|2| & FDR<0.05 
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Fusion Positive vs. Fusion Negative Expression Analysis 
In our studies, we have consistently found that approximately 85% of IMTs harbor therapeutically 
targetable kinase 
fusions (as 
determines by 
NGS or ALK IHC). 
There are no data 
to aid in directing 
clinical treatment 
for the remaining 
15%; therefore, 
we sought to 
identify expression 
differences 
between fusion 
positive and fusion 
negative samples 
that may give 
insight into 
pathogenesis and 
potential 
therapeutic 
treatments. Differential expression analysis was performed on a cohort of 15 samples (case numbers 
1-7, 9-12, and 66-69), 3 of which were negative for a kinase fusion, and 12 were positive for a kinase 
fusion. We identified a group of 145 DEGs (FC=>|2|, p=<0.05) (Figure 2.7A,B). (Only one gene, 
GBE1, exhibited significantly different expression when adjusting the analysis for multiple 
comparisons (FDR<=0.05), likely due to small sample size). KEGG Pathway and Gene Ontology term 
enrichment analyses revealed up-regulation of cellular components related to extracellular space and 
exosomes and down-regulation of pathways related to the biosynthesis of antibiotics and cellular 
components involved in a proteinaceous extracellular matrix in fusion positive samples (Table S2.3). 
SPIA results showed activation of PPAR signaling and cytokine-cytokine receptor interactions in 
fusion negative samples (Table S2.6). 
 
 
Figure 2.6: Differential Expression Analysis of RANBP2-ALK Expressing IMTs vs. All Other IMTs 
A. Heat map depicting the significant differentially expressed genes in RANBP2-ALK expressing IMTs 
(cases 1, 2, 3) vs. all other IMTs (cases 4-7, 9-12, 66, 67, 69). RANBP2-ALK cases are marked with a 
dark gray bar, and all other IMT cases are marked with a light gray bar. Red indicates increased 
expression, and blue indicates decreased expression relative to the mean. B. Volcano plot depicting the 
overall spread of differential expression of each gene for RANBP2-ALK expressing IMTs (cases 1,2,3) 
vs. all other IMT cases (cases 4-7,9-12,66,67,69). Black= Fold change <|2|; Blue = Fold change >=|2|; 
Red is FDR<0.05; Green is Fold Change>=|2| & FDR<0.05 
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Case # Age Sex  Anatomical Location Fusion 
1 9 M abdomen RANBP2-ALK 
2 14 M abdomen RANBP2-ALK 
3 11 M abdomen RANBP2-ALK 
4 7 F chest CLTC-ALK 
5 0.5 F abdomen SEC31L1-ALK 
6 9 M eye, orbit-right NA 
7 13 M lung TFG-ROS1 
8 4 M bladder FN1-ALK 
9 4 F lung TFG-ROS1 
10 6 M Lung, lower left lobe TPM3-ALK 
11 0.5 M Right posterior thigh TPM4-ALK 
12 17 F lung upper lobe NA 
13 3 F abdomen TPM4-ALK 
14 5 M abdomen TPM4-ALK 
15 9 F kidney, left NA 
16 13 M bladder ALK (IHC) 
17 8 F bladder FN1-ALK 
18 0.5 M floor of mouth KIF5B-ALK 
19 14 M kidney TFG-ROS1 
20 16 M bladder ALK (IHC) 
21 2 M lung, left ALK (IHC) 
22 8 F abdomen ALK (IHC) 
23 8 M lung NA 
24 10 M abdomen NA 
25 16 F small bowel NA 
26 14 F mesentery NA 
27 16 F mesentery NA 
28 22 F buttock/pelvis YWHAE-ROS1 
29 38 F lung EML4-ALK  
30 8 M mesentery TFG-ROS1 
31 5 M lung NA 
32 41 M nasopharynx TPM3-ALK 
33 12 F peritoneum NAB2-PDGFRB 
34 6 M omentum RANBP2-ALK 
35 7 F mesentery LMNA-ALK 
36 2 F mesentery TPM3-ALK 
37 3 F mesentery TPM4-ALK 
38 29 M mesentery TPM4-ALK 
39 36 F lung FN1-ALK 
40 13 M lung ALK (IHC) 
41 2 M bladder ALK (IHC) 
42 11 F lung EML4-ALK   
43 7 M mesentery TPM3-ALK 
44 20 F mesentery TPM3-ALK 
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Case # Age Sex  Anatomical Location Fusion 
45 1 M mesentery ALK (IHC) 
46 6 F lung SEC31L1-ALK 
47 4 M mesentery ALK (IHC) 
48 14 M pelvis TFG-ALK 
49 26 F bladder FN1-ALK 
50 26 F bladder CLTC-ALK 
51 14 M mesentery CLTC-ALK 
52 18 F bladder FN1-ALK 
53 10 M mesentery ALK (IHC) 
54 9 F lung CLTC-ALK 
55 4 F lung CLTC-ALK 
56 0.5 F shoulder PRKAR1A-ALK 
57 6 M lung TFG-ROS1 
58 9 M small bowel LMNA-ALK 
59 17 F bladder serosa and pelvis ALK (IHC) 
60 5 M small bowel mesentery ALK (IHC) 
61 14 F stomach NA 
62 16 F pelvic and mesentery CARS-ALK 
63 9 M thumb TPM4-ALK 
64 4 F stomach TFG-ROS1 
65 0.5 F abdomen EEF1G-ALK 
66 12 F uterus NA 
67 9 F lung CLTC-ALK 
68 4 F abdomen NA 
69 1.5 M abdomen NOTCH1-PDGFRB 
 
 
SNVs 
Aside from the presence of kinase fusions, little is known regarding the mutational landscape of IMT. 
This results in the use of therapies without much rational to support them in the ~15% of patients 
whose tumors are kinase fusion negative or for kinase fusion positive patients whose disease has 
progressed on targeted therapy. Using RNAseq of 18 distinct patient samples, we sought to identify 
cancer associated single nucleotide variants (SNVs) that may give insight into the pathogenesis of 
IMT and nominate potential therapies. We found that each sample harbored between 20 and 52 
cancer associated SNVs. We noted that many of the SNVs were common amongst the samples. 
There were 30 SNVs shared by at least 25% of the samples (N>=5) (Figure 2.8A, Table S2.7), 
including a RPL22 frameshift insertion (44 A duplication, K15 frame shift) that occurred in every 
sample with a variant allele frequency (VAF) <40% in all samples, and TP53 C98G (P33R) that 
Table 2.3: Clinicopathological Features of the entire IMT Cohort. All 69 IMT cases analyzed to date are 
represented. Cases positive by ALK IHC only were considered ALK positive and noted ALK as the fusion by 
IHC. 
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occurred in 17/18 samples. ROS1 fusions shared the least number of common SNVs (17/30). SNVs 
excluding ROS1 samples were in SETD2, ATRX, DHX15, CROCC, IGLL5, TET2, NUP98, LRIG1, 
KMT2A, GAK, KMT2C, MGA, and ZFHX3. We also noted that a NCOR1 frameshift (636A duplication, 
V213 frame shift) consisted of a low percentage of ALK samples relative to the other 29 commonly 
shared SNVs. The common SNVs more exclusive to fusion positive tumors were DHX15 frameshift 
(1224A duplication, Q409 frame shift), CROCC G2072A (R691H), RHOA A485G (K162R), TSC1 
T965C (M322T) and KMT2A frameshift (9308 A duplication, Q3103 frame shift) while those more 
exclusive to 
fusion 
negative 
tumors were 
MTAP 
G166A 
(V56I) and 
ZFHX3 
G247T 
(A83S) 
(Figure 
2.8B). Both 
MTAP and 
ZFHX3 are 
considered 
tumor 
suppressors. 
 
In order to 
further 
determine 
significance of these common SNVs, we assessed the variant allele frequencies (VAFs). Interestingly, 
while the RPL22 SNV was present in all samples, it always occurred as one of the lowest allele 
frequencies (VAF< 40% (Tables S2.8-S2.25)). The SNVs consistently having the highest allele 
frequencies, homozygous in most cases, were TP53, DDX31, IL7R, ZNF384, SETD2, and ATRX  
(Tables S2.8-S2.25). We wanted to know if there was a common pathway in which these shared 
SNVs occurred. GO term enrichment analysis of the 30 shared SNVs revealed a striking involvement 
Figure 2.7: Differential Expression Analysis of Kinase Fusion Positive vs. Kinase Fusion Negative IMTs. 
A. Heat map depicting the significant differentially expressed genes in kinase fusion positive tumors (cases 1-
5,7,9-11,67,69) vs. fusion negative tumors (cases 6,12,66). Fusion positive cases are marked with a dark gray 
bar, and fusion negative cases are marked with a light gray bar. Red indicates increased expression, and blue 
indicates decreased expression relative to the mean. B. Volcano plot depicting the overall spread of l differential 
expression of each gene for fusion positive tumors (cases 1-5,7,9-11,67,69) vs. fusion negative tumors (cases 
6,12,66). Black= Fold change <|2|; Blue = Fold change >=|2|; Red is FDR<0.05; Green is Fold Change>=|2| & 
FDR<0.05 
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of the VEGF pathway and chromatin remodeling proteins, including histone methylation (Table 
S2.26). 
 
We also explored additional SNVs occurring in the majority (2/4) of fusion negative samples. We 
found that 3 of 4 fusion negative samples shared the PIK3R1 G978A (M326I) mutation, and half 
shared the EGFR G1562A (R51K) mutation. Both of these aberrations occurred with high allele 
frequencies (VAF> 50% (Figure 2.9, Tables S2.8-S2.25)). 
 
2.5  Discussion 
 
It is well established that ALK fusions occur in ~50% of IMT12-14, and clinical studies of ALK inhibitors 
have proven effective in ALK positive IMT21,22. Recent NGS studies of IMT have revealed the 
presence of targetable kinase fusions in ALK negative tumors including ROS1, PDGFRB, RET, and 
NTRK314,18,19. In targeted NGS studies of relatively large cohorts of this rare tumor, the majority of 
tumors have been found to harbor a kinase fusion14, emphasizing the importance of utilizing NGS 
diagnostic tools to improve clinical decision making for this disease. Nothing yet is known on the 
genomic or transcriptomic level for those that do not harbor kinase fusions or for kinase fusion 
positive tumors which progress of therapy, highlighting the need for further genomic and tumor 
expression studies that may help us understand IMT pathogenesis and identify rational therapeutic 
options.  
 
Our study aimed to increase the knowledge surrounding this rare and heterogeneous tumor, coupling 
clinicopathologic and transcriptomic data, specifically regarding the presence of kinase fusions, 
differences in gene expression between cohorts of pre-determined clinical significance, and the 
presence of cancer associated SNVs.  
 
Consistent with our previous report, we have identified targetable kinase fusions in 84% of our entire 
IMT cohort (N=69) including ALK, ROS1, and PDGFRB kinases (as determined by NGS and ALK 
IHC). We did not find any predilection for different fusions (as determined by the kinase type or 5’ 
partner) for specific anatomical locations, age, or gender (Table 2.2). 
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A 
B 
Figure 2.8: Genes Harboring Cancer Associated SNVs Shared by at Least 25% of IMTs Evaluated. 
 All 18 IMTs undergoing RNAseq analysis were assessed for SNVs. Variants were filtered based on a list of 383 pre-defined cancer 
genes. The variants were maintained if they were exonic, had a damaging function, previously reported in COSMIC, and were 
considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele frequency below 0.05, depth 
below 10, a prevalence of greater than 10% in the 1000 Genomes Project or if no annotations were present. Genes harbouring 
SNVs shared by at least 25% of samples are displayed. A. The number of positive tumors for each fusion category is represented. 
ALK N=11; ROS1 N=2; PDGFRB N=1; Fusion negative N=4 B. The percent of positive tumors within each category is represented. 
Fusion positive N=14; Fusion negative N=4. 
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Previous literature reports show that older patients (>40 years) tend have ALK negative tumors5,19. 
The average patient age in our cohort was 11 years with the oldest patient being 41 years of age. We 
did not find a correlation 
between the 
presence/absence of a 
kinase fusion and age, 
or for anatomical 
location or gender 
(Table 2.2).  
 
We report several novel 
fusion findings, 
including: (a) a new 
ALK fusion partner, 
EEF1G; (b) a new 
PDGFRB fusion 
partner, NOTCH1; (c) 
novel ALK fusion 
partner for IMT 
specifically, including 
KIF5B-ALK which also 
occurs in NSCLC; and 
(d) novel variants of previously reported ALK fusions, including 4 variants of FN1-ALK which differ 
based on both the FN1 and ALK genomic breakpoints (Table 2.1, Figure 2.3). The full biological and 
clinical significance of different fusion variants that vary by the specific 5’ partner protein (such as 
TFG-ALK vs. TPM3-ALK) or the length of the same 5’ partner protein (such as the four different FN1-
ALK variants identified in this study) is unknown, but previous clinical and pre-clinical studies suggest 
that there are biochemical differences that affect efficacy of TKIs and Hsp90 inhibitors40-46. We also 
made an interesting observation regarding fusions in which TFG is the 5’ protein. TFG was a 5’ 
partner for both ALK and ROS1; however, the breakpoints in TFG differed between TFG-ALK and 
TFG-ROS1. The TFG breakpoint in TFG-ROS1 disrupts the coiled-coil oligomerization domain 
resulting in a shorter coiled-coil domain for TFG-ROS1. The significance of this difference is 
unknown. It is possible that this breakpoint is required for an in-frame fusion. Another factor to 
consider is the retention of the transmembrane domain of ROS1 in the TFG-ROS1 fusions. The  
Figure 2.9: Shared SNVs Present in Fusion Negative Tumors. 
All 18 IMTs undergoing RNAseq analysis were assessed for SNVs. Variants were filtered 
based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered 
pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 
Genomes Project or if no annotations were present. Depicted are genes harbouring SNVs 
shared by at leas 50% of fusion negative tumors, beyond the 30 most commonly shared SNVs 
in all IMT cases. The number of tumors harboring the shared SNV is represented. Total N=4. 
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presence of a transmembrane domain with the shorter coiled-coil may be more favorable in terms of 
disorder. The role of disorder in oncogenic kinase fusions and how it relates to the findings in this 
study are further discussed in chapter 4. 
 
There have been different clinical observations reported regarding pulmonary vs. extra-pulmonary 
tumors1,4,36,37. Additionally, these tumors may bring clinical challenges due to the location, resulting in 
a physician needing to consider systemic therapies over surgical resection. We are able to report 
that, similar to IMT overall, 82% of pulmonary IMTs also were kinase fusion positive (Table 2.2). 
While this was a small cohort for comparison, all of the pulmonary fusions were either ALK or ROS1. 
Given the potential challenges in operative management of these tumors, and the observation that 
pulmonary tumors are less likely to recur1,36,37, physicians may consider neo-adjuvant crizotinib 
treatment for patients with pulmonary IMTs when up-front resection is not possible. 
 
Studying the IMT transcriptome presents many challenges and limitations including the gap in 
knowledge regarding cell of origin and tumor rarity resulting in small cohorts. The former results in an 
imprecise normal control for comparison. Because of this, we chose to perform comparisons by 
grouping our samples based on previously described clinical categories such as RANBP2-ALK 
harboring IMTs (likely eIMS) vs. conventional IMT, pulmonary vs. extra-pulmonary, and fusion 
positive vs. fusion negative. Unfortunately, due to small sample size, made even smaller when slpit 
into the comparison groupings, no genes were identified as being significant from differential 
expression analyses after adjusting for multiple-test correction. As IMT is rare, it can be difficult to 
obtain enough samples to comparatively evaluate by this method, so we chose to continue the 
analysis with differentially expressed genes exhibiting a p value<= 0.05 and a FC >=|2| to infer those 
genes that are biologically significant. Regarding differential expression between extra-pulmonary vs. 
pulmonary IMT, SPIA showed greater activation of the cell cycle in extra-pulmonary tumors. IMTs 
tend to grow quite large1,3 and therefore have a growing demand for nutrients. This may be better 
supplied to extra-pulmonary (abdominal) tumors resulting in greater activation of the cell cycle. For 
the comparison of RANBP2-ALK IMTs vs. all other IMTs, SPIA showed inhibition of extra-cellular 
matrix interactions in RANBP2-ALK tumors and activation of chemokines. This is interesting since 
eIMS are known to be clinically more aggressive with a tendency toward metastasis and have a 
different inflammatory profile8,10,11,47. When assessing the signaling pathway impact of differentially 
expressed genes between fusion negative and fusion positive samples, we identified activation of the 
PPAR pathway in fusion negative samples, specifically through PPARγ. The PPAR pathway, involved 
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in metabolism and inflammation48,49, is targeted by some anti-diabetic drugs, and is a potential target 
for anti-cancer therapies49. 
 
Our analysis of cancer associated SNVs revealed a set of 30 variants commonly shared between at 
least 25% of samples. Importantly, all but two of the most commonly shared SNVs occur in both 
fusion negative and fusion positive samples indicating that this cohort of SNVs is likely indicative of 
IMT pathogenesis as a disease. Further analysis of this gene set revealed significant involvement of 
the VEGF pathway and regulation of chromatin (Table S2.26). Given the average size of IMTs1,3, and 
therefore demand for blood supply, this is not necessarily surprising. Functions of these genes 
include but are not limited to histone methylation50, chromosome segregation51, and centrosome 
cohesion52. Many of the genes in this set are involved in the p53 pathway, and TP53 C98G (P33R) 
was present in 17/18 samples. A mutation in ribosomal protein RPL22 was present in all samples, 
although with low allele frequency. Interestingly, two of the other shared SNVs occurred in RNA 
helicases, DDX31 and DHX15, which are involved in ribosome biogenesis53. Some have postulated 
that stress in ribosomal biogenesis may allow for selective pressures toward cells that override 
pathways regulating ribosome biogenesis such as mTOR54. Interestingly, DDX31 is also involved in 
p53 regulation through interactions with NPM155. Taken together, this suggests IMTs are undergoing 
stress in ribosome biogenesis and may even suggest this as an early cancer-initiating step in IMT. 
Developing drugs targeting ribosome biogenesis is already underway. 
 
Further assessment of shared SNVs in the fusion negative cohort revealed a potentially significant 
mutation in PIK3R1. According to cBioPortal, this particular mutation, M326I, has been reported in 
several cancers such as adrenocortical carcinoma, chondroblastic osteosarcoma, renal cell 
carcinoma, neuroblastoma, acute myeloid leukemia, mixed germ cell tumor, and hepatoblastoma. 
Deletion of this amino acid results in truncation and has been reported in glioblastoma multiforme and 
renal cell carcinoma. It is considered a loss of function and oncogenic56,57. This mutation was present 
in all but one fusion negative sample and consistently at high allele frequency. 
 
In summary, our findings support the use of NGS diagnostics to help direct therapy for IMT. Other 
rational therapeutic options, though not tested clinically in this tumor type, could include agents 
targeting angiogenesis and the VEGF pathway, such as bevacizumab, or epigenetic modulators, 
such as azacitidine or valproic acid. Unfortunately, there are currently no published IMT cell lines or 
mouse models in which to study the efficacy of these agents against IMT. In order to better 
understand IMT pathogenesis and study drug candidates, we must collaborate globally to work to 
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develop patient cell line models and overcome this limitation to better study the disease and fully 
understand this rare tumor.  
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Chapter 3 
ALK FUSION VARIANTS 
Adapted from: Merrida A. Childress, Stephen M. Himmelberg, Huiqin Chen, Wanleng Deng, Michael 
A. Davies, Christine M. Lovly, ALK Fusion Partners Impact Response to ALK Inhibition: Differential 
Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res. 2018 
 
3.1 Abstract 
Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are detected in 
numerous tumor types. Although more than 30 distinct 5’ fusion partner genes have been reported, 
treatment of ALK-rearranged cancers is decided without regard to which 5’ partner is present. There 
is little data addressing how the 5’ partner affects the biology of the fusion or responsiveness to ALK 
tyrosine kinase inhibitors (TKIs).  Based on the hypothesis that the 5’ partner influences the intrinsic 
properties of the fusion protein, cellular functions that impact oncogenic potential, and sensitivity to 
ALK TKIs, clonal 3T3 cell lines stably expressing seven different ALK fusion variants were generated 
Biochemical and cellular assays were used to assess the efficacy of various ALK TKIs in clinical use, 
transformative phenotypes, and biochemical properties of each fusion. All seven ALK fusions induced 
focus formation and colonies in soft agar, albeit to varying degrees. IC50s were calculated for 
different ALK TKIs (crizotinib, ensartinib, alectinib, lorlatinib) and consistent differences  (5-10 fold) in 
drug sensitivity were noted across the seven ALK fusions tested. Finally, biochemical analyses 
revealed negative correlations between kinase activity and protein stability. These results 
demonstrate that the 5’ fusion partner plays an important biological role that affects sensitivity to ALK 
TKIs.  
 
Implications 
This study shows that the 5' ALK fusion partner influences ALK TKI drug sensitivity. As many other 
kinase fusions are found in numerous cancers, often with overlapping fusion partners, these studies 
have ramifications for other kinase-driven malignancies. 
 
3.2 Introduction  
 
Genomic rearrangements involving the gene which encodes anaplastic lymphoma kinase (ALK) have  
been described in a broad spectrum of malignancies including anaplastic large cell lymphoma 
(ALCL), diffuse large B cell lymphoma, inflammatory myofibroblastic tumor (IMT), glioma, non-small 
cell lung cancer (NSCLC), colorectal, breast, ovarian, and esophageal cancer6. ALK rearrangements 
 52 
have been identified in up to 8% of NSCLC cases7 and in up to 50% of IMTs, a soft tissue tumor 
predominantly diagnosed in children8. The resulting ALK fusion proteins all retain the entire kinase 
domain of ALK at the C-terminus, and the N-terminus consists of an entirely different protein. These 
fusion proteins are validated therapeutic targets. Several large international trials have now validated 
that patients with ALK positive (ALK+) lung cancer derive improved clinical outcomes from treatment 
with ALK TKIs (Supplementary Table S3.1), leading to FDA approval of agents such as crizotinib, 
ceritinib, alectinib, brigatinib, and lorlatinib. Similar trials have also been completed in ALK+ IMT and 
ALCL9, and there have been case reports of response to ALK TKI therapy in patients with renal cell 
carcinoma and colon carcinoma harboring ALK fusions10.  
 
Although ALK fusions are validated targets for cancer therapy, precision regarding how to best target 
these fusions clinically is lacking in comparison to other oncogenic drivers like mutant Epidermal 
Growth Factor Receptor (EGFR) or retinoic acid receptor alpha (RARα) fusions, where it is known 
that different variants dictate drug sensitivity11,12. For example, in EGFR-mutant NSCLC, it is known 
that different EGFR kinase domain mutations confer varying degrees of sensitivity or resistance to 
EGFR directed therapies11. Likewise, for RARα fusions found in subtypes of leukemia, it is known that 
the particular gene fused to RARα not only affects response to therapy but also can be a therapeutic 
target itself12. Greater than 30 distinct ALK fusion partners have been identified, including TPM-3/-4, 
CLTC, LMNA, PRKAR1A, EML4, RANBP2, TFG, FN1, KIF5B, and many others5,8. Although many 
different 5’ partner genes have been reported for ALK, even within the same cancer type, there is 
currently little data to address the question of how different fusion partners may affect pretreatment 
clinical characteristics, disease responsiveness to targeted therapies, or acquired resistance. 
Therefore, treatment of ALK+ cancers is currently decided without considering which fusion partner is 
present. However, recent retrospective clinical studies in ALK+ NSCLC suggest a difference in 
progression-free survival based on the specific ALK fusion variant present13-15.  As next-generation 
sequencing technologies continue to be approved by regulatory agencies, clinicians will know both 
the 5’ partner and the 3’ kinase involved in the fusion. Therefore, it is imperative that the nuances of 
the various ALK fusions are better understood, including determining the therapeutic implications of 
the various ALK fusions to bring more precision to patient care. Herein, we sought to test the 
hypothesis that the 5’ ALK fusion partner influences the intrinsic properties of the fusion protein as 
well as the cellular functions that impact overall oncogenic potential and sensitivity to ALK targeted 
therapy. 
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3.3  Materials and Methods 
 
Cell Culture: NIH 3T3 cells were a kind gift from Dr. William Pao16. NIH3T3 cells stably expressing 
ALK F1174L were a kind gift of Dr. Marc Ladanyi 17. Cell line authentication was not performed after 
receipt of the cells. NIH3T3 cells were maintained in DMEM (Mediatech, Corning, NY, USA), 
supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA), and penicillin 
(100U/mL)/streptomycin (100μg/mL) (Mediatech) at 37°C, 5% CO2 for maintenance culture and all 
experiments unless noted otherwise. Plat GP cells were obtained from Cell Biolabs and cultured in 
RPMI 1640 (Mediatech), supplemented with 10% FBS (Atlanta Biologicals), and 2μg/mL blasticidin 
(Invitrogen, Grand Island, NY, USA). All cell lines were routinely evaluated for mycoplasma 
contamination. The latest date these cell lines were tested was September 2017. 
 
Expression Constructs cDNAs for EML4-ALK E13:A20 (variant 1, V1), EML4-ALK E6a/b:A20 
(variant 3, V3), KIF5B-ALK, TFG-ALK, PRKAR1A-ALK, FN1-ALK, RANBP2-ALK, and wild-type (WT) 
ALK receptor were synthesized by GeneArt, (ThermoFisher, Grand Island, NY, USA) and subcloned 
into the pMXs-Puro retroviral vector  (Cell Biolabs, San Diego, CA, USA) using EcoRI and NotI or 
PacI. Genomic breakpoints we previously reported for TFG-ALK, PRKAR1A-ALK, and RANBP2-ALK 
were used to generate these cDNAs8. The EML4-ALK V1, EML4-ALK V3, KIF5B-ALK, and FN1-ALK 
cDNA sequences were generated using previously described breakpoints18-21. 
 
Viral Transduction and Clonal Selection Retroviral vectors were individually transfected into the 
Plat GP packaging cell line (HEK293 cells stably expressing a gag-pol internal ribosome entry 
site)(Cell Biolabs). Viral media was harvested 48 hours post transfection and pelleted. The viral pellet 
was re-suspended in DMEM and applied to NIH 3T3 cells. Transduced NIH 3T3 cells were treated 
with 2μg/mL puromycin (Invitrogen) beginning at 48 hours post transduction for a minimum of two 
weeks. Single cell clones were grown until confluent in a 6-well plate at which time half of the cells 
were harvested for lysate, and half were frozen and stored for later culture. Lysate for each clone was 
run on the same gel and probed for total ALK expression (Cell Signaling, #3333). Clones exhibiting 
relatively equal expression for all ALK fusions were selected for expansion, except EML4-ALK V3, for 
which the lowest expressing clone of 20 tested (data not shown) was selected. Cells were maintained 
in DMEM, supplemented with 10% FBS, penicillin (100U/mL)/streptomycin (100μg/mL), and 2μg/mL 
puromycin at 37°C, 5% CO2 for maintenance culture and experiments unless noted otherwise. Cells 
were cultured and used for experiments for up to 12 weeks after thawing. All cell lines were routinely 
evaluated for mycoplasma contamination. The latest date these cell lines were tested was September 
 54 
2017. 
 
Immunoblot and Antibodies The following primary antibodies were obtained from Cell Signaling 
Technology (Danvers, MA, USA): ALK mAb Rabbit (#3333), ALK mAb Mouse (3791S), ALK (D5F3) 
mAb Rabbit (#3633) and pALK Y1604 (#3341S). The actin antibody (A2066) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The following secondary antibodies were obtained from LiCor 
(Lincoln, NE, USA): IRDye 680RD Goat anti-Mouse (#92668070), and IRDye 800 Goat anti-Rabbit 
(#92632211). For infrared (IR) immunoblot, cells were harvested, washed in PBS, and lysed in KRAS 
buffer [50 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 1% triton X-100, 0.5% Na Deoxy Cholate, 0.1% 
SDS, 40 nmol/L sodium fluoride, 1mM sodium orthovanidate, and complete protease inhibitors 
(Roche Diagnostics, Indianapolis, IN, USA)]. Signal detection was obtained using the LiCor Odyssey 
scanner system and quantified using iMageStudio Lite software (LiCor). 
 
Reverse Phase Protein Lysate Microarrays (RPPA) NIH 3T3 cell lines stably expressing ALK 
fusion variants, WT ALK, ALK F1174L, and empty vector control cells were grown in normal culture 
conditions. Lysates were harvested using the lysis buffer recommended by the MD Anderson RPPA 
core [1% Triton X‐100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM 
NaF, 10 mM Na pyrophosphate, 1mM sodium orthovanidate, 10% glycerol, containing freshly added 
protease and phosphatase inhibitors]. Protein concentrations were adjusted to 1.5μg/μL. Samples 
were prepared as instructed by the MD Anderson RPPA Core using 4xSDS sample buffer [40% 
Glycerol, 8% SDS, 0.25M Tris‐HCL, pH 6.8. (β-mercaptoethanol added at 1/10 of the volume 
immediately before use)], boiled for 5 minutes, and stored at -80°C until sample submission. Three 
separate biological replicates for each cell line type were tested. All of the samples were assayed for 
the expression of 304 phospho-protein or total protein analytes using the reverse phase protein lysate 
microarrays (RPPA), as described (https://www.mdanderson.org/research/research-resources/core-
facilities/functional-proteomics-rppa-core/rppa-process.html).  
 
RPPA Analysis: The loading control normalized and log2 transformed RPPA data were imported and 
analyzed using R packages. Unsupervised hierarchical clustering analysis was performed to check 
the data quality and the association between cell lines. The heat map shows that the empty vector 
transferred and wild type cell line are well separated with other cell lines. 
 
RPPA Statistical analysis: One-Way analysis of variance (ANOVA) was used to assess the 
differences in protein expressions between cell lines on a feature-by-feature basis. First, for one 
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protein at a time, we carried out an over-all F test to detect any significant difference among the 
means of all the groups. Next, for the proteins identified in this process, we then compared between 
desired cell line groups to identify the sources of difference. The R library “multcomp” was used for 
this purpose. Note that the fold change (FC) values were calculated as the estimated ratio between 
the 2 groups in comparison, with the following conventional modification: For the ratios > 1 (up-
regulation), FCs were noted as the same as the ratio. For the ratios ≤ 1 (down-regulation), FCs were 
noted as the negative inverse of the ratio. Furthermore, to account for multiple testing, we estimated 
the false discovery rates (FDR) of the overall test of the model using the Benjamini-Hochberg 
method. The criteria of protein selection for each pairwise comparison were: 1. Significant in overall 
F-test (FDR adjusted p-value<0.05); 2. Significant in pairwise comparison. (Raw p-value<0.05). 3. 
The FC between groups is at least 1.5. 
 
In order to calculate pathway activity scores, RPPA data were median-centered and normalized by 
standard deviation across all samples for each component to obtain the relative protein level. The 
pathway score is then the sum of the relative protein level multiplied by its weight of all components in 
a particular pathway. The similar comparisons as protein level were applied to the pathway scores. 
 
Focus Formation NIH 3T3 cell lines stably expressing ALK fusion variants were trypsinized to 
disrupt cell adhesions, seeded at 4000 cells/well in 24 well plates, and allowed to grow for 8 days in a 
cell culture incubator containing an IncuCyte ZOOM (Essen BioSciences, Ann Arbor, MI, USA). Foci  
were quantified manually from daily images acquired by the IncuCyte ZOOM. 
 
Soft Agar Assays NIH 3T3 cell lines stably expressing ALK fusion variants were trypsinized to 
disrupt cell adhesions. 1.5mL of 0.5% agar/complete media were added to each well in a 6 well plate 
and allowed to solidify. Cells were seeded on top of the 0.5% agar/complete media layer at a density 
of 5000 cells/well in complete media containing 0.3% agar. After the agar solidified, 200μL of media 
was added on top and changed every week. Cultures were grown at 37°C in 5% CO2 for 6 weeks. 
Colony formation was quantified using the GelCount system (Oxford Optronix, United Kingdom). 
Inhibitors: Crizotinib, alectinib, lorlatinib, and ganetespib were purchased from Selleck Chemicals 
(Houston, TX, USA). Ensartinib was obtained from Xcovery (Palm Beach Gardens, FL). 
Cycloheximide was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
Drug Response Curves NIH 3T3 cell lines stably expressing ALK fusion variants were seeded at 
2000 cells/well in 96 well plates using the Multidrop Combi dispenser (ThermoFisher). Cells were 
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treated with increasing doses of each inhibitor. 72 hours post drug treatment propidium Iodide (PI) 
(Sigma-Aldrich) and Hoechst 33342 (Invitrogen) were added to a concentration of 0.4μg/mL and 
4μg/mL respectively using the Multidrop Combi dispenser and allowed to incubate for 20 minutes at 
37°C. For automated high-content imaging, the ImageXpress Micro XL (Molecular Devices, San Jose, 
CA) is integrated with a Thermo F3 robotic arm.  Whole-well imaging was captured with a 4x objective 
using DAPI and Texas Red filters. Total nuclei and PI+ cells were counted using the multi-wavelength 
cell scoring application module in the MetaXpress software. Dose response curves, using live cell 
counts (total nuclei - PI+), and IC50s were generated using GraphPad Prism™ version 7 (GraphPad 
software, La Jolla, CA, USA). 
 
Kinase Assays ALK variants were immunoprecipitated from NIH 3T3 cells lines stably expressing 
ALK fusion variants and controls using a monoclonal anti-ALK antibody (Cell Signaling #3633) 
Lysates were pre-cleared with Protein A Sepharose beads (Invitrogen). After 1 hour in primary 
antibody, Protein A Sepharose beads (Invitrogen) were added for 1 hour. Beads were washed 4x in 
PBS as directed in the manufacturer’s protocol. Kinase assays were performed using the Universal 
Kinase Assay Kit (Takara, Clontech, Japan) according to the manufacturer’s instructions. An aliquot 
of the immunoprecipitate, equal to the amount used in each in vitro kinase assay, was assessed by  
immunoblot for total ALK (Cell Signaling #3333). After completion of the in vitro kinase assay, the 
data was analyzed with a two-step normalization process: (1) Total ALK expression for each variant 
was calculated using iMageStudio Lite (LiCor) and normalized to (divided by) the WT ALK 
expression. (2) Kinase activity of each fusion was then normalized to (divided by) expression and  
represented as relative to WT ALK. Kinase assays were performed in the absence of known ALK 
ligand.  
 
Protein Stability Assays  NIH 3T3 cell lines stably expressing ALK fusion variants were seeded in 6 
well plates. 24 hours after seeding, cells were treated with 50μg/mL cycloheximide (Sigma-Aldrich) for 
2, 8, 16, or 24 hours, harvested for lysate, and probed for total ALK protein (Cell Signaling, #3191S) 
by IR Western blot. Total ALK variant expression was normalized to the actin loading control. 
 
Data Analysis and Statistical Considerations Each experiment was performed with three biological 
replicates and repeated at least three times. IR Western blots were visualized using the LiCor 
Odyssey scanner system and quantified using ImageStudio Lite (LiCor), and ALK phosphorylation 
and total ALK protein expression were normalized to the actin loading control. Kinase assays were 
measured using the Synergy MX microplate reader (BioTek). All graphs and statistical analyses were 
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generated using GraphPad Prism™ software and a p value<0.05 as the threshold for statistical 
significance. For comparing more than two conditions, the Kruskal-Wallis or Tukey tests were used. 
 
3.4  Results 
 
Expression of ALK fusion variants in NIH3T3 cells  
At present, there are limited cell lines that harbor endogenous ALK fusions, and these models are 
limited to EML4-ALK and NPM-ALK. To study the effects of multiple 5’ partners, we selected seven 
different ALK fusions for exogenous expression: FN1-ALK, KIF5B-ALK, RANBP2-ALK, TFG-ALK, 
PRKAR1A-ALK, EML4-ALK E13:A20 (variant 1, V1; exon 13 of EML4 fused to exon 20 of ALK), and 
EML4-ALK E6b:A20 (variant 3b, V3b, exon 6b of EML4 fused to exon 20 of ALK) (Table 3.1, Fig. 
3.1). These fusion variants have all been detected in IMT and/or NSCLC8,19,21, the two tumor types 
with the most clinical data regarding the efficacy of ALK inhibition.  
 
Of the greater than 30 ALK fusion partners which have been described, we selected these particular 
variants because they produce fusion proteins of different molecular weights which differ in protein 
subdomain structure, particularly with respect to the putative oligomerization domains (Fig. 3.1), and  
subcellular localizations (Table 3.1). Full-length ALK receptor, either WT or F1174L mutated, were 
used as controls. The F1174L mutation in the ALK kinase domain confers ligand-independent, 
constitutive activity of the receptor, representing a positive comparator for oncogenic activity while the 
full length WT ALK receptor is expected to be inactive unless ligand is added39,40. 
 
A challenge to consider in studying ALK fusion variants comparatively is that each variant is under the 
control of the 5’ fusion partner’s regulatory elements, which vary from fusion partner to fusion partner 
and cell type to cell type. To address this issue, all variants were placed under the control of the LTR 
in the PMXs-Puro retroviral vector. We stably transduced the seven distinct ALK variants (Table 3.1, 
Fig. 3.1) into NIH 3T3 cells to generate isogenic cell line models41 and selected clones in which the 
specific ALK fusion proteins were expressed at relatively equivalent levels (Supplementary Fig. 
S3.1). We confirmed the expression of each fusion at the expected molecular weight (Table 3.1, 
Supplementary Fig. S3.1). For FN1-ALK, we noted an additional lower molecular weight band at 
approximately 75kD, as previously described for this fusion variant18. 
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In further support of our cell line models, we performed Reverse Phase Protein Array (RPPA) in order 
to quantitatively evaluate changes in protein expression induced by each active ALK variant (Fig. 3.2, 
Supplementary Fig. S3.2). This extensively validated assay evaluates the relative expression of 304  
cancer related proteins and phospho-proteins from each sample simultaneously (Supplementary 
Table S3.1), allowing for confident, quantitative comparisons. The most significantly changed proteins 
between the negative control cell lines (WT ALK, empty vector) and those expressing an ALK fusion 
or the constitutively active mutant, ALK F1174L are shown in Fig. 3.2 (Supplementary Table S3.2). 
We observed a clear shift in the protein expression profile between the negative control cell lines (WT 
ALK, empty vector) and those expressing an ALK fusion or the constitutively active mutant, ALK 
F1174L (Fig. 3.2). 
FN1-ALK 
KIF5B-ALK 
RANBP2-ALK 
TFG-ALK  
PRKAR1A-ALK 
EML4-ALK V1  
EML4-ALK V3b 
Oligomerization Domains: 
Docking/
dimerization* 
TPR  
ALK Transmembrane domain 
ALK Kinase domain 
Coiled-coil FN I, II, or III Heavy/light chain 
WD repeats 
PB1 
Figure 3.1 Schematic representation of ALK fusion variants utilized in this study. Depicted are the structures of each ALK 
fusion variant in this study (scaled relative to each other). The ALK portion of the protein is represented in dark blue. The 5' 
partner proteins are represented in red, green, gray, orange, yellow, teal, or pink. Putative oligomerization domains within the 5’ 
partner protein are also represented. *The “dimerization/docking” domain of PRKAR1A
22
. Note that the shape of the 
oligomerization domain in this figure does not necessarily represent the true shape of the protein domain. 
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ALK fusion partners confer differential oncogenic properties  
 Next, we sought to determine if the 5’ partner affects transforming and proliferative properties. Using 
the NIH 3T3 cell line models, we first assessed focus formation, an established assay used to 
evaluate the ability of oncogenes to overcome contact inhibition. As expected, cells expressing empty 
vector and WT ALK did not support focus formation, while the ALK F1174L cells (the positive control) 
lost contact inhibition and were able to form foci (Fig. 3.3A). We observed that all seven distinct ALK 
fusion variants also supported focus formation, albeit to different degrees. Notably, FN1-ALK 
exhibited the most robust ability to form foci, more than double the amount of the positive control 
(ALK F1174L). Similarly, when assessed for anchorage independent growth (Fig. 3.3B), all fusions 
produced colonies in soft agar. However, only FN1-ALK produced significantly more colonies than the  
ALK Fusion Variant 
Protein 
Length
#
 
(predicted 
MW) 
Tumor 
Types 
Reported 
Subcellular 
Localization 
Reported function of the 5’ fusion partner 
FN1-ALK
18
 
1799 
(198kD) 
IMT
8
, 
Ovarian
18 
Plasma membrane, 
Cytoplasmic
18 
Fibronectin, FN1: glycoprotein found in a 
dimer or multimer at the cell surface and in 
extracellular matrix
23
. 
KIF5B-ALK
19
 
1481 
(163kD) 
NSCLC
19
, IMT* 
Cytoplasmic
19
 
Kinesin Heavy Chain, KIF5B: microtubule-
dependent motor involved in distribution of 
mitochondria and lysosomes and regulation of 
centrosome and nuclei
24
. 
RANBP2-ALK
8
 
1427 
(157kD) 
IMT
8
, 
DLBCL
25
 
Nuclear periphery, 
Cytoplasmic
26
 
Ran Binding Protein, RANBP2: large 
scaffold and mosaic cyclophilin-related 
nucleoporin involved in the Ran-GTPase 
cycle
27
. 
TFG-ALK
8
 
800 
(88kD) 
NSCLC
28
 
IMT
8
, 
ALCL
29
, 
PTC
30
 
Cytoplasmic
31
 
Tyrosine Kinase Fused Gene, TFG: localizes 
to the endoplasmic reticulum (ER) exit sites 
and modulates ER export.
32
 May function at the 
ER/ERGIC interface to concentrate COPII-
coated vesicles and link exit sites on the ER to 
ERGIC membranes.
33
 Inhibitory regulator of the 
ubiquitin-proteasome system
34
. 
PRKAR1A-ALK
8
 
727 
(80kD) 
IMT
8 
Cytoplasmic* 
Protein Kinase A Type 1 Regulatory 
subunit, PRKAR1A: dissociated from the 
inactive holoenzyme upon cAMP binding
35,36
. 
EML4-ALK V1
21
 
1057 
(116kD) 
NSCLC
21 
Cytoplasmic
37
 
Echinoderm Microtubule Associated 
Protein-Like 4, EML4: WD-repeat protein 
possibly affecting microtubule formation and 
dynamics
38
. 
EML4-ALK V3b
20
 
781 
(86kD) 
NSCLC
20
 Cytoplasmic
37
 
Echinoderm Microtubule Associated 
Protein-Like 4, EML4: WD-repeat protein 
possibly affecting microtubule formation and 
dynamics
38
. 
Table 3.2: Properties of the ALK fusion variants described in this study. This table details the ALK fusions chosen for 
this study, published functions of the 5’ partner protein, protein length, expected molecular weight, cancers in which the fusion 
variant has been reported, and published subcellular localization of the ALK fusion protein. Genomic breakpoints used to 
synthesize the cDNA’s that generate these proteins came from literature reports and are cited in the ALK Variant column. 
#
Protein length represented as the number of amino acids. *Data from findings in this study. 
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other fusions (Fig. 3.3B). Like ALK F1174L, FN1-ALK retains the trans-membrane domain of ALK 
(Fig. 3.1) – due to an alternative breakpoint within the ALK locus - and exhibits similar doubling time 
(data not shown), yet FN1-ALK forms significantly more foci and more colonies in soft agar than ALK 
F1174L, suggesting that properties belonging to FN1 specifically are likely responsible for this 
hyperactive phenotype. These findings reaffirm the hypothesis that the 5’ fusion partner plays a role 
in oncogenic properties.   
 
 
ALK fusion variants exhibit differential response to ALK tyrosine kinase inhibition 
Previous retrospective clinical studies have suggested that tumors harboring different ALK fusion 
variants may display different responses to ALK TKI therapy13-15. It is unclear from a biochemical 
perspective why this is the case since each ALK fusion protein contains the entire ALK tyrosine 
kinase domain, and all of the ALK TKIs in clinical use function as ATP mimetics. The efficacy of ALK 
TKIs against different ALK variants, differing only by the 5’ fusion partner, has not been directly 
compared in vitro. We generated eight-point dose response curves to evaluate the efficacy of 
crizotinib, the first FDA-approved ALK TKI, against each ALK fusion variant. 3T3 cells stably 
A B 
P<0.0001 
NS 
C
o
lo
n
y
 N
u
m
b
e
r 
P<0.0001 
Figure 3.3. ALK fusion variants confer differential transformation ability. (A) ALK variant 3T3 cell line models were seeded 
in triplicate at 4000 cells per well in 24 well dishes and allowed to grow for 8 days. Using the Incucyte ZOOM, 16 images were 
obtained daily for each well. The number of foci present at day 8 is represented. Experiments were repeated three times. (B) 
ALK variant 3T3 cell line models were seeded in triplicate atop a 0.5% solid agar layer in complete media containing 0.3% agar 
at 5000 cells/well in 6 well plates and allowed to grow for 6 weeks. Colonies were counted using the GelCount machine. Data 
represented are the number of colonies at week 6. Experiments were repeated three times. Note: all 3 replicate experiments are 
represented in both A and B. 
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transduced with empty vector, full length WT ALK receptor, or full length ALK receptor encoding 
known activating mutation, F1174L, were used as controls. We observed a dose dependent decrease 
in cell viability across all cell lines (Fig. 3.4A, Supplementary Fig. S3.3). However, we noted that the 
efficacy of crizotinib was not uniform across all fusions tested. To verify on-target effects of crizotinib, 
we assessed ALK auto-phosphorylation by immunoblot (Supplementary Fig. S3.3). We calculated 
IC50 values for crizotinib against each ALK variant cell line and found a > 5 fold difference in 
responsiveness (Fig. 3.4C). Cells expressing TFG-ALK exhibited the lowest IC50 (87.36 nM), while 
cells expressing PRKAR1A-ALK exhibited the highest IC50 (461.8 nM) (Fig. 3.4A, C). 
To determine if this was a drug class effect, we also investigated the efficacy of second generation 
ALK TKIs, alectinib and ensartinib, as well as the third generation ALK TKI, lorlatinib (Fig. 3.4B, 
Supplementary Fig. S3.3, Supplementary Table S3.3). These inhibitors are known to be more 
potent against the target (ALK) compared to the first generation ALK TKI,crizotinib42-44. Notably, there 
was a >10 fold difference in IC50s across the fusions for second and third generation ALK TKIs and 
less efficacy against the empty vector control cells. When comparing across inhibitors, PRKAR1A-
ALK was consistently the least sensitive fusion (highest IC50 values) to all 4 distinct ALK TKIs 
evaluated. However, we noted that the order of fusion sensitivity did not remain consistent for the 
other 6 ALK fusion variants (Fig. 3.4C). For instance, KIF5B-ALK was highly sensitive to ensartinib 
(IC50 24.3 nM) but was one of the least sensitive fusions to crizotinib (IC50 405.1 nM) and lorlatinib  
(IC50 89.1 nM). These data support the hypothesis that drug efficacy is influenced by the specific 
fusion partner present and also highlight the importance of selecting the “right” ALK inhibitor for each 
fusion. 
 
Tyrosine kinase activity of ALK fusion variants 
Many structural and biochemical properties of the fusion proteins have the potential to contribute to 
differences in response to ALK TKIs that we observed (Fig. 3.4), including 
dimerization/oligomerization, intrinsic kinase activity, and protein stability. Previous studies have 
shown that the fusion partner contributes a dimerization domain to assist in auto-activation of the 
kinase. For example, EML4 contains a coiled-coiled domain in the N-terminus, and when this coiled-
coil domain is abrogated through mutation, the resultant EML4-ALK fusion loses transforming 
properties21. Many fusion partners contain coiled-coil domains or other known dimerization domains; 
however, not all fusion partners have an obvious dimerization motif. Similar to other tyrosine kinases, 
phospho-ALK to total ALK ALK must dimerize to auto-activate and signal downstream21,45,46. Pathway 
analysis of the RPPA data, comparing WT ALK to each ALK fusion variant or ALK F1174L 
individually, revealed significant up-regulation of the RAS/MAPK pathway in FN1-ALK, KIF5B-ALK, 
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Figure 3.4. ALK fusion variants exhibit differential response to ALK TKIs. NIH 3T3 cells expressing the indicated ALK 
variants were   treated with increasing concentrations of crizotinib (A) or lorlatinib (B) for 72 hours. Propidium iodide (PI) and 
Hoechst 33342 were added and allowed to incubate for 20 minutes before imaging on the ImageXpress. Dose response curves 
were generated by determining total live cells (# of Hoechst positive cells minus # of PI positive cells) at each dose of ALK TKI. A 
non-linear regression of the data is represented here. Experiments were performed with 6 replicates per drug concentration and 
repeated three times. One representative experiment is shown here. (C) IC50s with 95% confidence intervals were generated 
with the data from the dose response curves (in 3A,B, S3A, B) using GraphPad Prism. 
RANBP2-ALK, and ALK F1174L (Supplementary Table S3.4). When assessing the auto-
phosphorylation site of ALK, a surrogate for enzymatic activity of the ALK tyrosine kinase domain, we 
observed differences in the ratio of from one fusion to the next (Fig. 3.5A). Interestingly, those 
variants, which exhibited a pALK/ALK ratio of 0.5 or greater, also had significant RAS/MAPK pathway 
activation (Supplementary Table S3.4).  
 
It is currently unknown if different fusions vary with respect to kinase activity, but structural differences 
between the various 5’ partners, including the oligomerization domains (Fig. 3.1), could alter the 
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dimerization ability and therefore activation dynamics of the fusion and/or accessibility of the catalytic 
domain in ALK.  To further evaluate relative kinase activity, we immunoprecipitated the ALK fusions 
and measured the enzymatic activity against an exogenous peptide substrate, using previously 
validated assays14,17. Controlling for the amount of protein immunoprecipitated, we calculated the 
kinase activity for each variant relative to WT ALK (Fig. 3.5B, Supplementary Fig. S3.4). As 
expected, the known activating mutation, ALK F1174L, exhibited two-fold greater kinase activity 
compared to WT ALK. We also observed that all 7 ALK fusion proteins possessed in vitro kinase 
activity, albeit to different extents. RANBP2-ALK and KIF5B-ALK exhibited the highest relative 
activity; approximately 5 fold greater than the activity of WT ALK. These results are notable because 
the portion of ALK in each of these fusion proteins is the same, with the exception of FN1, which 
contains the ALK trans-membrane domain in addition to the ALK kinase domain and C terminus. 
Interestingly, kinase activity towards an exogenous substrate (Fig. 3.5B) did not directly correlate with 
ALK auto-phosphorylation ratios (Fig. 3.5A). 
 
Stability of ALK fusion proteins 
Next, we sought to evaluate the stability or turnover rates of the seven distinct ALK fusions47. We 
performed a time course study to assess fusion protein stability by treating cells with cycloheximide to 
inhibit new protein synthesis. We observed marked differences in the turnover rates of the various 
ALK fusion proteins (Fig. 3.5C). Levels of EML4-ALK V3, PRKAR1A-ALK, and TFG-ALK did not 
decrease over the cycloheximide time course. In contrast, KIF5B-ALK, FN1-ALK, RANBP2-ALK, and 
EML4-ALK V1 all showed a time dependent decrease in ALK protein levels, with KIF5B-ALK having 
the highest turnover rate. To ensure that the rapid degradation of KIF5B-ALK and FN1-ALK was not a 
result of cytotoxicity, we performed the experiment with shorter time intervals. As expected, we saw a 
gradual decrease in total ALK over time (Supplementary Fig. S3.5A). Overall, we were able to 
confirm a negative correlation between kinase activity and protein stability at 16 hours post 
cycloheximide treatment (Supplementary Fig. S3.5B). While we observed a negatively correlative 
pattern between protein stability and crizotinib sensitivity, it did not reach statistical significance 
(Supplementary Fig. S3.5C).  
 
Previous studies have shown EML4-ALK to be a client of Heat Shock Protein 90 (HSP90), and 
HSP90 inhibitors have been in clinical trials for ALK fusion NSCLC48. In light of our cycloheximide 
results, we thought the FN1-ALK, KIF5B-ALK, and RANBP2-ALK may show significant sensitivity to 
HSP90 inhibition. Therefore, we challenged our cell lines with ganetespib, an HSP90 inhibitor in 
clinical use. Surprisingly, only EML4-ALK variant 1 and 3 were sensitive to HSP90 inhibition 
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(Supplementary Fig. S3.5D). This suggests that the instability or turnover of FN1-ALK, KIF5B-ALK, 
and RANBP2-ALK may not be due to difficulties in protein folding. 
 
3.5 Discussion 
 
While clinical results with ALK TKIs are promising, more granular data is needed to increase 
 
Figure 3.5. ALK fusion variants exhibit differences in kinase activity and protein turnover. (A) Lysates from the ALK 
Variant 3T3 cell line models were run out by SDS-PAGE and blotted for pALK (Y1604), total ALK, and actin. Membranes were 
visualized using the LiCor Odyssey and quantified with iMageStudio Lite. The pALK and ALK signals were normalized to the 
actin in the corresponding lane. The respective pALK/ALK ratios are shown below each lane. (B) Kinase assays were 
performed in triplicate for each ALK variant. ALK variants were immunoprecipitated from the 3T3 cell line model lysates using a 
polyclonal ALK antibody (Cell Signaling) and Sepharose A beads. An additional aliquot of the immunoprecipitated product was 
run on SDS-PAGE for quantification of total ALK per sample. Kinase activity was determined using a standard curve provided 
with the assay. Activity was normalized to the total ALK immunoprecipitated. Represented is the expression-normalized activity 
relative to the WT ALK control. Experiments were performed three times. One representative experiment is shown here. (C) 
ALK variant expressing 3T3 cell line models were treated with 50ug/mL of cycloheximide for 2, 8, 16, or 24 hours. Lysates were 
run on SDS-PAGE and probed for total ALK (Cell Signaling). Percent ALK remaining in each sample compared to the vehicle 
control treated sample is depicted below each respective lane. NOTE: Quantifications for FN1-ALK and ALK F1174L include 
both the high and low molecular weight bands. Experiments were repeated three times. Once representative experiment is 
shown here. 
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therapeutic precision. Studies involving point mutations in the ALK kinase domain that confer 
resistance to ALK TKI therapy have revealed that different point mutations confer varying degrees of 
sensitivity and resistance to the numerous ALK TKIs in clinical use49. However, our understanding of 
how the 5’ partner protein plays a role in therapeutic response is lacking. As next-generation 
sequencing technologies continue to come to the forefront of clinical diagnostics, clinicians will not 
only know the mutational status of the ALK kinase domain but also the 5’ partner involved in the 
fusion. Therefore, it is vital that we lay the foundation for determining the therapeutic implications of 
the 5’ protein.  
 
Our studies demonstrate that the 5’ partner affects the biochemical and cellular properties of the ALK 
fusion protein, including kinase activity, protein stability, transformative potential, and – importantly – 
response to ALK TKIs. For example, FN1-ALK exhibited the greatest ability to form foci and colonies 
in soft agar. Of note, FN1-ALK is the only ALK fusion studied which retains the ALK trans-membrane 
domain (Fig. 3.1). However, it is unlikely that the retention of this domain alone results in increased 
colony formation because the full length ALK receptor harboring the constitutively active F1174L 
mutation retains the ALK trans-membrane domain but did not display the same level of transformative 
ability. Two cases of EML4-ALK fusions, which retain the trans-membrane domain, have been 
reported50,51. Given that EML4 is not a secreted protein with known extracellular interactions38, it is 
unknown how this non-canonical breakpoint may affect transformation in this case.   
 
In our biochemical analyses, we identified fusions which exhibited more rapid protein turnover than 
others, yet these data did not correlate with sensitivity to HSP90 inhibition. We noted that the fusions,  
which exhibited the shortest half-life (KIF5B-ALK, FN1-ALK, RANBP2-ALK, and EML4-ALK V1), also 
had the highest kinase activity. While ALK trafficking biology is not completely understood, especially 
in the context of ALK fusions, it is known that many RTKs will turnover upon activation. One study of 
the full length ALK receptor has shown that ALK undergoes lysosomal degradation upon activation 
rather than receptor recycling52. This could be a potential explanation for the differential degradation 
times of the fusions. 
 
Furthermore, we evaluated the efficacy of four distinct and clinically relevant ALK TKIs across the 
seven fusion variants. At present, the assumption in the field remains that since all ALK fusion 
proteins retain the entire ALK kinase domain, that the efficacy of ALK TKI therapy will be analogous  
across all the fusions. However, our data point to a different conclusion. We consistently noted a 5-10 
fold difference in the measured IC50 value for the four ALK TKIs – crizotinib, alectinib, ensartinib, and 
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lorlatinib – against the seven distinct fusions tested, supporting our hypothesis that the 5’ partner 
protein can affect response to ALK inhibition (Fig. 3.4A, Supplementary Fig. S3.3). Indeed, IMT 
patients harboring the RANBP2-ALK fusion, which is less sensitive to ALK TKI in our study, also 
seem to exhibit more aggressive disease and less sensitivity to ALK TKI therapy26,53. There are many 
structural and biochemical properties of the fusion proteins which have the potential to contribute to 
differences in response to ALK TKIs, including: 1) the type of oligomerization domains present; 2) the 
stoichiometry of oligomerization: dimers,54 trimers,37,55 and multimers56,57; 3) the intrinsic kinase 
activity of the fusion protein17; 4) protein-protein interactions, which may differ based on the domain 
structure of the fusion partner; 5) length of the 5’ partner; 6) protein folding, tertiary structure, and 
degree of disorder; and 7) protein stability. Additional in silico modeling coupled with rigorous model 
systems will be necessary to dissect these critical issues. 
 
Kinase fusions are known to localize differently based on the 5’ partner (Table 3.1) even for those, 
which share the same 5’ partner (and therefore promoter) but vary in the amount of that protein 
present in the fusion, such as the EML4-ALK variants37,58. This could allow for different protein 
interactions. Differential pathway activation based on ALK localization has been shown in Medves et 
al. 2011. Additionally, in Armstrong et al. 2004 where investigators explored phenotypes of 5 different 
ALK fusions in NIH 3T3 cell lines, differences in pathway activation were also seen. Our RPPA data 
clearly shows significant changes in total and phospho-protein expression profiles when an active 
ALK variant is expressed (Figure 3.2) and also shows expression differences between the ALK 
variants (Figure 3.2, Supplementary Figure S3.2, and Supplementary Tables 3.2-3.3). The RPPA 
data was revisited throughout the study in search for insight into to different phenotypes assessed. 
The only correlation that we found was that those variants, which exhibited a pALK/ALK ratio of 0.5 or 
greater, also had significant RAS/MAPK pathway activation. While the RPPA panel at the MD 
Anderson core includes many of the most highly implicated cancer associated proteins, the panel is, 
by definition, limited in scope. Therefore, if there are other proteins (or additional phosphorylation 
sites) that are playing important roles in the phenotypes reported in this study, they may be missed. 
There is also a similar bias in the pathway analysis pipeline in that there are pathways defined that 
are mostly confined or well understood in other adult solid tumors such as breast cancer. This  
pathway analysis pipeline also does not include pathway definitions for other important cancer 
phenotypes such as migration/metastasis and metabolism.  
 
Finally, we noted that the relative sensitivity (in terms of ranked IC50 value) of a given fusion was not 
consistent across all inhibitors tested. For example, while KIF5B-ALK was one of the least sensitive 
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fusions towards crizotinib, this same fusion was one of the most sensitive towards ensartinib (Fig. 
3.1C), suggesting that drug selection may necessitate knowledge of the specific fusion partner in 
order to select the most efficacious inhibitor amongst the several FDA-approved or investigational 
ALK TKIs in clinical use (Supplementary Table S3.3). In support of these data, two recent 
retrospective clinical analyses have shown that NSCLC patients whose tumors harbor different 
EML4-ALK fusion variants – defined by the amount of EML4 contained within the fusion (the ALK 
portion is the same) – experience different responses upon treatment with distinct ALK TKIs. In one 
study, NSCLC patients with tumors harboring EML4-ALK variant 3a/b exhibited longer progression 
free survival (PFS) when treated with lorlatinib compared to patients whose tumors harbored EML4-
ALK variant 1. However, the reciprocal responses where observed with crizotinib15. Overall, our data, 
coupled with this retrospective clinical data, support the need for further prospective investigation 
regarding the role of the 5’ fusion partner in dictating therapeutic response.  
 
Adding to the complexity, greater than 30 different 5’ fusion partners have been reported for ALK 
fusions alone (Fig. 3.6). Furthermore, several oncogenic tyrosine kinase fusions have been reported 
in solid tumor and hematologic malignancies, including ROS1, RET, and NTRK1, amongst others5, 
and the 5’ fusion partners can overlap between these different kinases (Fig. 3.6). For example, TFG 
has been a reported 5’ partner for ALK, ROS1, and NTRK fusions8,59. It is not feasible to extensively 
study each kinase fusion in the laboratory. To approach this complex problem, a high-throughput, 
computational approach to assess the effect of the 5’ protein on the kinase and how it may alter drug 
binding could be greatly beneficial. Interestingly, a recent study in RET-rearranged NSCLC reported 
that patients harboring the KIF5B-RET fusion exhibited significantly less sensitivity to RET inhibition 
than patients harboring other RET fusions60. In our study KIF5B-ALK was also one of the least 
sensitive ALK fusions to crizotinib and lorlatinib. Given that KIF5B reduced the response for both the 
ALK and RET kinase fusion, we may be able to make conclusions about the effects of a 5’ partner 
that can be applied across multiple kinase fusions such as ALK, RET, ROS1, and NTRK1/2/3.  
 
Current limitations in this study include the lack of clinical data to corroborate our findings. This is 
partly due to the lack of reporting of the specific fusion variant including the 5’ partner in clinical 
studies. Additionally, studies that may report the specific variants, such as Drilon et al. 2018, may not 
be statistically powered to compare outcomes based on the variant. In order to fill this gap in 
knowledge, the design of future clinical trials will need to include prospective analysis of the specific 
fusion variants. 
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In summary, our findings contribute to the preliminary studies in the emerging field of fusion biology, 
adding further evidence that the 5’ partner of kinase fusion variants plays a significant role in the 
biological functions of the fusion that can affect cellular phenotypes and response to targeted 
therapies. Future clinical trials will need to prospectively consider ALK TKI efficacy in terms of the 
fusion partner present upon enrollment into the trial. Furthermore, given the large number of possible 
fusion variants that may be detected in the clinic, high-throughput computational and modeling 
studies will be necessary in order to support therapeutic decision-making. 
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Chapter 4 
DISCUSSION AND FUTURE DIRECTIONS 
4.1 Overview 
The final chapter is divided into three sections: the first is focused on Inflammatory Myofibroblastic 
Tumor (IMT); the second is focused on the study of oncogenic kinase fusions with an emphasis on 
Anaplastic Lymphoma Kinase (ALK) fusions, and the third is reserved for concluding remarks. 
Sections will discuss remaining questions in the field and future directions of the studies described in 
chapters 2 and 3.  
 
4.2 Inflammatory Myofibroblastic Tumor 
 
IMT Biology 
There are several challenges in studying rare tumor types, and this often results in large gaps in 
understanding of the biology behind the disease. IMT is no exception. One obstacle that slows down 
research progress in IMT is the lack of an appropriate model system. To date, there are no published 
patient derived IMT cell lines or mouse models. This creates a challenge in understanding IMT 
biology as well as testing potential therapeutics pre-clinically. There are two big questions which pose 
as obstacles for developing a valid model: 1) What is the cell of origin for IMT? and 2) What is the role 
of the inflammatory infiltrate in this tumor? To begin to determine the cell of origin, we can use 
genomic and whole transcriptome data to give us insight into cell type and pathogenesis. Hypotheses 
can begin to be made regarding the cell type based on known tumor histology including positive or 
negative diagnostic markers and transcriptome data. Then known oncogenic drivers in IMT, such as 
ALK fusions, or other kinase fusions (in addition to tumor suppressor mutations such as mutant p53) 
can be used to initiate transformation in these cell types in mice. Similar approaches have been used 
to determine the cell of origin for other soft tissue sarcomas, such as rhabdomyosarcoma1.  
 
With an appropriate IMT mouse model, the role of the inflammatory infiltrate can then be studied. We 
may also approach learning about the inflammatory/tumor relationship by sorting tumor cells from the 
inflammatory cells in fresh tissue samples. Once sorted, RNA sequencing and/or proteomic profiling 
can be performed on the cohorts separately to give us a view of their distinct expression profiles. 
Additionally, experiments evaluating the effects of combining the cells in culture can be performed to 
learn more about their interactions and relationship. Since we don’t currently know the role of the 
inflammatory cells in IMT, models systems which exclude this cell type such as cell lines and PDX, 
may produce questionable results for testing therapeutics. However, given the natural role of 
 76 
myofibroblasts2,3, it is possible that IMT is the result of wound healing gone astray. Since we know 
that the majority of these tumors are driven by oncogenic kinase fusions and that the tumors typically 
demonstrate significant regression upon treatment with a kinase inhibitor 4, the inflammatory infiltrate 
may have little to do with driving tumor progression and more to do with promoting tumor initiation. In 
this case cell line models and PDX models may be well suited for initial pre-clinical drug testing.  
 
Treatment Paradigms 
Increasing data supports the conclusion that Inflammatory Myofibroblastic Tumor (IMT) is a kinase 
fusion driven disease with ~85% of cases harboring a rearrangement in kinases ALK, ROS1, 
PDGFRB, RET, or NTRK35-7. Fortunately, all of these kinases are therapeutically targetable with 
tyrosine kinase inhibitors (TKIs) currently in clinical use. Patients with ALK positive IMTs have been 
successfully treated with the ALK TKI, crizotinib, in clinical trials4,8. Response to crizotinib (which 
incidentally also targets ROS1) in ROS1 positive IMTs has also been reported5. The positive 
response to TKIs in this disease highlights the importance of using next generation sequencing 
(NGS) diagnostic tools to identify effective therapies for IMT patients. Since there are no TKIs with 
FDA approval for use in IMT, patients must be granted compassionate use of the agent. The 
increased presence of ‘basket trials’ that enroll patients based on molecular profile vs. cancer type 
give hope for the approval of such agents in rare cohorts of patients such as these. 
 
While the identification of kinase fusions in such a large percentage of IMTs significantly changes the 
repertoire of effective therapeutic options, we are still left with few rational therapies for the fusion 
negative cohort. Our studies have shown that IMTs, regardless of fusion status, harbor mutations 
affecting chromatin remodeling and the Vascular Endothelial Growth Factor (VEGF) pathway. 
Myofibroblasts are naturally involved in wound healing, and IMTs tend to be very large tumors2,3,9,10. 
Both of these characteristics require increased angiogenesis, supporting the validity of these data. 
Fortunately, VEGF is also targetable with agents in current clinical use. For clinical utility, it would be 
helpful to identify histological biomarkers that indicate high VEGF activity to allow for therapy 
selection or patient stratification. Such a biomarker could be used to construct a clinical trial for the 
use of VEGF TKIs in IMT.  Interestingly, the histone deacetylase inhibitor, valproic acid, has also 
shown anti-angiogenic properties in addition to its epigenetic regulation11, making it an attractive drug 
candidate.  
 
Within kinase fusion positive IMTs, additional therapeutic questions remain. As more and more 
patients are treated with TKIs, it is likely that we will need to address mechanisms of acquired 
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resistance to therapy. ALK TKI resistant IMTs have already been reported12,13. Additionally, there is 
the question of efficacy of a TKI against different fusion variants defined by the 5’ fusion partner 
present.  Evidence in non-small cell lung cancer (NSCLC) suggests TKIs are differentially efficacious 
against fusions variants that differ by the 5’ partner14-17. Kinase fusions in IMT are even more diverse 
than NSCLC5. In our own studies alone, we have identified 17 different ALK fusion variants that differ 
by the specific 5’ protein (such as TFG-ALK vs. RANBP2-ALK) or by various lengths of the same 5’ 
protein, such as the 4 FN1-ALK variants described in chapter 2. Addressing these gaps in knowledge 
can be a challenge as the study subjects of interest, fusion negative and therapy resistant, are small 
cohorts within an already rare disease. Success will require locking arms in collaboration with 
researchers and physicians in multiple institutions in order to obtain enough samples or prospectively 
monitor enough patients to draw confident conclusions. 
 
4.3  ALK Fusions 
 
Discussion and Unpublished Results 
All ALK fusion proteins described to date contain the entire ALK tyrosine kinase domain, and since 
ALK tyrosine kinase inhibitors (TKIs) are ATP mimetics, one might anticipate the drug efficacy to be 
similar from one fusion to the next. However, retrospective analyses of clinical data suggest that 
progression free survival differs based on the ALK fusion variant present, where the variant is defined 
by the presence of a specific 5’ partner gene. While our studies have corroborated this notion, a 
thorough mechanistic explanation of differential sensitivity is still lacking. There are many structural 
and biochemical properties of the fusion proteins which have the potential to contribute to differences 
in response to ALK TKIs, including: 1) the type of oligomerization domains present; 2) the 
stoichiometry of oligomerization: dimers, 18 trimers, 19,20and multimers21,22; 3) the intrinsic kinase 
activity of the fusion protein23; 4) protein-protein interactions, which may differ based on the domain 
structure of the fusion partner; 5) length of the 5’ partner; 6) protein folding, tertiary structure, and 
degree of disorder; 7) subcellular localization; and 8) protein stability. 
 
Data from Armstrong et al. 200424 and Armstrong et al. 200725 suggest that the ALK fusion may 
interact with the wild-type 5’ partner protein. This is certainly another factor to consider. This 
interaction may alter the normal processes in which the wild-type 5’ partner is involved which can 
have numerous effects on the cell including those that may affect drug efficacy. For example, it is 
possible that this interaction could result in a dominant negative effect, binding up a large portion of 
the WT 5’ partner and disabling its function. For a protein such as PRKAR1A, which was included in 
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our study, this may result in a disruption in PKA signaling since PRKAR1A is a part of the PKA 
holoenzyme and regulates its activity. Interestingly, total PKA and its activating phospho-protein sites 
(AMPKα pT172, AMPK-α2 pS345), which are on the RPPA panel we performed, were not 
significantly changed in the PRKAR1A-ALK cell line. However, the RPPA data did reveal that the 
mTOR pathway was significantly down-regulated in this cell line exhibiting a fold change = |57| (Table 
S3.4), and PRKA, located upstream of mTOR, is known to have an inhibitory effect on mTOR 
activity26. Since the RPPA pathway analysis is restricted toward particular pathways, I decided to 
interrogate the list of proteins showing significantly different expression between the PRKAR1A-ALK 
and WT ALK NIH 3T3 cell line models (Table S3.2) using WebGestalt27 over representation 
enrichment analysis to identify other pathway associations. Indeed, the AMPK (PRKA) signaling 
pathway is in the top three enriched categories (Table 4.1). The significant disruption of the mTOR 
and AMPK pathways could explain why the PRKAR1A-ALK cell line was a consistent outlier in our 
study. The endogenous role of 5’ partner proteins in regulation of other critical pathways will be 
important to consider moving forward. 
 
Category Name 
Observed # 
of Genes 
Expected # 
of Genes FDR 
HIF-1 signaling pathway 8 0.43 1.72E-06 
mTOR signaling pathway 7 0.64 3.50E-04 
AMPK signaling pathway 6 0.52 9.53E-04 
EGFR tyrosine kinase inhibitor resistance 5 0.34 1.34E-03 
Longevity regulating pathway 5 0.39 2.22E-03 
Endocrine resistance 5 0.41 2.24E-03 
AGE-RAGE signaling pathway in diabetic complications 5 0.42 2.24E-03 
Glioma 4 0.27 3.76E-03 
Proteoglycans in cancer 6 0.84 3.76E-03 
 
Armstrong et al. 2004 also demonstrated that the fusions were differentially able to activate PI3K and 
JAK-STAT signaling. Furthermore, the ability of the different ALK fusions to activate PI3K kinase 
Table 4.1: Enriched Categories from the Differentially Expressed Proteins between the PRKAR1A-ALK NIH3T3 Cell Line 
and the WT ALK NIH3T3 Cell Line. 
The table exhibits the enriched categories (determined by KEGG analysis) represented in the differentially expressed proteins 
between PRKAR1A-ALK expressing NIH3T3 cell lines and WT ALK expressing NIH3T3 cell lines (from table S3.2). The observed 
number of genes in this differential gene set that occurred in the category is listed under “Observed # of Genes”, and the expected 
number of genes observed for any given gene set that is interrogated is listed under “Expected # of Genes”. The FDR is the 
Benjamini-Hochberg FDR. 
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activity correlated with the fusion’s transendothelial migration properties. However, migratory data 
studied in this context must be applied with care. This cellular phenotype and its relation to tumor 
metastasis are not directly applicable due to the high dependency of metastasis on cell/tumor type. 
For example, these same fusions also occur in IMT, which rarely has distant metastasis5,28,29. Further, 
those that do experience distance metastasis are usually ALK negative28,29. From our published 
data29 it does not appear that signaling differences between the fusions in our study correlate with 
transformative potential (foci or colony formation), and we did not assess migration. Cellular 
phenotypes such as metastasis and migration would more appropriately studied in the endogenous 
expression setting, ideally under the native promoter and cancer cell/tissue type.  
 
In our published work30, we identified a 
negative correlation between fusion kinase 
activity and fusion protein turnover. To 
determine if the rapid turnover rate of 
KIF5B-ALK is a phenotype intrinsic to the 
fusion protein or conferred by the 5’ 
partner, I performed a time course study to 
assess the stability of the fusion protein as 
well as the wild type 5’ protein by treating 
cells with cycloheximide to inhibit new 
protein synthesis. In contrast to the KIF5B-
ALK fusion protein, which exhibits a half-
life of approximately 2 hours, protein levels of wild type KIF5B did not decrease over the 
cycloheximide time course (Figure 4.1). Based on our data regarding protein turnover and kinase 
activity, in addition to the findings in previous studies of EML4-ALK variant 1, which is a fusion 
between exon 13 of EML4 and exon 20 of ALK, and EML4-ALK variant 3, which is a fusion between 
exon 6 of EML4 and exon 20 of ALK20,32, we suspect that the explanation of differential sensitivity is 
related to the intrinsic structural and biochemical properties of the fusion protein itself, which 
contribute to kinetic activity and protein stability. These in turn may then affect the ability of a fusion to 
activate particular signaling pathways more than others, such as the RAS/MAPK pathway activation, 
which we’ve shown to be more highly active in cell lines harboring fusions that have greater kinetic 
activity and protein stability. One additional, plausible explanation for why differences in protein 
expression and phospho-protein profiles are seen is that these fusions may each interact with 
different proteins and pathways. These fusions localize differently based on the 5’ partner, even for 
Figure 4.1 KIF5B-ALK is Less Stable Than Wild Type KIF5B 
NIH 3T3 cells stably expressing KIF5B-ALK were treated with 
50ug/mL of cycloheximide for 2, 8, 6, or 8 hours. Lysates were run 
on SDS-PAGE and probed for total ALK, KIF5B, and Actin.  
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those that share the same 5’ partner but vary in the amount of that protein present in the fusion, such 
as the EML4-ALK20,32 fusion variants. This could allow for different protein interactions.  Differential 
pathway activation based on ALK localization has also been shown in previous studies19,24,31. 
 
We have assessed the subcellular localization of the ALK fusions studied in chapter 3 by ALK 
immunofluorescence (IF). We noted that some fusions appeared to aggregate or form puncta, such 
as FN1-ALK, KIF5B-ALK, TFG-ALK, and PRKAR1A-ALK, while others were more diffusely 
cytoplasmic (Figure 4.2). Based on the pattern of fluorescence and studies reporting on wild type 
ALK and ALK F1174L localization33 or localization of the wild type 5’ proteins, I hypothesize that FN1-
ALK is aggregating in the endoplasmic reticulum and compartments of the golgi apparatus along with 
the plasma membrane; and KIF5B-ALK is localizing to the centrosome. Further co-localization studies 
are needed to test these hypotheses and to identify any correlation to downstream pathway 
activation. Overall, there are many cellular and structural factors that have the potential to play a role 
in the response to ALK TKIs. This results in an explanation that is likely multifactorial and potentially 
different for each fusion.  
Figure 4.2: ALK Immunofluorescence in NIH 3T3 Cells Stably Expressing ALK Variants. 
ALK subcellular localization was assessed in NIH 3T3 cells expressing the indicated ALK variants using mAb ALK D5F3 and Alexa-
fluor-549 fluorochrome conjugated secondary antibody. Dapi stain was used for nuclear detection. Cells were imaged using a 
LSM710 Meta inverted confocal microscope at 63x. A 20μm scale bar is shown in each image. 
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Ongoing Studies and Future Directions 
Our overall goal is to build a rule set that predicts the best TKI for each fusion. In order to do this we 
must determine the mechanism behind TKI efficacy and identify key factors that predict response to 
variable ALK TKIs. Ideally these factors could be modeled or predicted computationally to allow for 
high throughput evaluation. Previous studies have shown that the fusion partner contributes a 
dimerization domain that is sufficient and necessary for auto-activation of the kinase and 
transformation ability32,34. Many fusion partners contain coiled-coil domains or other known 
dimerization domains; however, not all fusion partners have an obvious dimerization motif. Structural 
differences between the various 5’ partners, including the oligomerization domains, additional 
structured domains present, and the length and/or degree of disorder of the region between the 
oligomerization domain of the 5’ partner and the kinase domain of ALK could alter the dimerization 
ability -the extent in which oligomerization occurs (dimers, trimers, multimers) or the strength of the 
oligomerization- and therefore activation dynamics of the fusion and/or accessibility of the catalytic 
domain in ALK.  
 
In our on-going work, we are 
collaborating with investigators 
within the Vanderbilt Center for 
Structural Biology to gain more 
detailed mechanistic insights into 
the differences in drug sensitivity 
observed amongst the various 
ALK fusion proteins, by attempting 
to generate computational models 
that can predict possible 
oligomerization states of each 
fusion, disordered regions 
between structured domains, as 
well as distances in 3D space and 
flexibility of the “linker” region of 
the fusion protein: the region 
between the oligomerization domain and the kinase domain (Figure 4.3). Using these predictions 
along with wet lab experiments, we hope to generate testable hypotheses regarding how these 
Figure 4.3:  “Linker” Region of EML4-ALK Variants. 
Diagram depicts a simplistic example of the structure of two EML4-ALK fusion 
variants with oligomerization domains and kinase domains represented. Exons 
included for each protein within the fusion variant are stated in the following 
format:  first letter of the 5’ protein and the last exon included in the fusion 
preceding the breakpoint: A (for ALK)and the first exon included in the fusion 
following the breakpoint. For example, for EML4-ALK variant 1 (V1) exons 1-13 
of EML4 and exons 20-29 of ALK are present in the fusion protein; this is stated 
as E13:A20.ALK is represented in dark blue, and EML4 is represented in steel 
blue. The black brackets indicate the “linker” region in question. 
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characteristics may be affecting kinase activity, activation potential of the fusion, and drug sensitivity. 
For example, we may find that fusions with a short and inflexible distance between the 
oligomerization domain and kinase domain all perform equally in terms of kinase activity and/or drug 
sensitivity. We can 
then make 
modifications to these 
fusions to make them 
longer and more 
flexible, or we can 
make longer fusions 
shorter and more 
inflexible to test this 
prediction. In addition, 
we expect that 
geometrical 
constraints imposed 
by a “linker” may 
prevent two kinase 
domains from 
assembling into the symmetric dimer conformation necessary for activation. For example, a “linker” 
that is too long or too rigid may fail to bring kinase domains together into a productive assembly. We 
expect that this property may also be reflective of the sensitivity to ALK TKI’s. For example, the longer 
and more flexible this region is, the less sensitive they may be to inhibition by an ALK TKI due to 
steric interference by the 5’ partner and the protein associations that may come along with it. This 
multipronged approach will be used to build a rule set to classify fusions based on response to ALK 
TKIs (Figure 4.4). 
 
In collaboration with the Jens Meiler laboratory, we began by constructing the predictive structures 
and estimating the effective distances of the linker regions (defined as the region between the 
putative oligomerization domain in the 5’ partner protein and the ALK kinase domain) of the 7 ALK 
fusions discussed throughout chapter 3 (Table 4.2). However, we believe that the best way to begin 
to test this hypothesis, is to first ask the question in a more simple system, controlling for the many 
cellular and biochemical properties that different 5’ proteins introduce into the experiment. 
 
Figure 4.4: Future Directions: Study Approach and Output 
Flow schema depicting the approach to building a rule set that can be used to classify fusions 
based on sensitivity to a TKI that can then be rapidly translated into the clinic. 
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ALK Variant Structural model 
Effective 
Distance 
EML4-ALK V1 
 
830 Å 
FN1-ALK 
 
210 Å 
KIF5B-ALK 
 
210 Å 
PRKAR1A-ALK 
 
250 Å 
RANBP2-ALK 
 
190 Å 
TFG-ALK 
 
580 Å 
EML-ALK V3 
 
800 Å 
ALK F1174L 
 
210 Å 
  Table 4.2: Predictive Structural Models of ALK Fusion Variants and ‘Linker’ Region Lengths 
Computational predictions of the structure of the ALK fusion variants were made using crystal structure data in the Protein Data Bank, 
RaptorX server, and PyMOL. The effective distance represents the maximum distance between the nearest putative oligomerization 
domain and the ALK kinase domain in 3 dimensional space. It was calculated by summing the distance between N- and C-termini of 
all intervening structured domains, and adding the number of unstructured residues multiplied by 3.4 Angstroms, to represent the 
length of a fully extended polypeptide chain. 
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Therefore, further studies will first focus only on naturally occurring variants in which the 5’ partner 
remains the same, differing only by the amount of the protein present, for example, EML4-ALK 
variants 1, 2, 3a/b, and 5a/b or TFG-ALK variants 1, 2, and 4 (Figure 4.5).  One interesting study 
looking at the 
structural 
implications of 
fusion proteins 
describes different 
mechanisms by 
which disorder 
affects oncogenic 
function35. The 
authors describe 
EML4-ALK in 
particular as being 
a ‘special case’ 
when compared to 
other ALK fusion 
proteins such as 
TFG-ALK and 
NPM-ALK due to 
the importance of structural domains beyond the coiled-coil oligomerization domain for oncogenic 
function of the fusion. The various breakpoints within EML4 often disrupt these ordered domains. The 
disruption of ordered domains, that are not highly repetitive, is an odd and unexpected characteristic 
of viable fusion proteins34, and studies have shown that this disruption in EML4-ALK causes problems 
with protein folding and the biology of the fusion such as proper localization20,33. This may explain 
why only the EML4-ALK variants –of all the fusions we tested in our studies- were sensitive to 
inhibition of the chaperone protein, Hsp90. With this in mind further studies should include both 
EML4-ALK and TFG-ALK variants. Since both EML4 and TFG have been reported as ALK fusion 
partners in NSCLC and IMT5, it would be interesting to evaluate these fusions in multiple cellular 
settings, such as AALE and NIH 3T3 cells, to see if the results are cell type dependent. The AALE 
cell line, immortalized normal human lung epithelium, would represent the cellular background for 
NSCLC while the NIH3T3’s, immortalized mouse fibroblast, would represent the cellular background 
for IMT.  
Figure 4.5: Naturally Occurring EML4-ALK and TFG-ALK Variants. 
Schematic displays the most common, naturally occurring variants of EML4-ALK and TFG-ALK in 
cancer. Exons included for each protein within the fusion variant are stated in the following format:  
first letter of the 5’ protein and the last exon included in the fusion preceding the breakpoint : A (for 
ALK)and the first exon included in the fusion following the breakpoint. For example, for EML4-ALK 
variant 1 (V1) exons 1-13 of EML4 and exons 20-29 of ALK are present in the fusion protein; this is 
stated as E13:A20. Oligomerization and kinase domains represented. ALK is shown in dark blue, and 
the 5’ proteins, EML4 and TFG, are shown in steel blue. 
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I hypothesize that there will be categories of different structural mechanisms that affect oncogenic 
function and different classes of fusions within those mechanistic categories. For example, studies of 
the EML4-ALK fusion variants may reveal one structural mechanism, which may be based on fusions 
that survive breakpoint interruptions of ordered domains, and within that mechanism, multiple classes 
of fusions are delineated that correspond with ALK TKI response. Studies of the TFG-ALK variants 
may reveal another structural mechanism, and within that mechanism, multiple classes of fusions 
corresponding with ALK TKI response. These studies may provide the first two “structural, 
mechanistic categories” into which additional fusions may then be assigned.  
 
Extending these studies to the FN1-ALK variants detected in our IMT cases described in chapter 2 
would be an interesting addition since these fusions retain the ALK transmembrane domain and vary 
in the length of FN1 as well as ALK. These would likely add another “structural, mechanistic 
category”. Additionally, two cases of EML4-ALK retaining the ALK transmembrane domain have been 
reported36,37. It would be interesting to compare it determine if it behaves more like the FN1-ALK 
fusions or more like the other EML4-ALK variants.  
 
Similarly, further studies may include the addition of other kinase fusions, particularly those that have 
common 5’ partner proteins with ALK fusions, such as the TFG-ROS1 variants detected in our IMT 
cases in chapter 2. These TFG-ROS1 fusions retain the ROS1 transmembrane domain. Thus, it 
would be interesting to compare its function to the TFG-ALK variants, the naturally occurring ALK 
fusions that retain the ALK transmembrane domain, or a TFG-ALK fusion designed to retain the ALK 
transmembrane domain. 
 
4.4 Concluding Remarks 
 
While clinical results with targeted therapies are promising for kinase fusion positive cancers, our 
studies indicate that it is not sufficient to only consider the kinase when determining the best therapy. 
The non-kinase partner protein affects drug efficacy, and more detailed clinical data and pre-clinical 
investigations are warranted to increase therapeutic precision. To move the needle forward, we must 
address current limitations including the lack of prospective clinical data detailing the specific fusion 
and tissue collection. Prospective clinical data that specifies the 5’ partner protein and kinase in the 
fusion is necessary to corroborate pre-clinical, mechanistic studies. Additionally, the design of future 
clinical trials will need to include prospective analysis of the specific fusion variants and will need to 
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prospectively consider ALK TKI efficacy in terms of the fusion partner present upon enrollment into 
the trial. Furthermore, to progress pre-clinical translational studies, collecting tissue to generate 
patient derived cell line models that harbor different fusion variants are also needed to increase 
accuracy of pre-clinical results. In addition, given the large number of possible fusion variants that 
may be detected in the clinic, it is vital that we determine the mechanisms by which the 5’ proteins 
affect therapeutic response in a way that can be evaluated with high-throughput computational and 
modeling studies, which can then be rapidly translated for therapeutic decision-making. 
 
This is an exciting time for translational cancer research. As the vision of precision medicine 
continues to unfold and NGS technologies continue to come to the forefront of clinical diagnostics, 
there will be an abundance of personalized clinical and genomic data. It is critical that the 
translational science keep up with this pace in order to feed rational information back into the clinical 
system and progress medical treatment in a timely manner. Therefore, it is imperative that basic 
scientists and physicians work together to keep translational science ahead of the curve, collecting 
tissue and clinical data prospectively, and designing rational translational studies that can rapidly re-
inform clinical practice.  
 
4.5  Methods 
 
 
RPPA KEGG Analysis Proteins exhibiting significant differential expression (FC>=|2|, Adj. p-value 
<=0.05) between PRKAR1A-ALK expressing NIH3T3 cells and WT ALK expressing NIH3T3 cells 
were entered as the “Gene List” interrogated using the Web-based GEne SeT AnaLysis Toolkit (Web 
Gestalt). Parameters included: organism of interest = hsapiens; method of interest = 
overrepresentation enrichment analysis (ORA); functional database class = pathway; functional 
database name = KEGG. The reference set for enrichment analysis was ‘genome_protein-coding’.  
http://www.webgestalt.org/results/Project_wg_result1536084351/Report_wg_result1536084351.html 
 
Immunoblot and Antibodies The following primary antibodies were obtained from Cell Signaling 
Technology (Danvers, MA, USA): ALK mAb Mouse (3633S), ALK mAb Mouse (3791S) and ALK 
D5F3 mAb Rabbit (#3633). The KIF5B primary antibody (ab167429, EPR10276(B)) was obtained 
from ABCAM (Cambridge, MA, USA). The actin antibody (A2066) was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). The following secondary antibodies were obtained from LiCor (Lincoln, NE, 
USA): IRDye 680RD Goat anti-Mouse (#92668070), and IRDye 800 Goat anti-Rabbit (#92632211). 
Alexa-fluor549 (A-11032) fluorochrome-conjugated secondary antibody was obtained from Invitrogen 
(Grand Island, NY, USA).For infrared (IR) immunoblot, cells were harvested, washed in PBS, and 
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lysed in KRAS buffer [50 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 1% triton X-100, 0.5% Na Deoxy 
Cholate, 0.1% SDS, 40 nmol/L sodium fluoride, 1mM sodium orthovanidate, and complete protease 
inhibitors (Roche Diagnostics, Indianapolis, IN, USA)]. Signal detection was obtained using the LiCor 
Odyssey scanner system and quantified using iMageStudio Lite software (LiCor). 
 
Protein Stability Assay NIH 3T3 cells stably expressing KIF5B- ALK were seeded in 6 well plates. 
24 hours after seeding, cells were treated with 50μg/mL cycloheximide (Sigma-Aldrich) for 2, 4, 6, or 
8 hours, harvested for lysate, and probed for total ALK protein (Cell Signaling, #3191S), KIF5B 
(ABCAM, ab167429, EPR10276(B)), and actin (A2066) by IR Western blot.  
 
Immunofluorescence NIH 3T3 cell lines stably expressing ALK variants were seeded on 8 chamber 
slides (20,000 cells per chamber) and cultured until nearly confluent. Cells were fixed with ice cold 
100% methanol for 20 minutes at 4°C and washed three times in 0.5% PBST. Cells were incubated in 
blocking buffer [1x PBST, 1% BSA, 0.2% Triton™ X-100] for 30 minutes at room temperature and 
washed 3 times with PBS. Cells incubated in 200μL of diluted ALK D5F3 primary antibody (Dilution: 
1:200) overnight at 4°C. Cells were washed 3 times with PBS and incubated in an Alexa-fluor549 
fluorochrome-conjugated secondary antibody (1μg/mL) dilution in the dark for 2 hours at room 
temperature. Cells were rinsed 3 times with PBS. Chambers were removed, Prolong® Gold Antifade 
Reagent with DAPI and coverslips were applied and sealed. Slides were stored horizontally at 4°C 
with minimal light exposure. Slides were imaged using a LSM710 Meta (Zeiss, Pleasantville, NY, 
USA) inverted confocal microscope. 
 
Molecular Modeling Models of the ALK fusion proteins were generated using crystal structures from 
the Protein Data Bank for proteins and domains of known structure (PDB codes 5fto, 4cgb, 5ojf, 1ipg, 
3im4, 3r8q, 5l73). The RaptorX server38 was used to build models for loops and un-templated 
domains (ALK N-terminus and Gly-rich domains, RanBP2), resulting in models that are unlikely to be 
accurate in atomic detail, but approximately correct in size. Models of each domain were combined in 
an extended arrangement using PyMOL39, and unstructured inter-domain regions were represented 
as flexible loops. The effective distance metric represents the maximum distance between the 
nearest putative oligomerization domain (usually a coiled-coil) and the ALK kinase domain. It was 
calculated by summing the distance between N- and C- termini of all intervening structured domains, 
and adding the number of unstructured residues multiplied by 3.4 Angstroms, to represent the length 
of a fully extended polypeptide chain. 
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APPENDIX 
 
Supplemental Tables 
 
 
Category Term Count P Value Genes 
Fold 
Enrichment 
Bonferroni FDR 
U
p
-r
e
g
u
la
te
d
 
KEGG 
PATHWAY 
hsa04141:Protein 
processing in endoplasmic 
reticulum 
7 1.06E-05 
HSPH1, HERPUD1, XBP1, 
CRYAB, HSPA1A, HSPA1B, 
DNAJB1 
12.44 6.02E-04 0.010 
Biological 
Processes 
GO:1900034~regulation of 
cellular response to heat 
6 1.16E-06 
HSPH1, CRYAB, BAG3, HSPA1A, 
HSPA1B, DNAJB1 
31.24 4.53E-04 0.002 
Biological 
Processes 
GO:0010941~regulation of 
cell death 
4 2.37E-06 
CRYAB, JUND, HSPA1A, 
HSPA1B 
142.00 9.23E-04 0.003 
Biological 
Processes 
GO:1902236~negative 
regulation of endoplasmic 
reticulum stress-induced 
intrinsic apoptotic signaling 
pathway 
4 1.37E-05 
HERPUD1, XBP1, HSPA1A, 
HSPA1B 
82.21 0.005 0.019 
D
o
w
n
-r
e
g
u
la
te
d
 
Biological 
Processes 
GO:0006954~inflammatory 
response 
6 3.84E-05 
CYBB, MYD88, LIPA, LYN, 
S100A9, LGALS9 
13.99 0.012 
0.051 
 
 
Table S2.1: KEGG and GO term enrichment analysis for Differentially Expressed Genes in Pulmonary vs Extra-pulmonary IMT.   
The 74 genes exhibiting significantly different expression in pulmonary tumors vs extra-pulmonary tumors (FC=>|2|, p=<.05) were used for KEGG Pathway and Gene Ontology term 
enrichment analysis. Up-regulated and down-regulated genes were assessed separately. Shown are the analyses results displaying an FDR<=.05. The ‘category’ column references 
the type of test performed. The ‘count’ column displays the number of genes associated with the term that were in the set of differentially expressed genes evaluated. Statistics are 
calculated based on the count and the expected count. 
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Category Term Count P Value Genes 
Fold 
Enrichment 
Bonferro
ni 
FDR 
U
p
-r
e
g
u
la
te
d
 
Biological 
Processes 
GO:0006954~inflammatory 
response 
17 1.35E-06 
C3AR1, LIPA, S100A8, LYN, 
AIF1, HCK, LY86, S100A9, 
LYZ, ITGB2, CCL4, LGALS9, 
MIF, CYBA, CYBB, MYD88, 
PYCARD 
4.46 0.002 0.002 
Biological 
Processes 
GO:0050900~leukocyte 
migration 
9 3.11E-05 
C3AR1, PTPN6, LYN, GRB2, 
FCER1G, ITGB2, SIRPA, 
SLC7A7, MIF 
7.33 0.038 0.051 
KEGG 
PATHWAY 
hsa04142:Lysosome 15 1.94E-09 
LIPA, AP1B1, PSAP, LGMN, 
CTSS, M6PR, DNASE2, 
ATP6V0C, CD68, AP1S2, 
LAPTM5, NAGA, CTSD, 
MCOLN1, ATP6V0D1 
8.32 3.10E-07 2.34E-06 
KEGG 
PATHWAY 
hsa04145:Phagosome 12 1.38E-05 
ATP6V0C, CYBA, CYBB, 
CORO1A, ITGB2, CTSS, 
FCGR3A, ATP6V0D1, M6PR, 
TUBB3, TUBA1C, ATP6V1F 
5.26 0.002 0.017 
Cellular 
Components 
GO:0070062~extracellular 
exosome 
73 1.39E-16 
S100A8, CNDP2, FERMT3, 
LGMN, PGD, S100A9, CD53, 
RPS2, SYNGR2, YBX1, GPX1, 
FAM49B, CREG1, H2AFY, 
SERPINA1, H2AFX, CSK, 
ATP6V0D1, FCGR3A, TUBB3, 
RHOG, FTL, NT5C, LAIR1, 
LYN, LYZ, TCN2, SIRPA, 
VASP, ATP6V1F, GLUL, 
RENBP, DNPH1, CD320, 
NME1, VAMP8, CTSD, CSTA, 
RAB13, VSIG4, LCP1, BID, 
AHCY, GRB2, APOC1, ITGB2, 
TPM3, MIF, ATP6V0C, 
2.69 2.68E-14 1.44E-13 
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HNRNPM, TPI1, ARPC3, 
NAGA, IDH1, GALE, 
ARHGDIB, PTPN6, LIPA, 
PSAP, ALYREF, TOMM40, 
S100A10, COTL1, LGALS9, 
DNASE2, LSP1, HYOU1, 
P2RX4, CORO1A, BLVRB, 
H3F3A, LTA4H, SH3BGRL3 
Cellular 
Components 
GO:0005829~cytosol 61 2.48E-07 
AP1B1, S100A8, CNDP2, AIF1, 
AP2S1, PGD, S100A9, 
DTYMK, RPS2, GPX1, AP1S2, 
MYD88, HMOX1, CSK, 
IMPDH1, DUS1L, RHOG, 
NT5C, FTL, IRAK1, LYN, 
EXOSC4, HMGA1, VASP, 
ATP6V1F, GLUL, RENBP, 
ARRB2, VAMP8, NME1, 
RNF135, PARVB, SRXN1, 
LCP1, BID, AHCY, GRB2, 
MAPKAPK3, UPP1, CYTH4, 
RPL38, TPM3, TPI1, ARPC3, 
SYN1, PYCARD, IDH1, GALE, 
ARHGDIB, ODC1, PTPN6, 
PLEK, AIMP2, HCK, ALYREF, 
NPL, CORO1A, PLK2, ID2, 
BLVRB, LTA4H 
1.91 5.98E-05 3.20E-04 
Cellular 
Components 
GO:0016020~membrane 42 1.96E-05 
BID, ORAI1, LST1, PNKD, 
FERMT3, ITGB2, EHBP1L1, 
RPS2, HNRNPM, LPXN, CD68, 
FAM49B, ARPC3, HMOX1, 
ATP6V0D1, ARHGDIB, FTL, 
DDX39A, PTPN6, PLEK, 
MPP1, AIMP2, EFTUD2, 
HCLS1, ALYREF, M6PR, 
SIRPA, PNPLA6, CD163, 
ATP6V1F, LSP1, PPIF, P2RX4, 
CYBA, HYOU1, CORO1A, 
CD320, VAMP8, NME1, GRK6, 
NCLN, CLN6 
1.98 0.005 0.025 
D o w n - r e g u l a t e d
 
KEGG hsa04610:Complement 6 3.90E-06 PLAT, CFH, SERPING1, C1R, 23.11 2.11E-04 0.004 
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PATHWAY and coagulation cascades C1S, PLAU 
Biological 
Processes 
GO:0030198~extracellular 
matrix organization 
9 6.36E-08 
LUM, COL6A3, COL1A2, 
ITGB5, COL6A1, POSTN, 
MFAP2, DCN, CYR61 16.06 2.78E-05 8.98E-05 
Biological 
Processes 
GO:0007155~cell 
adhesion 
9 3.61E-05 
WISP1, COL6A3, ITGB5, 
COL6A1, POSTN, MFAP4, 
THBS2, GAS6, CYR61 6.86 0.016 0.051 
Cellular 
Components 
GO:0031012~extracellular 
matrix 
16 9.40E-16 
PLAT, LUM, EFEMP1, POSTN, 
DCN, MMP14, ECM1, TIMP3, 
HTRA1, FBLN2, COL6A3, 
COL1A2, COL6A1, MFAP4, 
THBS2, CYR61 
19.70 8.17E-14 9.66E-13 
Cellular 
Components 
GO:0005576~extracellular 
region 
24 3.03E-12 
PLAT, IL6ST, LUM, EFEMP1, 
SERPING1, C1R, C1S, DCN, 
ECM1, TIMP3, GAS6, 
CLEC11A, HTRA1, FBLN2, 
COL6A3, CFH, COL1A2, 
COL6A1, MFAP2, MFAP4, 
THBS2, PLAU, ANGPTL4, 
CYR61 
5.43 2.79E-10 3.31E-09 
Cellular 
Components 
GO:0005578~proteinaceou
s extracellular matrix 
12 1.01E-10 
CTHRC1, WISP1, FBLN2, 
LUM, COL6A3, EFEMP1, 
COL1A2, POSTN, ECM1, 
TIMP3, CYR61, ANGPTL4 
16.32 9.27E-09 1.10E-07 
Cellular 
Components 
GO:0005615~extracellular 
space 
19 4.92E-09 
PLAT, CTHRC1, IL6ST, LUM, 
EFEMP1, POSTN, SERPING1, 
DCN, ECM1, TIMP3, GAS6, 
CLEC11A, WISP1, HTRA1, 
COL6A3, CFH, COL1A2, 
PLAU, ANGPTL4 
5.14 4.52E-07 5.37E-06 
Cellular 
Components 
GO:0070062~extracellular 
exosome 
25 3.64E-08 
SLC44A1, IL6ST, LUM, ITGB5, 
GJA1, C1R, C1S, TIMP3, 
HTRA1, COL6A3, CFH, 
COL6A1, NDRG1, NT5E, 
PLAT, CLMP, EFEMP1, 
SERPING1, ECM1, GAS6, 
3.24 3.35E-06 3.98E-05 
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FBLN2, CYBRD1, COL1A2, 
MFAP4, PLAU 
Cellular 
Components 
GO:0005589~collagen 
type VI trimer 
3 2.12E-05 
COL6A3, COL6A1, DCN 
364.48 0.002 0.023 
Table S2.2: KEGG and GO term enrichment analysis for Differentially Expressed Genes in RANBP2-ALK Expressing IMTs vs. All Other IMTs. 
The 235 genes exhibiting significantly different expression in RANBP2-ALK expressing tumors vs. all other IMTs (FC=>|2|, p=<.05) were used for KEGG Pathway and Gene 
Ontology term enrichment analysis. Up-regulated and down-regulated genes were assessed separately. Shown are the analyses with an FDR<=.05. The ‘category’ column 
references the type of test performed. The ‘count’ column displays the number of genes associated with the term that were in the set of differentially expressed genes evaluated. 
Statistics are calculated based on the count and the expected count. 
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Category Term Count P Value Genes 
Fold 
Enrichment 
Bonferroni FDR 
U
p
-r
e
g
u
la
te
d
 
Cellular 
Components 
GO:0005615~extracellular 
space 
14 2.44E-06 
APOL1, RNASET2, FAM20C, 
SEMA4B, CMTM7, SERPINB4, 
LBP, CTSB, CFI, C2, QSOX1, 
GOLM1, TIMP1, CTSW 
4.74 1.98E-04 0.003 
Cellular 
Components 
GO:0070062~extracellular 
exosome 
18 2.53E-05 
HIST2H2AA3, HIST2H2AA4, 
FAM20C, COLEC12, CD74, 
TIMP1, ACVR1B, RAC2, 
RNASET2, HSPA7, SERPINB4, 
C2, CFI, CTSB, LBP, QSOX1, 
GOLM1, CD7 
2.92 0.002 0.027 
D
o
w
n
-r
e
g
u
la
te
d
 
KEGG 
PATHWAY 
ptr01130:Biosynthesis of 
antibiotics 
10 1.52E-05 
ALDH1B1, ACO1, ECHS1, ACLY, 
PCYOX1, CAT, HADH, ACSS2, 
ALDH3A2, MDH1 
6.48 0.002 0.018 
Cellular 
Components 
GO:0005578~proteinaceous 
extracellular matrix 
8 3.78E-05 
ASPN, ADAMTS1, SPARC, 
COL5A3, COL16A1, ECM2, 
SPON2, SLIT3 
8.58 0.003 0.042 
 
Table S2.3: KEGG and GO term enrichment analysis for Differentially Expressed Genes in Fusion Positive vs Fusion Negative IMT.  
The 145 genes exhibiting significantly different expression in fusion positive tumors vs fusion negative tumors(FC=>|2|, p=<.05) were used for KEGG Pathway and Gene Ontology 
term enrichment analysis. Up-regulated and down-regulated genes were assessed separately. Shown are the analyses with an FDR<=.05. The ‘category’ column references the 
type of test performed. The ‘count’ column displays the number of genes associated with the term that were in the set of differentially expressed genes evaluated. Statistics are 
calculated based on the count and the expected count. 
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Pathway Name FDR Status KEGG Link 
Cell cycle 3.60E-07 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04110+4171+4172+4173+4174+4176+23594+4998+64
682+8697+983+701+5111+5347+4085+699+8556+2810+1111+5591+6502+90
88+9232+5925+7157+991+995+8318+990+993+891+9133+890+902+898+727
2+1031+1869+1871+3065 
Neuroactive ligand-receptor 
interaction 
0.001 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04080+5645+3952+2690+2908+2904+9568+2918+743
3+6344+117+2696+1394+134+7253+3973+56923+4886+2358+153+1134+114
5 
 
Table S2.4: Signaling Pathway Impact Analysis for Differentially Expressed Genes in Pulmonary vs Extra-pulmonary IMT 
The 74 genes exhibiting significantly different expression in pulmonary tumors (FC=>|2|, p=<.05) were used for SPIA analysis. Shown are the analyses with an FDR<=.05. 
  
98 
 
 
 
Pathway Name FDR Status KEGG Link 
Neuroactive ligand-receptor 
interaction 
0.002 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04080+1511+5645+2743+2903+5025+2917+6344+574
5+1902+5724+2859+5028+5032+134+5737+5732+5729+3973+2149+2151+23
57+2358+2359+719+185+3351+3356+1131+1134 
ECM-receptor interaction 0.003 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04512+284217+3908+1278+1291+1293+1311+7058+3
685+3693+22801+8515+5649 
Fc gamma R-mediated phagocytosis 0.009 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04666+2214+2209+3055+4067+6850+23533+6199+10
451+7409+5879+10810+10093+10094+10095+10109+10552+998+8976+1794
+7408+3985+1072+55616+382+1759+653361+56848 
Lysosome 0.011 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04142+245972+527+533+537+9114+1509+1511+1513
+1519+1520+1522+5641+2548+4668+2990+3988+1777+53+427+5660+76823
9+968+1497+26503+7805+1201+256471+1211+4074+51172+162+8905+8907
+8943+23062+26088+57192 
Fc epsilon RI signaling pathway 0.011 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04664+2207+2206+2534+7124+5609+23533+695+685
0+4067+5605+3845+4893+2885+5322+5879+5881+10451+7409 
Natural killer cell mediated cytotoxicity 0.017 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04650+5533+2534+7124+6452+6850+10870+2207+73
05+5777+637+355+80329+100507436+23533+5605+369+3845+4893+2885+5
3358+5879+5881+10451+7409+3455+2214+3689 
Regulation of actin cytoskeleton 0.024 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04810+10093+10094+10095+10109+10552+5216+897
6+10152+10787+3071+23191+10458+1072+3985+7414+1729+4478+5829+54
99+4638+55740+5063+998+5879+5881+387+10451+7409+5605+369+23533+
55970+1131+22801+3684+3685+3689+3693+8515+3845+4893+2260+3645+2
247+2259+56034+2149 
Chemokine signaling pathway 0.025 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04062+1230+1234+729230+2919+388372+6348+6349
+6351+6356+6357+2268+3055+4067+5829+387+23533+53358+10681+2783+
2787+2793+55970+2885+2870+408+409+10451+7409+998+108+111+5906+8
976+653361+5566+3845+4893+1794+5879+4793+2931 
Tuberculosis 0.025 Activated 
http://www.genome.jp/dbget-
bin/show_pathway?hsa05152+22925+5878+245972+527+533+537+9114+841
99 
 
1+1509+808+817+56848+2209+2214+11151+5533+3689+3684+4802+4615+7
099+7096+7124+637+3112+1520+387+4046+64581+6850+2207+7040+3654+
3588 
Calcium signaling pathway 0.041 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04020+4842+7416+10105+817+5533+683+2903+5025
+56848+4638+84812+5261+84876+1131+185+2149+3356+3973+5724+5737+
808+292+293+108+5566+8913 
Pancreatic secretion 0.041 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04972+1131+6558+6344+6522+5645+1359+5322+722
0+683+108+111+4218+9545+5906+387+5879 
 
Table S2.5: Signaling Pathway Impact Analysis for Differentially Expressed Genes in RANBP2-ALK Expressing IMTs vs. All Other IMTs. 
The 235 genes exhibiting significantly different expression in RANBP2-ALK expressing tumors (FC=>|2|, p=<.05) were used SPIA. Shown are the analyses with an FDR<=.05. 
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Pathway Name FDR Status KEGG Link 
PPAR signaling pathway 0.002 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa03320+364+5105+5346+2167+6258+5468+34+33+196
2+4023+10580+6319+1622+4199 
Cytokine-cytokine receptor interaction 0.002 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa04060+91+3561+3560+8809+3556+3554+657+658+36
06+943+939+356+4049+1956+3586+3082+56034+2690+3559+1438+7173+12
71+3590+3592+3952+1440+1234+10344+6356+10663+2833+3577+3579+954
7+7133+2920 
Amoebiasis 0.033 Inhibited 
http://www.genome.jp/dbget-
bin/show_pathway?hsa05146+10319+3554+3592+5293+5330+5613+3586+12
78+50509+7414+5055+6317+6318 
 
Table S2.6: Signaling Pathway Impact Analysis for Differentially Expressed Genes in Fusion Positive vs Fusion Negative IMT.  
The 145 genes exhibiting significantly different expression in fusion positive tumors (FC=>|2|, p=<.05) were used for SPIA. Shown are the analyses with an FDR<=.05. 
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Gene SNV (amino acid change) 
# Cases 
Harboring SNV 
RPL22 44 A duplication (K15 frame shift) 18 
TP53 C98G (P33R) 17 
DDX31 A2395G (I799V) 17 
IL7R G412A (V138I) 16 
ZNF384 1194_1196 deletion (398_399 deletion) 14 
SETD2 C5885T (P1962L) 14 
ATRX 2404 A duplication (R802 frame shift) 13 
NCOR1 636 A duplication (V213 frame shift) 11 
DHX15 1224 A duplication (Q409 frame shift) 10 
CROCC G5337C (E1779D) 10 
IGLL5 C67T (R23C) 10 
SIRPA C300A (N100K) 7 
TET2 T5162G (L1721W) 8 
RHOA A526G (R176G) 9 
NUP98 C3424G (Q1142E) 7 
MTAP G166A (V56I) 7 
ZCCHC7 1617 A duplication (R539 frame shift) 8 
KDR A1416T (Q472H) 7 
JMJD1C C5393T (P1798L) 7 
TSC1 T812C (M271T) 5 
CHD4 396_398 deletion (132_133 deletion) 6 
LRIG1 C2705T (A902V) 6 
FLT4 C1804T (H602Y) 7 
KMT2A 9308 A duplication (Q3103 frame shift) 5 
OSMR G1733A (G578D) 5 
NOTCH1 G3836A (R1279H) 6 
GAK A3500G (K1167R) 6 
KMT2C 13940 A duplication (K4647 frame shift) 6 
MGA 6953 A duplication (Q2318 frame shift) 5 
ZFHX3 G5146A (D1716N) 5 
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Table S2.7: Cancer Associated SNVs Shared by at Least 25% of IMTs Evaluated. All 18 IMTs undergoing RNAseq analysis were assessed for SNVs. Variants were filtered 
based on a list of 383 pre-defined cancer genes. The variants were maintained if they were exonic, had a damaging function, previously reported in COSMIC, and were considered 
pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 
Genomes Project or if no annotations were present. Variants present in at least 25% of samples are displayed here. 
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
C
a
s
e
 1
 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
34 1.00 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon1
2:c.C5885T:p.P1962L 38 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 82 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 52 1.00 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c.
C731T:p.T244I 28 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:c
.G2671C:p.E891Q,ATRX:N
M_000489:exon9:c.G2785
C:p.E929Q 
12 1.00 
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chr5 134115992 134115992 C A TCF7 
Non-
synonymous 
SNV 
TCF7:NM_213648:exon1:c.
C55A:p.P19T,TCF7:NM_00
1134851:exon2:c.C55A:p.P
19T,TCF7:NM_201632:exo
n2:c.C55A:p.P19T,TCF7:N
M_201634:exon2:c.C55A:p
.P19T,TCF7:NM_003202:e
xon3:c.C400A:p.P134T 
11 0.73 
chr19 41238005 41238005 C T AXL 
Non-
synonymous 
SNV 
AXL:NM_001278599:exon4
:c.C41T:p.P14L,AXL:NM_0
01699:exon7:c.C845T:p.P2
82L,AXL:NM_021913:exon
7:c.C845T:p.P282L 
11 0.64 
chr7 92774737 92774737 C T CDK6 
Non-
synonymous 
SNV 
CDK6:NM_001145306:exo
n3:c.G328A:p.D110N,CDK
6:NM_001259:exon3:c.G32
8A:p.D110N 
10 0.60 
chr4 105275794 105275794 A G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exon
11:c.A5284G:p.I1762V 33 0.55 
chr19 34466925 34466925 C T UBA2 
Non-
synonymous 
SNV 
UBA2:NM_005499:exon16:
c.C1652T:p.P551L 224 0.53 
chr9 132911517 132911517 A G TSC1 
Non-
synonymous 
SNV 
TSC1:NM_001162427:exo
n9:c.T812C:p.M271T,TSC1
:NM_000368:exon10:c.T96
5C:p.M322T,TSC1:NM_00
1162426:exon10:c.T965C:
p.M322T 
21 0.52 
chr3 179209622 179209622 A G PIK3CA 
Non-
synonymous 
SNV 
PIK3CA:NM_006218:exon7
:c.A1173G:p.I391M 14 0.50 
chr1 92837557 92837557 A G RPL5 
Non-
synonymous 
SNV 
RPL5:NM_000969:exon6:c.
A629G:p.Y210C 3446 0.48 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
24 0.46 
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M_001135734:exon11:c.15
42_1544del:p.514_515del 
chr11 3702551 3702551 G C NUP98 
Non-
synonymous 
SNV 
NUP98:NM_016320:exon2
3:c.C3424G:p.Q1142E,NU
P98:NM_139132:exon23:c.
C3424G:p.Q1142E 
55 0.45 
chr19 41253609 41253609 C T AXL 
Non-
synonymous 
SNV 
AXL:NM_001278599:exon1
4:c.C1133T:p.T378I,AXL:N
M_001699:exon16:c.C1910
T:p.T637I,AXL:NM_021913
:exon17:c.C1937T:p.T646I 
19 0.42 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 29 0.41 
chr4 105235006 105235006 G A TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exon
3:c.G1064A:p.G355D,TET2
:NM_017628:exon3:c.G106
4A:p.G355D 
10 0.40 
chr2 43225479 43225479 C T ZFP36L2 
Non-
synonymous 
SNV 
ZFP36L2:NM_006887:exon
2:c.G325A:p.G109S 62 0.37 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:c
.G166A:p.V56I 26 0.35 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:exo
n2:c.C300A:p.N100K,SIRP
A:NM_001040022:exon3:c.
C300A:p.N100K,SIRPA:N
M_080792:exon3:c.C300A:
p.N100K 
301 0.31 
chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:exo
n2:c.284_285insGT:p.D95f
s,SIRPA:NM_001040022:e
xon3:c.284_285insGT:p.D9
5fs,SIRPA:NM_080792:exo
n3:c.284_285insGT:p.D95f
s 
266 0.31 
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chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.286_287del:p.L96fs,SI
RPA:NM_001040022:exon
3:c.286_287del:p.L96fs,SI
RPA:NM_080792:exon3:c.
286_287del:p.L96fs 
276 0.30 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:ex
on7:c.636dupA:p.V213fs,N
COR1:NM_001190440:exo
n9:c.963dupA:p.V322fs,NC
OR1:NM_006311:exon10:c
.963dupA:p.V322fs 
39 0.26 
chr20 1915338 1915338 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:exo
n2:c.C319A:p.R107S,SIRP
A:NM_001040022:exon3:c.
C319A:p.R107S,SIRPA:N
M_080792:exon3:c.C319A:
p.R107S 
294 0.23 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
3177 0.22 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.387_389del:p.129_13
0del,SIRPA:NM_00104002
2:exon3:c.387_389del:p.12
9_130del,SIRPA:NM_0807
92:exon3:c.387_389del:p.1
29_130del 
255 0.20 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:exo
n5:c.A526G:p.R176G 15 0.20 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon6:
c.1224dupA:p.Q409fs 
218 0.20 
chr20 1915344 1915344 G A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:exo
n2:c.G325A:p.G109S,SIRP
A:NM_001040022:exon3:c.
G325A:p.G109S,SIRPA:N
M_080792:exon3:c.G325A:
p.G109S 
293 0.19 
 
107 
 
Table S2.8: All Cancer Associated SNVs Called for Case 1. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
C
a
s
e
 2
 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
19 1.00 
chr2 29193500 29193500 G C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:c.
C4587G:p.D1529E 59 1.00 
chr2 29193615 29193615 T C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:c.
A4472G:p.K1491R 52 1.00 
chr2 29222392 29222392 C T ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon22:c.
G3467A:p.C1156Y 21 1.00 
chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:exo
n2:c.284_285insGT:p.D95f
s,SIRPA:NM_001040022:e
xon3:c.284_285insGT:p.D9
5fs,SIRPA:NM_080792:exo
n3:c.284_285insGT:p.D95f
s 
11 1.00 
chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.286_287del:p.L96fs,SI
RPA:NM_001040022:exon
3:c.286_287del:p.L96fs,SI
RPA:NM_080792:exon3:c.
286_287del:p.L96fs 
11 1.00 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:exo
n2:c.C300A:p.N100K,SIRP
A:NM_001040022:exon3:c.
C300A:p.N100K,SIRPA:N
M_080792:exon3:c.C300A:
p.N100K 
11 1.00 
109 
 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.387_389del:p.129_13
0del,SIRPA:NM_00104002
2:exon3:c.387_389del:p.12
9_130del,SIRPA:NM_0807
92:exon3:c.387_389del:p.1
29_130del 
11 1.00 
chr7 22731420 22731420 T A IL6 
Non-
synonymous 
SNV 
IL6:NM_000600:exon5:c.T
486A:p.D162E 22 0.59 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
25 0.52 
chr6 44250093 44250093 G A 
HSP90AB
1 
Non-
synonymous 
SNV 
HSP90AB1:NM_00127196
9:exon5:c.G587A:p.R196K,
HSP90AB1:NM_00127197
0:exon5:c.G587A:p.R196K,
HSP90AB1:NM_00127197
1:exon5:c.G443A:p.R148K,
HSP90AB1:NM_00127197
2:exon5:c.G557A:p.R186K,
HSP90AB1:NM_007355:ex
on5:c.G587A:p.R196K 
666 0.48 
chr3 128486108 128486108 C T GATA2 
Non-
synonymous 
SNV 
GATA2:NM_001145662:ex
on3:c.G490A:p.A164T,GAT
A2:NM_032638:exon3:c.G
490A:p.A164T,GATA2:NM
13 0.46 
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_001145661:exon4:c.G490
A:p.A164T 
chr5 35876347 35876347 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon8:c.
C1241T:p.T414M 16 0.44 
chr5 150123172 150123172 G A PDGFRB 
Non-
synonymous 
SNV 
PDGFRB:NM_002609:exo
n15:c.C2053T:p.R685C 21 0.43 
chr9 132595027 132595027 T C DDX31 
Nonsynonym
o-us SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 
39 0.33 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 13 0.31 
chr5 38883969 38883969 T G OSMR 
Non-
synonymous 
SNV 
OSMR:NM_001168355:exo
n5:c.T561G:p.H187Q,OSM
R:NM_003999:exon5:c.T56
1G:p.H187Q 
23 0.30 
chr1 16946292 16946292 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.A2170G:p.M724V 10 0.30 
chr22 22893780 22893780 G C IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:exo
n2:c.G287C:p.C96S 65 0.28 
chrX 147937529 147937529 - A FMR1 
frameshift 
insertion 
FMR1:NM_001185075:exo
n11:c.1055dupA:p.E352fs,
FMR1:NM_001185076:exo
n11:c.1055dupA:p.E352fs,
FMR1:NM_001185081:exo
n11:c.1055dupA:p.E352fs,
FMR1:NM_001185082:exo
n11:c.1055dupA:p.E352fs,
FMR1:NM_002024:exon11:
c.1055dupA:p.E352fs 
16 0.25 
chr2 144399760 144399760 - T ZEB2 
frameshift 
insertion 
ZEB2:NM_001171653:exo
n7:c.1354dupA:p.M452fs,Z
EB2:NM_014795:exon8:c.1
426dupA:p.M476fs 
17 0.24 
111 
 
chr18 12836849 12836849 - A PTPN2 
frameshift 
insertion 
PTPN2:NM_001308287:ex
on2:c.115dupT:p.Y39fs,PT
PN2:NM_001207013:exon
3:c.202dupT:p.Y68fs,PTPN
2:NM_002828:exon3:c.202
dupT:p.Y68fs,PTPN2:NM_
080422:exon3:c.202dupT:p
.Y68fs,PTPN2:NM_080423
:exon3:c.202dupT:p.Y68fs 
98 0.21 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
3185 0.20 
chr16 4260224 4260224 T G TFAP4 
Non-
synonymous 
SNV 
TFAP4:NM_003223:exon6:
c.A688C:p.T230P 20 0.20 
chr3 49360990 49360990 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:exo
n5:c.A485G:p.K162R 10 0.20 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon6:
c.1224dupA:p.Q409fs 
69 0.13 
 
Table S2.9: All Cancer Associated SNVs Called for Case 2. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
C
a
s
e
 3
 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
14 1.00 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon1
2:c.C5885T:p.P1962L 26 1.00 
chr16 3717472 3717472 G A TRAP1 
Non-
synonymous 
SNV 
TRAP1:NM_001272049:ex
on1:c.C37T:p.R13C,TRAP
1:NM_016292:exon1:c.C37
T:p.R13C 
17 0.65 
chr5 38921762 38921762 G A OSMR 
Non-
synonymous 
SNV 
OSMR:NM_003999:exon12
:c.G1733A:p.G578D 42 0.62 
chr3 179209622 179209622 A G PIK3CA 
Non-
synonymous 
SNV 
PIK3CA:NM_006218:exon7
:c.A1173G:p.I391M 13 0.62 
chr11 3679646 3679646 C T NUP98 
Non-
synonymous 
SNV 
NUP98:NM_139132:exon3
0:c.G4759A:p.E1587K,NU
P98:NM_016320:exon31:c.
G4981A:p.E1661K 
36 0.56 
chr10 63193075 63193075 G A JMJD1C 
Non-
synonymous 
SNV 
JMJD1C:NM_001282948:e
xon15:c.C5393T:p.P1798L,
JMJD1C:NM_032776:exon
16:c.C5939T:p.P1980L 
19 0.53 
113 
 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
68 0.50 
chr12 14456621 14456621 A T ATF7IP 
Non-
synonymous 
SNV 
ATF7IP:NM_001286514:ex
on7:c.A2053T:p.N685Y,AT
F7IP:NM_001286515:exon
7:c.A2053T:p.N685Y,ATF7I
P:NM_018179:exon7:c.A20
56T:p.N686Y,ATF7IP:NM_
181352:exon7:c.A2080T:p.
N694Y 
19 0.42 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:c
.A1416T:p.Q472H 27 0.33 
chr1 16945542 16945542 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
15:c.G2072A:p.R691H 16 0.25 
chr2 112830485 112830485 T C IL1B 
Non-
synonymous 
SNV 
IL1B:NM_000576:exon7:c.
A686G:p.E229G 13 0.23 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
2370 0.22 
chr1 16953387 16953387 T A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
21:c.T3092A:p.L1031Q 16 0.19 
chr1 16953389 16953389 G A CROCC 
Non-
synonymous 
CROCC:NM_014675:exon
21:c.G3094A:p.E1032K 
16 0.19 
114 
 
SNV 
chr1 16953404 16953404 G C CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
21:c.G3109C:p.E1037Q 16 0.19 
chr17 59946728 59946728 - A RPS6KB1 
frameshift 
insertion 
RPS6KB1:NM_001272042:
exon14:c.1450dupA:p.Y48
3fs,RPS6KB1:NM_001272
060:exon15:c.1450dupA:p.
Y483fs,RPS6KB1:NM_003
161:exon15:c.1519dupA:p.
Y506fs,RPS6KB1:NM_001
272044:exon16:c.1360dup
A:p.Y453fs 
22 0.18 
chr22 22893804 22893804 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:exo
n2:c.A311G:p.K104R 257 0.18 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon6:
c.1224dupA:p.Q409fs 
66 0.14 
chr22 22893795 22893795 C G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:exo
n2:c.C302G:p.T101S 244 0.12 
 
Table S2.10: All Cancer Associated SNVs Called for Case 3. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
  
115 
 
 
 
 
  
Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
C
a
s
e
 4
 
chr11 3702551 3702551 G C NUP98 
Non-
synonymous 
SNV 
NUP98:NM_016320:exon2
3:c.C3424G:p.Q1142E,NU
P98:NM_139132:exon23:c.
C3424G:p.Q1142E 
13 1.00 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
11 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 
37 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 
40 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:c
.G2671C:p.E891Q,ATRX:N
M_000489:exon9:c.G2785
C:p.E929Q 
11 1.00 
chr20 32434666 32434666 G A ASXL1 
Non-
synonymous 
SNV 
ASXL1:NM_015338:exon1
2:c.G1954A:p.G652S 
14 0.71 
chr18 62979049 62979049 G A PHLPP1 
Non-
synonymous 
SNV 
PHLPP1:NM_194449:exon
17:c.G4772A:p.S1591N 
11 0.64 
chr9 37126685 37126685 G A ZCCHC7 
Non-
synonymous 
SNV 
ZCCHC7:NM_001289119:e
xon2:c.G353A:p.G118D,ZC
CHC7:NM_001289120:exo
n2:c.G353A:p.G118D,ZCC
HC7:NM_001289121:exon
2:c.G353A:p.G118D,ZCCH
C7:NM_032226:exon2:c.G
353A:p.G118D 
26 0.58 
116 
 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 
21 0.57 
chr4 55113391 55113391 C T KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon7:c.
G889A:p.V297I 
18 0.56 
chr4 849932 849932 T C GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exon
24:c.A3500G:p.K1167R,GA
K:NM_005255:exon27:c.A3
794G:p.K1265R 
194 0.52 
chr5 35876149 35876149 A C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon8:c.
A1043C:p.N348T 
18 0.50 
chr5 150070264 150070264 C T CSF1R 
Non-
synonymous 
SNV 
CSF1R:NM_001288705:ex
on8:c.G1237A:p.G413S,CS
F1R:NM_005211:exon9:c.
G1237A:p.G413S 
72 0.49 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
33 0.48 
chr2 208243593 208243593 C T IDH1 
Non-
synonymous 
SNV 
IDH1:NM_001282386:exon
6:c.G532A:p.V178I,IDH1:N
M_001282387:exon6:c.G5
32A:p.V178I,IDH1:NM_005
896:exon6:c.G532A:p.V178
I 
128 0.48 
chr3 12612044 12612044 T C RAF1 Non- RAF1:NM_002880:exon3:c 52 0.46 
117 
 
synonymous 
SNV 
.A226G:p.M76V 
chr15 41568909 41568909 A G TYRO3 
Non-
synonymous 
SNV 
TYRO3:NM_006293:exon9
:c.A1139G:p.N380S 
10 0.40 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c.
C731T:p.T244I 
20 0.40 
chr1 81951044 81951044 T C ADGRL2 
Non-
synonymous 
SNV 
ADGRL2:NM_001297705:e
xon7:c.T1519C:p.S507P,A
DGRL2:NM_001297706:ex
on7:c.T1519C:p.S507P,AD
GRL2:NM_012302:exon7:c
.T1519C:p.S507P,ADGRL2
:NM_001297704:exon8:c.T
1519C:p.S507P 
26 0.38 
chr9 136500769 136500769 G A NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exon
31:c.C5717T:p.A1906V 
26 0.35 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:c
.A1416T:p.Q472H 
13 0.31 
chr4 55106779 55106779 A G KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:c
.T1444C:p.C482R 
19 0.26 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
2818 0.23 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:e
xon9:c.1617dupA:p.R539fs
,ZCCHC7:NM_001289120:
exon9:c.1617dupA:p.R539f
s,ZCCHC7:NM_001289121
:exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_032226:ex
on9:c.1617dupA:p.R539fs 
40 0.20 
chr2 197416764 197416764 - T SF3B1 
frameshift 
insertion 
SF3B1:NM_012433:exon6:
c.642dupA:p.L215fs 
62 0.15 
 
Table S2.11: All Cancer Associated SNVs Called for Case 4. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
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frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon1
2:c.C5885T:p.P1962L 45 1.00 
chr5 68292320 68292320 G A PIK3R1 
Non-
synonymous 
SNV 
PIK3R1:NM_181504:exon2
:c.G168A:p.M56I,PIK3R1:N
M_181524:exon2:c.G78A:p
.M26I,PIK3R1:NM_181523:
exon8:c.G978A:p.M326I 
28 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:c
.G2671C:p.E891Q,ATRX:N
M_000489:exon9:c.G2785
C:p.E929Q 
10 1.00 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
77 0.99 
chr4 105275672 105275672 T G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exon
11:c.T5162G:p.L1721W 11 0.73 
chr1 16138117 16138117 G T EPHA2 
Non-
synonymous 
SNV 
EPHA2:NM_004431:exon5:
c.C1048A:p.P350T 46 0.67 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 38 0.61 
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chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 10 0.60 
chr1 81952012 81952012 A G ADGRL2 
Non-
synonymous 
SNV 
ADGRL2:NM_001297705:e
xon8:c.A1652G:p.K551R,A
DGRL2:NM_001297706:ex
on8:c.A1652G:p.K551R,AD
GRL2:NM_012302:exon8:c
.A1652G:p.K551R,ADGRL
2:NM_001297704:exon9:c.
A1652G:p.K551R 
44 0.59 
chr3 66380763 66380763 C T LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon18
:c.G2869A:p.A957T 16 0.56 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
20 0.55 
chr19 15179425 15179425 G T NOTCH3 
Non-
synonymous 
SNV 
NOTCH3:NM_000435:exon
21:c.C3399A:p.H1133Q 144 0.50 
chr10 63168077 63168077 C T JMJD1C 
Non-
synonymous 
SNV 
JMJD1C:NM_001282948:e
xon25:c.G7045A:p.E2349K
,JMJD1C:NM_032776:exon
26:c.G7591A:p.E2531K 
109 0.49 
chr8 127738294 127738294 A G MYC 
Non-
synonymous 
SNV 
MYC:NM_002467:exon2:c.
A77G:p.N26S 182 0.48 
chr19 1627366 1627366 A G TCF3 
Non-
synonymous 
SNV 
TCF3:NM_001136139:exo
n5:c.T359C:p.L120P,TCF3:
NM_003200:exon6:c.T359
C:p.L120P 
47 0.47 
chr4 54264951 54264951 C T PDGFRA 
Non-
synonymous 
SNV 
PDGFRA:NM_006206:exo
n5:c.C661T:p.L221F 129 0.46 
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chr3 66380453 66380453 G C LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon19
:c.C3092G:p.P1031R 22 0.45 
chr8 105802428 105802428 G C ZFPM2 
Non-
synonymous 
SNV 
ZFPM2:NM_012082:exon8:
c.G2346C:p.E782D 33 0.45 
chr19 41352971 41352971 C G TGFB1 
Non-
synonymous 
SNV 
TGFB1:NM_000660:exon1:
c.G74C:p.R25P 102 0.44 
chr13 28311623 28311623 G A FLT1 
Non-
synonymous 
SNV 
FLT1:NM_002019:exon27:
c.C3602T:p.P1201L 29 0.38 
chr15 41762197 41762197 - A MGA 
frameshift 
insertion 
MGA:NM_001080541:exon
21:c.6953dupA:p.Q2318fs,
MGA:NM_001164273:exon
22:c.7580dupA:p.Q2527fs 
20 0.30 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:ex
on7:c.636dupA:p.V213fs,N
COR1:NM_001190440:exo
n9:c.963dupA:p.V322fs,NC
OR1:NM_006311:exon10:c
.963dupA:p.V322fs 
22 0.27 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:e
xon9:c.1617dupA:p.R539fs
,ZCCHC7:NM_001289120:
exon9:c.1617dupA:p.R539f
s,ZCCHC7:NM_001289121
:exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_032226:ex
on9:c.1617dupA:p.R539fs 
50 0.24 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:exo
n3:c.396_398del:p.132_13
3del,CHD4:NM_001273:ex
on4:c.417_419del:p.139_1
40del 
46 0.22 
chr19 10160049 10160049 - T DNMT1 
frameshift 
insertion 
DNMT1:NM_001379:exon1
4:c.1009dupA:p.M337fs,DN
MT1:NM_001130823:exon
15:c.1057dupA:p.M353fs 
19 0.21 
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chr7 152146689 152146689 - T KMT2C 
frameshift 
insertion 
KMT2C:NM_170606:exon5
3:c.13940dupA:p.K4647fs 29 0.21 
chr22 20092882 20092882 - A DGCR8 
frameshift 
insertion 
DGCR8:NM_022720:exon8
:c.1681dupA:p.S560fs 54 0.20 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 3085 0.20 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon6:
c.1224dupA:p.Q409fs 118 0.19 
chr2 197416764 197416764 - T SF3B1 
frameshift 
insertion 
SF3B1:NM_012433:exon6:
c.642dupA:p.L215fs 89 0.12 
 
Table S2.12: All Cancer Associated SNVs Called for Case 5. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
68 1.00 
chr5 68292320 68292320 G A PIK3R1 
Non-
synonymous 
SNV 
PIK3R1:NM_181504:exon2
:c.G168A:p.M56I,PIK3R1:N
M_181524:exon2:c.G78A:p
.M26I,PIK3R1:NM_181523:
exon8:c.G978A:p.M326I 
45 1.00 
chr8 105802747 105802747 C G ZFPM2 
Non-
synonymous 
SNV 
ZFPM2:NM_012082:exon8:
c.C2665G:p.Q889E 20 1.00 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 26 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:c
.G2671C:p.E891Q,ATRX:N
M_000489:exon9:c.G2785
C:p.E929Q 
19 1.00 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c.
C731T:p.T244I 18 0.83 
chr9 136506781 136506781 C T NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exon
23:c.G3836A:p.R1279H 16 0.75 
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chr7 55161562 55161562 G A EGFR 
Non-
synonymous 
SNV 
EGFR:NM_005228:exon13
:c.G1562A:p.R521K,EGFR:
NM_201282:exon13:c.G15
62A:p.R521K,EGFR:NM_2
01284:exon13:c.G1562A:p.
R521K 
11 0.73 
chr3 47121396 47121396 C T SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon3:
c.G3240A:p.M1080I 13 0.62 
chr5 180621758 180621758 G A FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon13:
c.C1804T:p.H602Y,FLT4:N
M_182925:exon13:c.C1804
T:p.H602Y 
15 0.60 
chr14 34761774 34761774 C T BAZ1A 
Non-
synonymous 
SNV 
BAZ1A:NM_182648:exon2
3:c.G4130A:p.R1377K,BAZ
1A:NM_013448:exon24:c.
G4226A:p.R1409K 
78 0.59 
chr3 66380453 66380453 G C LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon19
:c.C3092G:p.P1031R 58 0.57 
chr14 34761902 34761902 A T BAZ1A 
Non-
synonymous 
SNV 
BAZ1A:NM_182648:exon2
3:c.T4002A:p.N1334K,BAZ
1A:NM_013448:exon24:c.T
4098A:p.N1366K 
93 0.56 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon1
2:c.C5885T:p.P1962L 45 0.56 
chr3 66380763 66380763 C T LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon18
:c.G2869A:p.A957T 30 0.50 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:c
.G166A:p.V56I 25 0.48 
chr7 22731420 22731420 T A IL6 
Non-
synonymous 
SNV 
IL6:NM_000600:exon5:c.T
486A:p.D162E 103 0.46 
chr4 108048727 108048727 G A LEF1 
Non-
synonymous 
SNV 
LEF1:NM_001130714:exon
10:c.C1106T:p.T369M 144 0.44 
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chr9 8485834 8485834 G A PTPRD 
Non-
synonymous 
SNV 
PTPRD:NM_002839:exon2
8:c.C2983T:p.R995C 18 0.44 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 80 0.44 
chr9 37126781 37126781 G A ZCCHC7 
Non-
synonymous 
SNV 
ZCCHC7:NM_001289119:e
xon2:c.G449A:p.R150Q,ZC
CHC7:NM_001289120:exo
n2:c.G449A:p.R150Q,ZCC
HC7:NM_001289121:exon
2:c.G449A:p.R150Q,ZCCH
C7:NM_032226:exon2:c.G
449A:p.R150Q 
36 0.42 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 66 0.41 
chr1 16137994 16137994 C T EPHA2 
Non-
synonymous 
SNV 
EPHA2:NM_004431:exon5:
c.G1171A:p.G391R 20 0.40 
chr8 127738294 127738294 A G MYC 
Non-
synonymous 
SNV 
MYC:NM_002467:exon2:c.
A77G:p.N26S 49 0.39 
chr12 6667904 6667915 
TGCTGCT
GCTGC 
- ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1185_1196del:p.39
5_399del,ZNF384:NM_133
476:exon10:c.1350_1361d
el:p.450_454del,ZNF384:N
M_001135734:exon11:c.15
33_1544del:p.511_515del 
20 0.35 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 2067 0.23 
chrX 71122774 71122776 TGC - MED12 
Non-
frameshift 
deletion 
MED12:NM_005120:exon1
0:c.1385_1387del:p.462_4
63del 
10 0.20 
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chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:ex
on7:c.636dupA:p.V213fs,N
COR1:NM_001190440:exo
n9:c.963dupA:p.V322fs,NC
OR1:NM_006311:exon10:c
.963dupA:p.V322fs 
39 0.18 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:e
xon9:c.1617dupA:p.R539fs
,ZCCHC7:NM_001289120:
exon9:c.1617dupA:p.R539f
s,ZCCHC7:NM_001289121
:exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_032226:ex
on9:c.1617dupA:p.R539fs 
55 0.16 
chr22 22893804 22893804 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:exo
n2:c.A311G:p.K104R 40 0.15 
chr1 64873427 64873427 - T JAK1 
frameshift 
insertion 
JAK1:NM_002227:exon5:c.
425dupA:p.K142fs 97 0.13 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:exo
n3:c.396_398del:p.132_13
3del,CHD4:NM_001273:ex
on4:c.417_419del:p.139_1
40del 
52 0.12 
 
Table S2.13: All Cancer Associated SNVs Called for Case 6. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
35 1.00 
chr9 132911517 132911517 A G TSC1 
Non-
synonymous 
SNV 
TSC1:NM_001162427:exo
n9:c.T812C:p.M271T,TSC1
:NM_000368:exon10:c.T96
5C:p.M322T,TSC1:NM_00
1162426:exon10:c.T965C:
p.M322T 
22 0.64 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:c
.G166A:p.V56I 25 0.60 
chr5 38921762 38921762 G A OSMR 
Non-
synonymous 
SNV 
OSMR:NM_003999:exon12
:c.G1733A:p.G578D 78 0.56 
chr16 3781229 3781229 G T CREBBP 
Non-
synonymous 
SNV 
CREBBP:NM_001079846:
exon6:c.C1537A:p.L513I,C
REBBP:NM_004380:exon7
:c.C1651A:p.L551I 
10 0.50 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 36 0.50 
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chr5 38884097 38884097 T C OSMR 
Non-
synonymous 
SNV 
OSMR:NM_001168355:exo
n5:c.T689C:p.V230A,OSM
R:NM_003999:exon5:c.T68
9C:p.V230A 
75 0.43 
chr2 112832730 112832730 - T IL1B 
frameshift 
insertion 
IL1B:NM_000576:exon5:c.
397dupA:p.S133fs 
10 0.40 
chr1 16130268 16130268 C T EPHA2 
Non-
synonymous 
SNV 
EPHA2:NM_004431:exon1
5:c.G2627A:p.R876H 28 0.39 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 28 0.39 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 23 0.39 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:exo
n3:c.396_398del:p.132_13
3del,CHD4:NM_001273:ex
on4:c.417_419del:p.139_1
40del 
29 0.28 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:ex
on7:c.636dupA:p.V213fs,N
COR1:NM_001190440:exo
n9:c.963dupA:p.V322fs,NC
OR1:NM_006311:exon10:c
.963dupA:p.V322fs 
12 0.25 
chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:exo
n2:c.284_285insGT:p.D95f
s,SIRPA:NM_001040022:e
xon3:c.284_285insGT:p.D9
5fs,SIRPA:NM_080792:exo
n3:c.284_285insGT:p.D95f
s 
33 0.24 
chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.286_287del:p.L96fs,SI
RPA:NM_001040022:exon
3:c.286_287del:p.L96fs,SI
RPA:NM_080792:exon3:c.
286_287del:p.L96fs 
33 0.24 
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chr5 35867438 35867438 - A IL7R 
frameshift 
insertion 
IL7R:NM_002185:exon3:c.
355dupA:p.C118fs 
26 0.23 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
2470 0.22 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
14 0.21 
chr13 28389939 28389939 - T FLT1 
frameshift 
insertion 
FLT1:NM_001159920:exon
13:c.1825dupA:p.M609fs,F
LT1:NM_001160030:exon1
3:c.1825dupA:p.M609fs,FL
T1:NM_002019:exon13:c.1
825dupA:p.M609fs 
42 0.17 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:exo
n2:c.387_389del:p.129_13
0del,SIRPA:NM_00104002
2:exon3:c.387_389del:p.12
9_130del,SIRPA:NM_0807
92:exon3:c.387_389del:p.1
29_130del 
54 0.17 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:exo
n2:c.C300A:p.N100K,SIRP
A:NM_001040022:exon3:c.
C300A:p.N100K,SIRPA:N
M_080792:exon3:c.C300A:
p.N100K 
37 0.16 
 
Table S2.14: All Cancer Associated SNVs Called for Case 7. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 
22 1.00 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:c
.A1416T:p.Q472H 
10 0.80 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 
25 0.64 
chr5 38883969 38883969 T G OSMR 
Non-
synonymous 
SNV 
OSMR:NM_001168355:exo
n5:c.T561G:p.H187Q,OSM
R:NM_003999:exon5:c.T56
1G:p.H187Q 
75 0.56 
chr19 1627366 1627366 A G TCF3 
Non-
synonymous 
SNV 
TCF3:NM_001136139:exo
n5:c.T359C:p.L120P,TCF3:
NM_003200:exon6:c.T359
C:p.L120P 
38 0.55 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 
41 0.54 
chr10 63186253 63186253 T C JMJD1C 
Non-
synonymous 
SNV 
JMJD1C:NM_001282948:e
xon18:c.A6155G:p.N2052S
,JMJD1C:NM_032776:exon
19:c.A6701G:p.N2234S 
59 0.53 
chr12 103938446 103938446 C T HSP90B1 
Non-
synonymous 
SNV 
HSP90B1:NM_003299:exo
n7:c.C962T:p.P321L 
969 0.50 
chr22 22888120 22888120 C T IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:exo
n1:c.C67T:p.R23C 
102 0.49 
chr19 1627423 1627423 T C TCF3 
Non-
synonymous 
SNV 
TCF3:NM_001136139:exo
n5:c.A302G:p.K101R,TCF3
:NM_003200:exon6:c.A302
G:p.K101R 
32 0.47 
chr5 180624003 180624003 T C FLT4 
Non-
synonymous 
FLT4:NM_002020:exon11:
c.A1480G:p.T494A,FLT4:N
15 0.47 
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SNV M_182925:exon11:c.A1480
G:p.T494A 
chr9 136506781 136506781 C T NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exon
23:c.G3836A:p.R1279H 
13 0.46 
chr17 16057554 16057554 T C NCOR1 
Non-
synonymous 
SNV 
NCOR1:NM_001190440:ex
on39:c.A6043G:p.R2015G,
NCOR1:NM_006311:exon4
0:c.A6352G:p.R2118G 
22 0.45 
chr1 8014274 8014274 C T ERRFI1 
Non-
synonymous 
SNV 
ERRFI1:NM_018948:exon4
:c.G325A:p.D109N 
242 0.40 
chr9 132911517 132911517 A G TSC1 
Non-
synonymous 
SNV 
TSC1:NM_001162427:exo
n9:c.T812C:p.M271T,TSC1
:NM_000368:exon10:c.T96
5C:p.M322T,TSC1:NM_00
1162426:exon10:c.T965C:
p.M322T 
10 0.40 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:c
.G166A:p.V56I 
23 0.39 
chr2 208243593 208243593 C T IDH1 
Non-
synonymous 
SNV 
IDH1:NM_001282386:exon
6:c.G532A:p.V178I,IDH1:N
M_001282387:exon6:c.G5
32A:p.V178I,IDH1:NM_005
896:exon6:c.G532A:p.V178
I 
52 0.38 
chr22 23314009 23314009 C G BCR 
Non-
synonymous 
SNV 
BCR:NM_021574:exon20:c
.C3367G:p.L1123V,BCR:N
M_004327:exon21:c.C3499
G:p.L1167V 
118 0.36 
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chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
21 0.33 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 
2632 0.22 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:e
xon9:c.1617dupA:p.R539fs
,ZCCHC7:NM_001289120:
exon9:c.1617dupA:p.R539f
s,ZCCHC7:NM_001289121
:exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_032226:ex
on9:c.1617dupA:p.R539fs 
28 0.18 
chr3 30650379 30650379 - A TGFBR2 
frameshift 
insertion 
TGFBR2:NM_003242:exon
3:c.374dupA:p.E125fs,TGF
BR2:NM_001024847:exon
4:c.449dupA:p.E150fs 
70 0.17 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:exo
n5:c.A526G:p.R176G 
18 0.17 
chr9 21818093 21818093 G T MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon4:c
.G238T:p.A80S 
24 0.13 
Table S2.15: All Cancer Associated SNVs Called for Case 9. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exon
3:c.C98G:p.P33R,TP53:N
M_000546:exon4:c.C215G:
p.P72R,TP53:NM_0011261
12:exon4:c.C215G:p.P72R,
TP53:NM_001126113:exon
4:c.C215G:p.P72R,TP53:N
M_001126114:exon4:c.C21
5G:p.P72R,TP53:NM_0012
76695:exon4:c.C98G:p.P3
3R,TP53:NM_001276696:e
xon4:c.C98G:p.P33R,TP53
:NM_001276760:exon4:c.C
98G:p.P33R,TP53:NM_001
276761:exon4:c.C98G:p.P
33R 
20 1.00 
chr2 29193500 29193500 G C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:c.
C4587G:p.D1529E 56 1.00 
chr3 66381544 66381544 G A LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon17
:c.C2705T:p.A902V 104 1.00 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon2
0:c.A2395G:p.I799V 15 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:c
.G2671C:p.E891Q,ATRX:N
M_000489:exon9:c.G2785
C:p.E929Q 
10 1.00 
chrX 154400814 154400814 G A RPL10 
Non-
synonymous 
SNV 
RPL10:NM_001256577:ex
on6:c.G442A:p.V148I,RPL
10:NM_001256580:exon6:c
.G497A:p.S166N,RPL10:N
M_001303624:exon6:c.G6
05A:p.S202N,RPL10:NM_0
01303625:exon7:c.G605A:
3084 1.00 
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p.S202N,RPL10:NM_0060
13:exon7:c.G605A:p.S202
N 
chr2 29193615 29193615 T C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:c.
A4472G:p.K1491R 40 0.98 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_133
476:exon10:c.1359_1361d
el:p.453_454del,ZNF384:N
M_001135734:exon11:c.15
42_1544del:p.514_515del 
13 0.92 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c.
C731T:p.T244I 14 0.79 
chr1 120069346 120069346 C T NOTCH2 
Non-
synonymous 
SNV 
NOTCH2:NM_001200001:
exon1:c.G61A:p.A21T,NOT
CH2:NM_024408:exon1:c.
G61A:p.A21T 
27 0.70 
chr22 41177749 41177749 C T EP300 
Non-
synonymous 
SNV 
EP300:NM_001429:exon31
:c.C6038T:p.P2013L 20 0.55 
chr4 849720 849720 C T GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exon
25:c.G3595A:p.D1199N,G
AK:NM_005255:exon28:c.
G3889A:p.D1297N 
153 0.54 
chr4 108048727 108048727 G A LEF1 
Non-
synonymous 
SNV 
LEF1:NM_001130714:exon
10:c.C1106T:p.T369M 152 0.49 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c.
T197C:p.I66T 43 0.49 
chr5 150135834 150135834 T A PDGFRB 
Non-
synonymous 
PDGFRB:NM_002609:exo
n3:c.A85T:p.I29F 
83 0.48 
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SNV 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon1
2:c.C5885T:p.P1962L 23 0.43 
chr20 32071703 32071703 A G HCK 
Non-
synonymous 
SNV 
HCK:NM_001172129:exon
2:c.A41G:p.N14S,HCK:NM
_001172130:exon2:c.A104
G:p.N35S,HCK:NM_00117
2131:exon2:c.A41G:p.N14
S,HCK:NM_002110:exon2:
c.A104G:p.N35S,HCK:NM_
001172132:exon3:c.A44G:
p.N15S,HCK:NM_0011721
33:exon3:c.A41G:p.N14S 
28 0.43 
chr5 150077330 150077330 C T CSF1R 
Non-
synonymous 
SNV 
CSF1R:NM_001288705:ex
on5:c.G835A:p.V279M,CS
F1R:NM_005211:exon6:c.
G835A:p.V279M 
33 0.42 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c.
G412A:p.V138I 43 0.35 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2:
c.44dupA:p.K15fs 2278 0.22 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:e
xon9:c.1617dupA:p.R539fs
,ZCCHC7:NM_001289120:
exon9:c.1617dupA:p.R539f
s,ZCCHC7:NM_001289121
:exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_032226:ex
on9:c.1617dupA:p.R539fs 
53 0.17 
chr12 14478321 14478321 - A ATF7IP 
frameshift 
insertion 
ATF7IP:NM_001286514:ex
on12:c.2944dupA:p.P981fs
,ATF7IP:NM_001286515:e
xon12:c.2944dupA:p.P981f
s,ATF7IP:NM_018179:exo
n12:c.2947dupA:p.P982fs,
ATF7IP:NM_181352:exon1
2:c.2971dupA:p.P990fs 
46 0.15 
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chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon6:
c.1224dupA:p.Q409fs 96 0.13 
 
Table S2.16: All Cancer Associated SNVs Called for Case 10. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
15 1.00 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
97 1.00 
chr2 29193500 29193500 G C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:
c.C4587G:p.D1529E 196 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 19 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 23 1.00 
chr8 105802428 105802428 G C ZFPM2 
Non-
synonymous 
SNV 
ZFPM2:NM_012082:exon
8:c.G2346C:p.E782D 11 1.00 
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chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 24 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G2671C:p.E891Q,ATRX
:NM_000489:exon9:c.G27
85C:p.E929Q 
23 1.00 
chr7 148828812 148828812 C G EZH2 
Non-
synonymous 
SNV 
EZH2:NM_152998:exon5:
c.G436C:p.D146H,EZH2:
NM_001203247:exon6:c.
G553C:p.D185H,EZH2:N
M_001203248:exon6:c.G5
26C:p.D176H,EZH2:NM_0
01203249:exon6:c.G526C
:p.D176H,EZH2:NM_0044
56:exon6:c.G553C:p.D185
H 
24 0.75 
chr8 32756465 32756465 T C NRG1 
Non-
synonymous 
SNV 
NRG1:NM_001159996:ex
on5:c.T404C:p.M135T,NR
G1:NM_001160004:exon9
:c.T857C:p.M286T,NRG1:
NM_001160008:exon9:c.T
857C:p.M286T,NRG1:NM
_013957:exon9:c.T857C:p
.M286T,NRG1:NM_01396
0:exon9:c.T866C:p.M289T
,NRG1:NM_013964:exon9
:c.T866C:p.M289T,NRG1:
NM_013956:exon10:c.T88
1C:p.M294T 
12 0.75 
chr11 108304735 108304735 G A ATM 
Non-
synonymous 
SNV 
ATM:NM_000051:exon37:
c.G5557A:p.D1853N 26 0.62 
chr5 180618911 180618911 G A FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon21
:c.C2860T:p.P954S,FLT4:
NM_182925:exon21:c.C2
860T:p.P954S 
49 0.59 
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chr17 43071077 43071077 T C BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
14:c.A4696G:p.S1566G,B
RCA1:NM_007298:exon1
4:c.A1525G:p.S509G,BR
CA1:NM_007294:exon15:
c.A4837G:p.S1613G,BRC
A1:NM_007299:exon15:c.
A1525G:p.S509G,BRCA1:
NM_007300:exon16:c.A49
00G:p.S1634G 
11 0.55 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 67 0.54 
chr9 134048405 134048405 G A BRD3 
Non-
synonymous 
SNV 
BRD3:NM_007371:exon6:
c.C764T:p.A255V 19 0.53 
chr17 43092418 43092418 T C BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
9:c.A2972G:p.E991G,BR
CA1:NM_007294:exon10:
c.A3113G:p.E1038G,BRC
A1:NM_007300:exon10:c.
A3113G:p.E1038G 
10 0.50 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:
c.G166A:p.V56I 54 0.50 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:
c.A1416T:p.Q472H 92 0.49 
chr9 130885205 130885205 C T ABL1 
Non-
synonymous 
SNV 
ABL1:NM_005157:exon11
:c.C2915T:p.S972L,ABL1:
NM_007313:exon11:c.C2
972T:p.S991L 
68 0.49 
chr1 36472277 36472277 C T CSF3R 
Non-
synonymous 
SNV 
CSF3R:NM_000760:exon
8:c.G958A:p.D320N,CSF3
R:NM_156039:exon8:c.G9
58A:p.D320N,CSF3R:NM
_172313:exon8:c.G958A:
p.D320N 
31 0.48 
140 
 
chr9 131144699 131144699 A G NUP214 
Non-
synonymous 
SNV 
NUP214:NM_005085:exo
n12:c.A1714G:p.M572V 15 0.47 
chr10 43114671 43114671 G A RET 
Non-
synonymous 
SNV 
RET:NM_020630:exon11:
c.G2071A:p.G691S,RET:
NM_020975:exon11:c.G2
071A:p.G691S 
12 0.42 
chr7 129212026 129212026 C T SMO 
Non-
synonymous 
SNV 
SMO:NM_005631:exon12:
c.C1939T:p.P647S 24 0.42 
chr9 136505728 136505728 G T NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exo
n25:c.C4168A:p.P1390T 37 0.41 
chr3 49360990 49360990 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A485G:p.K162R 14 0.36 
chr12 49039800 49039800 G A KMT2D 
Non-
synonymous 
SNV 
KMT2D:NM_003482:exon
31:c.C7970T:p.A2657V 15 0.33 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:e
xon7:c.636dupA:p.V213fs,
NCOR1:NM_001190440:e
xon9:c.963dupA:p.V322fs,
NCOR1:NM_006311:exon
10:c.963dupA:p.V322fs 
26 0.27 
chr1 16945542 16945542 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
15:c.G2072A:p.R691H 17 0.24 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 2919 0.22 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:
exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_0012891
20:exon9:c.1617dupA:p.R
539fs,ZCCHC7:NM_0012
89121:exon9:c.1617dupA:
p.R539fs,ZCCHC7:NM_03
2226:exon9:c.1617dupA:p
.R539fs 
34 0.18 
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chr11 3699158 3699158 - T NUP98 
frameshift 
insertion 
NUP98:NM_016320:exon
25:c.3932dupA:p.N1311fs,
NUP98:NM_139132:exon
25:c.3932dupA:p.N1311fs 
66 0.14 
 
Table S2.17: All Cancer Associated SNVs Called for Case 11. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
13 1.00 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
12 1.00 
chr5 68292320 68292320 G A PIK3R1 
Non-
synonymous 
SNV 
PIK3R1:NM_181504:exon
2:c.G168A:p.M56I,PIK3R1
:NM_181524:exon2:c.G78
A:p.M26I,PIK3R1:NM_181
523:exon8:c.G978A:p.M3
26I 
53 1.00 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 14 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 12 0.75 
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chr19 15185631 15185631 C T NOTCH3 
Non-
synonymous 
SNV 
NOTCH3:NM_000435:exo
n13:c.G2000A:p.G667D 34 0.62 
chr15 41578151 41578151 A T TYRO3 
Non-
synonymous 
SNV 
TYRO3:NM_006293:exon
19:c.A2548T:p.I850L 57 0.60 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 16 0.56 
chr7 152162598 152162598 G A KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
43:c.C10979T:p.S3660L 13 0.54 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:
c.A1416T:p.Q472H 28 0.54 
chr5 180603313 180603313 C A FLT4 
Non-
synonymous 
SNV 
FLT4:NM_182925:exon30
:c.G3971T:p.R1324L 19 0.53 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 29 0.52 
chr16 67611435 67611435 - A CTCF 
frameshift 
insertion 
CTCF:NM_006565:exon3:
c.604dupA:p.A201fs 10 0.50 
chr17 59213482 59213482 A C SMG8 
Non-
synonymous 
SNV 
SMG8:NM_018149:exon3:
c.A2659C:p.M887L 30 0.50 
chr1 150578851 150578851 G A MCL1 
Non-
synonymous 
SNV 
MCL1:NM_021960:exon1:
c.C680T:p.A227V,MCL1:N
M_182763:exon1:c.C680T
:p.A227V,MCL1:NM_0011
97320:exon2:c.C221T:p.A
74V 
444 0.49 
chr16 8900578 8900578 T C USP7 
Non-
synonymous 
SNV 
USP7:NM_001286457:ex
on21:c.A2213G:p.D738G,
USP7:NM_003470:exon2
1:c.A2261G:p.D754G,US
P7:NM_001286458:exon2
2:c.A1964G:p.D655G 
57 0.47 
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chr8 105802428 105802428 G C ZFPM2 
Non-
synonymous 
SNV 
ZFPM2:NM_012082:exon
8:c.G2346C:p.E782D 13 0.46 
chr5 180624003 180624003 T C FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon11
:c.A1480G:p.T494A,FLT4:
NM_182925:exon11:c.A14
80G:p.T494A 
11 0.45 
chr4 849932 849932 T C GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exo
n24:c.A3500G:p.K1167R,
GAK:NM_005255:exon27:
c.A3794G:p.K1265R 
110 0.45 
chr20 53576098 53576098 T C ZNF217 
Non-
synonymous 
SNV 
ZNF217:NM_006526:exon
3:c.A2666G:p.D889G 25 0.44 
chr17 21015763 21015763 C T USP22 
Non-
synonymous 
SNV 
USP22:NM_015276:exon
6:c.G827A:p.R276Q 30 0.43 
chr22 22893804 22893804 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A311G:p.K104R 682 0.39 
chr22 22893795 22893795 C G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.C302G:p.T101S 568 0.38 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 2186 0.22 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:e
xon7:c.636dupA:p.V213fs,
NCOR1:NM_001190440:e
xon9:c.963dupA:p.V322fs,
NCOR1:NM_006311:exon
10:c.963dupA:p.V322fs 
21 0.19 
chr12 14424946 14424946 A T ATF7IP 
Non-
synonymous 
SNV 
ATF7IP:NM_001286514:e
xon2:c.A1031T:p.N344I,A
TF7IP:NM_001286515:ex
on2:c.A1031T:p.N344I,AT
F7IP:NM_018179:exon2:c
.A1031T:p.N344I,ATF7IP:
NM_181352:exon2:c.A105
5T:p.N352I 
11 0.18 
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chr12 14424947 14424947 T A ATF7IP 
Non-
synonymous 
SNV 
ATF7IP:NM_001286514:e
xon2:c.T1032A:p.N344K,A
TF7IP:NM_001286515:ex
on2:c.T1032A:p.N344K,A
TF7IP:NM_018179:exon2:
c.T1032A:p.N344K,ATF7I
P:NM_181352:exon2:c.T1
056A:p.N352K 
11 0.18 
chr19 15257070 15257070 G A BRD4 
Non-
synonymous 
SNV 
BRD4:NM_014299:exon8:
c.C1445T:p.P482L,BRD4:
NM_058243:exon8:c.C14
45T:p.P482L 
11 0.18 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C300A:p.N100K,SI
RPA:NM_001040022:exo
n3:c.C300A:p.N100K,SIR
PA:NM_080792:exon3:c.C
300A:p.N100K 
17 0.18 
chr20 1915338 1915338 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C319A:p.R107S,SI
RPA:NM_001040022:exo
n3:c.C319A:p.R107S,SIR
PA:NM_080792:exon3:c.C
319A:p.R107S 
18 0.17 
chr2 38986101 38986101 - T SOS1 
frameshift 
insertion 
SOS1:NM_005633:exon2
3:c.3724dupA:p.S1242fs 46 0.15 
chr20 1915344 1915344 G A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.G325A:p.G109S,SI
RPA:NM_001040022:exo
n3:c.G325A:p.G109S,SIR
PA:NM_080792:exon3:c.
G325A:p.G109S 
17 0.12 
chr2 197401450 197401450 - A SF3B1 Stop-gain 
SF3B1:NM_012433:exon1
7:c.2445dupT:p.K816_H8
17delinsX 
227 0.11 
chr22 22893794 22893794 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A301G:p.T101A 566 0.11 
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chr22 22893783 22893783 A T IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A290T:p.Y97F 421 0.09 
 
Table S2.18: All Cancer Associated SNVs Called for Case 12. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 
30 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 
68 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 
77 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G2671C:p.E891Q,ATRX
:NM_000489:exon9:c.G27
85C:p.E929Q 
96 1.00 
chr10 63214620 63214620 G C JMJD1C 
Non-
synonymous 
SNV 
JMJD1C:NM_001282948:
exon7:c.C1001G:p.T334S,
JMJD1C:NM_032776:exo
n8:c.C1547G:p.T516S 
49 0.63 
chr1 169594799 169594799 C T SELP 
Non-
synonymous 
SNV 
SELP:NM_003005:exon13
:c.G2180A:p.G727E 
13 0.62 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:
c.A1416T:p.Q472H 
109 0.57 
chr4 24576653 24576653 G A DHX15 
Non-
synonymous 
SNV 
DHX15:NM_001358:exon
2:c.C97T:p.R33C 
207 0.52 
chr3 66383278 66383278 G A LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon1
5:c.C2195T:p.P732L 
31 0.52 
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chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
32 0.47 
chrX 154400814 154400814 G A RPL10 
Non-
synonymous 
SNV 
RPL10:NM_001256577:ex
on6:c.G442A:p.V148I,RPL
10:NM_001256580:exon6:
c.G497A:p.S166N,RPL10:
NM_001303624:exon6:c.
G605A:p.S202N,RPL10:N
M_001303625:exon7:c.G6
05A:p.S202N,RPL10:NM_
006013:exon7:c.G605A:p.
S202N 
858 0.45 
chr12 14424747 14424747 G A ATF7IP 
Non-
synonymous 
SNV 
ATF7IP:NM_001286514:e
xon2:c.G832A:p.E278K,A
TF7IP:NM_001286515:ex
on2:c.G832A:p.E278K,AT
F7IP:NM_018179:exon2:c
.G832A:p.E278K,ATF7IP:
NM_181352:exon2:c.G85
6A:p.E286K 
104 0.44 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 
12 0.42 
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chr11 118505199 118505199 - A KMT2A 
frameshift 
insertion 
KMT2A:NM_001197104:e
xon27:c.9308dupA:p.Q31
03fs,KMT2A:NM_005933:
exon27:c.9299dupA:p.Q3
100fs 
15 0.40 
chr10 63208191 63208196 CTAAAC - JMJD1C 
Non-
frameshift 
deletion 
JMJD1C:NM_001282948:
exon9:c.2927_2932del:p.9
76_978del,JMJD1C:NM_0
32776:exon10:c.3473_347
8del:p.1158_1160del 
61 0.39 
chr1 16946274 16946274 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.G2152A:p.V718M 
11 0.27 
chr1 16946292 16946292 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.A2170G:p.M724V 
11 0.27 
chr19 4054601 4054601 G T ZBTB7A 
Non-
synonymous 
SNV 
ZBTB7A:NM_015898:exo
n2:c.C632A:p.A211E 
11 0.27 
chr19 4054604 4054604 G T ZBTB7A 
Non-
synonymous 
SNV 
ZBTB7A:NM_015898:exo
n2:c.C629A:p.A210D 
11 0.27 
chr20 56383154 56383154 A G AURKA 
Non-
synonymous 
SNV 
AURKA:NM_003600:exon
5:c.T397C:p.F133L,AURK
A:NM_198435:exon5:c.T3
97C:p.F133L,AURKA:NM
_198437:exon5:c.T397C:p
.F133L,AURKA:NM_1984
34:exon6:c.T397C:p.F133
L,AURKA:NM_198436:ex
on6:c.T397C:p.F133L,AU
RKA:NM_198433:exon7:c.
T397C:p.F133L 
15 0.27 
chr4 105275672 105275672 T G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.T5162G:p.L1721W 
27 0.26 
chr15 41762197 41762197 - A MGA 
frameshift 
insertion 
MGA:NM_001080541:exo
n21:c.6953dupA:p.Q2318f
s,MGA:NM_001164273:ex
on22:c.7580dupA:p.Q252
21 0.24 
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7fs 
chr20 56383135 56383135 A G AURKA 
Non-
synonymous 
SNV 
AURKA:NM_003600:exon
5:c.T416C:p.L139P,AURK
A:NM_198435:exon5:c.T4
16C:p.L139P,AURKA:NM
_198437:exon5:c.T416C:p
.L139P,AURKA:NM_1984
34:exon6:c.T416C:p.L139
P,AURKA:NM_198436:ex
on6:c.T416C:p.L139P,AU
RKA:NM_198433:exon7:c.
T416C:p.L139P 
14 0.21 
chrX 77681846 77681846 C A ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G3296T:p.R1099I,ATRX
:NM_000489:exon9:c.G34
10T:p.R1137I 
48 0.21 
chr19 4054607 4054607 A C ZBTB7A 
Non-
synonymous 
SNV 
ZBTB7A:NM_015898:exo
n2:c.T626G:p.V209G 
10 0.20 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 
573 0.19 
chr22 20092882 20092882 - A DGCR8 
frameshift 
insertion 
DGCR8:NM_022720:exon
8:c.1681dupA:p.S560fs 
31 0.16 
chr22 22893783 22893783 A T IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A290T:p.Y97F 
504 0.15 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon
6:c.1224dupA:p.Q409fs 
144 0.13 
chr10 21673692 21673692 A G MLLT10 
Non-
synonymous 
SNV 
MLLT10:NM_001195626:
exon10:c.A1394G:p.E465
G,MLLT10:NM_004641:ex
on11:c.A1394G:p.E465G 
23 0.13 
chr11 108293436 108293436 - A ATM 
frameshift 
insertion 
ATM:NM_000051:exon31:
c.4736dupA:p.Q1579fs 
90 0.12 
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chr10 21673696 21673696 G T MLLT10 
Non-
synonymous 
SNV 
MLLT10:NM_001195626:
exon10:c.G1398T:p.K466
N,MLLT10:NM_004641:ex
on11:c.G1398T:p.K466N 
26 0.12 
 
Table S2.19: All Cancer Associated SNVs Called for Case 13. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
22 1.00 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.387_389del:p.129_1
30del,SIRPA:NM_001040
022:exon3:c.387_389del:p
.129_130del,SIRPA:NM_0
80792:exon3:c.387_389de
l:p.129_130del 
26 1.00 
chrX 40074864 40074864 G A BCOR 
Non-
synonymous 
SNV 
BCOR:NM_001123383:ex
on4:c.C482T:p.A161V,BC
OR:NM_001123384:exon
4:c.C482T:p.A161V,BCO
R:NM_001123385:exon4:
c.C482T:p.A161V,BCOR:
NM_017745:exon4:c.C48
2T:p.A161V 
14 1.00 
chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:ex
on2:c.284_285insGT:p.D9
5fs,SIRPA:NM_00104002
2:exon3:c.284_285insGT:
p.D95fs,SIRPA:NM_0807
92:exon3:c.284_285insGT
56 0.95 
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:p.D95fs 
chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.286_287del:p.L96fs,
SIRPA:NM_001040022:ex
on3:c.286_287del:p.L96fs,
SIRPA:NM_080792:exon3
:c.286_287del:p.L96fs 
56 0.95 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C300A:p.N100K,SI
RPA:NM_001040022:exo
n3:c.C300A:p.N100K,SIR
PA:NM_080792:exon3:c.C
300A:p.N100K 
50 0.94 
chr20 1915338 1915338 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C319A:p.R107S,SI
RPA:NM_001040022:exo
n3:c.C319A:p.R107S,SIR
PA:NM_080792:exon3:c.C
319A:p.R107S 
32 0.91 
chr7 55161562 55161562 G A EGFR 
Non-
synonymous 
SNV 
EGFR:NM_005228:exon1
3:c.G1562A:p.R521K,EGF
R:NM_201282:exon13:c.G
1562A:p.R521K,EGFR:N
M_201284:exon13:c.G156
2A:p.R521K 
31 0.90 
chr20 1915344 1915344 G A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.G325A:p.G109S,SI
RPA:NM_001040022:exo
n3:c.G325A:p.G109S,SIR
PA:NM_080792:exon3:c.
G325A:p.G109S 
25 0.88 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 
10 0.70 
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chr9 136505767 136505767 G A NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exo
n25:c.C4129T:p.P1377S 
74 0.68 
chr3 142453222 142453222 G C ATR 
Non-
synonymous 
SNV 
ATR:NM_001184:exon46:
c.C7667G:p.T2556S 
57 0.63 
chr3 47121396 47121396 C T SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
3:c.G3240A:p.M1080I 
83 0.53 
chr19 41238025 41238025 G A AXL 
Non-
synonymous 
SNV 
AXL:NM_001278599:exon
4:c.G61A:p.V21M,AXL:N
M_001699:exon7:c.G865
A:p.V289M,AXL:NM_0219
13:exon7:c.G865A:p.V289
M 
132 0.52 
chr3 128486108 128486108 C T GATA2 
Non-
synonymous 
SNV 
GATA2:NM_001145662:e
xon3:c.G490A:p.A164T,G
ATA2:NM_032638:exon3:
c.G490A:p.A164T,GATA2:
NM_001145661:exon4:c.
G490A:p.A164T 
10 0.50 
chr4 105234042 105234042 C T TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n3:c.C100T:p.L34F,TET2:
NM_017628:exon3:c.C10
0T:p.L34F 
42 0.50 
chr5 150129960 150129960 C T PDGFRB 
Non-
synonymous 
SNV 
PDGFRB:NM_002609:exo
n10:c.G1376A:p.R459H 
380 0.50 
chr5 180624003 180624003 T C FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon11
:c.A1480G:p.T494A,FLT4:
NM_182925:exon11:c.A14
80G:p.T494A 
72 0.47 
chr1 119929089 119929089 C T NOTCH2 
Non-
synonymous 
SNV 
NOTCH2:NM_024408:exo
n23:c.G3779A:p.R1260H 
228 0.46 
chr8 127740499 127740499 C A MYC 
Non-
synonymous 
SNV 
MYC:NM_002467:exon3:c
.C906A:p.H302Q 
123 0.46 
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chr1 179108013 179108013 C T ABL2 
Non-
synonymous 
SNV 
ABL2:NM_001168236:exo
n11:c.G3191A:p.S1064N,
ABL2:NM_001168238:exo
n12:c.G2882A:p.S961N,A
BL2:NM_001168239:exon
12:c.G2837A:p.S946N,AB
L2:NM_005158:exon12:c.
G3209A:p.S1070N,ABL2:
NM_007314:exon12:c.G3
254A:p.S1085N,ABL2:NM
_001136000:exon13:c.G2
900A:p.S967N,ABL2:NM_
001168237:exon13:c.G29
45A:p.S982N 
53 0.43 
chr4 105275843 105275843 A G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.A5333G:p.H1778R 
21 0.43 
chr16 72950696 72950696 C A ZFHX3 
Non-
synonymous 
SNV 
ZFHX3:NM_001164766:e
xon2:c.G247T:p.A83S,ZF
HX3:NM_006885:exon3:c.
G2989T:p.A997S 
77 0.40 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A526G:p.R176G 
30 0.40 
chr19 15254239 15254239 C T BRD4 
Non-
synonymous 
SNV 
BRD4:NM_014299:exon1
1:c.G2071A:p.G691S,BR
D4:NM_058243:exon11:c.
G2071A:p.G691S 
58 0.40 
chr12 111434918 111434918 T C SH2B3 
Non-
synonymous 
SNV 
SH2B3:NM_001291424:e
xon1:c.T17C:p.L6P 
14 0.36 
chr16 3664410 3664410 - CGG TRAP1 
Non-
frameshift 
insertion 
TRAP1:NM_001272049:e
xon12:c.1273_1274insCC
G:p.G425delinsAG,TRAP
1:NM_016292:exon13:c.1
432_1433insCCG:p.G478
delinsAG 
38 0.34 
chr3 49360990 49360990 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A485G:p.K162R 
22 0.32 
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chr13 32332592 32332592 A C BRCA2 
Non-
synonymous 
SNV 
BRCA2:NM_000059:exon
10:c.A1114C:p.N372H 
26 0.31 
chr13 32379885 32379885 - A BRCA2 
frameshift 
insertion 
BRCA2:NM_000059:exon
23:c.9090dupA:p.T3030fs 
17 0.29 
chr3 49360951 49360951 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A524G:p.Y175C 
30 0.27 
chr11 118505199 118505199 - A KMT2A 
frameshift 
insertion 
KMT2A:NM_001197104:e
xon27:c.9308dupA:p.Q31
03fs,KMT2A:NM_005933:
exon27:c.9299dupA:p.Q3
100fs 
17 0.24 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 
365 0.21 
chr22 20092882 20092882 - A DGCR8 
frameshift 
insertion 
DGCR8:NM_022720:exon
8:c.1681dupA:p.S560fs 
19 0.21 
chr3 49360997 49360997 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A478G:p.R160G 
24 0.21 
chr6 113970875 113970875 - T HDAC2 
frameshift 
insertion 
HDAC2:NM_001527:exon
1:c.33dupA:p.V12fs 
58 0.21 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:ex
on3:c.396_398del:p.132_1
33del,CHD4:NM_001273:
exon4:c.417_419del:p.139
_140del 
150 0.19 
chr10 63214489 63214489 - T JMJD1C 
frameshift 
insertion 
JMJD1C:NM_001282948:
exon7:c.1131dupA:p.D378
fs,JMJD1C:NM_032776:e
xon8:c.1677dupA:p.D560f
s 
79 0.19 
chrX 77681846 77681846 C A ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G3296T:p.R1099I,ATRX
:NM_000489:exon9:c.G34
10T:p.R1137I 
76 0.18 
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chr18 63318650 63318650 C G BCL2 
Non-
synonymous 
SNV 
BCL2:NM_000633:exon2:
c.G17C:p.R6T,BCL2:NM_
000657:exon2:c.G17C:p.R
6T 
12 0.17 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:e
xon7:c.636dupA:p.V213fs,
NCOR1:NM_001190440:e
xon9:c.963dupA:p.V322fs,
NCOR1:NM_006311:exon
10:c.963dupA:p.V322fs 
98 0.15 
chr19 15178881 15178881 T C NOTCH3 
Non-
synonymous 
SNV 
NOTCH3:NM_000435:exo
n23:c.A3779G:p.Q1260R 
111 0.14 
chr1 16946292 16946292 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.A2170G:p.M724V 
23 0.13 
chr1 16946274 16946274 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.G2152A:p.V718M 
26 0.12 
chr22 22893804 22893804 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A311G:p.K104R 
873 0.08 
 
Table S2.20: All Cancer Associated SNVs Called for Case 14. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr10 19204380 19204380 G A MALRD1 
Non-
synonymous 
SNV 
MALRD1:NM_001142308:
exon16:c.G2177A:p.S726
N 
12 1.00 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
44 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 142 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 125 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G2671C:p.E891Q,ATRX
:NM_000489:exon9:c.G27
85C:p.E929Q 
116 1.00 
chrX 154400814 154400814 G A RPL10 
Non-
synonymous 
SNV 
RPL10:NM_001256577:ex
on6:c.G442A:p.V148I,RPL
10:NM_001256580:exon6:
c.G497A:p.S166N,RPL10:
NM_001303624:exon6:c.
G605A:p.S202N,RPL10:N
M_001303625:exon7:c.G6
05A:p.S202N,RPL10:NM_
1071 0.69 
159 
 
006013:exon7:c.G605A:p.
S202N 
chr1 179143010 179143010 C G ABL2 
Non-
synonymous 
SNV 
ABL2:NM_001136000:exo
n1:c.G35C:p.S12T,ABL2:
NM_001168239:exon1:c.
G35C:p.S12T,ABL2:NM_0
05158:exon1:c.G35C:p.S1
2T 
12 0.67 
chr1 16960806 16960806 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
27:c.A4081G:p.T1361A 16 0.63 
chr1 16969269 16969269 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
32:c.A5230G:p.S1744G 36 0.61 
chr16 72950696 72950696 C A ZFHX3 
Non-
synonymous 
SNV 
ZFHX3:NM_001164766:e
xon2:c.G247T:p.A83S,ZF
HX3:NM_006885:exon3:c.
G2989T:p.A997S 
56 0.59 
chr16 71648927 71648927 C T PHLPP2 
Non-
synonymous 
SNV 
PHLPP2:NM_001289003:
exon18:c.G3734A:p.R124
5Q,PHLPP2:NM_015020:
exon19:c.G3935A:p.R131
2Q 
12 0.58 
chr20 53576098 53576098 T C ZNF217 
Non-
synonymous 
SNV 
ZNF217:NM_006526:exon
3:c.A2666G:p.D889G 57 0.58 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c
.C731T:p.T244I 114 0.57 
chr7 152162598 152162598 G A KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
43:c.C10979T:p.S3660L 73 0.55 
chr9 8485834 8485834 G A PTPRD 
Non-
synonymous 
PTPRD:NM_002839:exon
28:c.C2983T:p.R995C 11 0.55 
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SNV 
chr7 55161562 55161562 G A EGFR 
Non-
synonymous 
SNV 
EGFR:NM_005228:exon1
3:c.G1562A:p.R521K,EGF
R:NM_201282:exon13:c.G
1562A:p.R521K,EGFR:N
M_201284:exon13:c.G156
2A:p.R521K 
127 0.54 
chr5 68292320 68292320 G A PIK3R1 
Non-
synonymous 
SNV 
PIK3R1:NM_181504:exon
2:c.G168A:p.M56I,PIK3R1
:NM_181524:exon2:c.G78
A:p.M26I,PIK3R1:NM_181
523:exon8:c.G978A:p.M3
26I 
193 0.52 
chr3 66380763 66380763 C T LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon1
8:c.G2869A:p.A957T 105 0.50 
chr4 54727298 54727298 A C KIT 
Non-
synonymous 
SNV 
KIT:NM_000222:exon10:c
.A1621C:p.M541L,KIT:NM
_001093772:exon10:c.A1
609C:p.M537L 
93 0.48 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 81 0.48 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:
c.G166A:p.V56I 113 0.48 
chr12 111434918 111434918 T C SH2B3 
Non-
synonymous 
SNV 
SH2B3:NM_001291424:e
xon1:c.T17C:p.L6P 30 0.47 
chr10 63177741 63177741 G C JMJD1C 
Non-
synonymous 
SNV 
JMJD1C:NM_001282948:
exon22:c.C6654G:p.D221
8E,JMJD1C:NM_032776:
exon23:c.C7200G:p.D240
0E 
233 0.46 
chr3 66380453 66380453 G C LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon1
9:c.C3092G:p.P1031R 153 0.46 
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chr19 15238894 15238894 - GCT BRD4 
Non-
frameshift 
insertion 
BRD4:NM_058243:exon1
9:c.3868_3869insAGC:p.
R1290delinsQR 
33 0.45 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 21 0.43 
chr4 849720 849720 C T GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exo
n25:c.G3595A:p.D1199N,
GAK:NM_005255:exon28:
c.G3889A:p.D1297N 
81 0.41 
chr15 41729314 41729314 T C MGA 
Non-
synonymous 
SNV 
MGA:NM_001080541:exo
n11:c.T3808C:p.C1270R,
MGA:NM_001164273:exo
n11:c.T3808C:p.C1270R 
47 0.40 
chr1 16954783 16954783 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
23:c.G3371A:p.R1124Q 13 0.38 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:
exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_0012891
20:exon9:c.1617dupA:p.R
539fs,ZCCHC7:NM_0012
89121:exon9:c.1617dupA:
p.R539fs,ZCCHC7:NM_03
2226:exon9:c.1617dupA:p
.R539fs 
29 0.28 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A526G:p.R176G 26 0.27 
chr1 16954740 16954740 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
23:c.G3328A:p.V1110M 15 0.27 
chr1 16946274 16946274 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.G2152A:p.V718M 40 0.25 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 763 0.20 
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chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:ex
on2:c.284_285insGT:p.D9
5fs,SIRPA:NM_00104002
2:exon3:c.284_285insGT:
p.D95fs,SIRPA:NM_0807
92:exon3:c.284_285insGT
:p.D95fs 
103 0.20 
chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.286_287del:p.L96fs,
SIRPA:NM_001040022:ex
on3:c.286_287del:p.L96fs,
SIRPA:NM_080792:exon3
:c.286_287del:p.L96fs 
104 0.20 
chr3 49360961 49360961 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A514G:p.S172G 26 0.19 
chr7 152177062 152177062 - T KMT2C 
frameshift 
insertion 
KMT2C:NM_170606:exon
38:c.8390dupA:p.K2797fs 101 0.19 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C300A:p.N100K,SI
RPA:NM_001040022:exo
n3:c.C300A:p.N100K,SIR
PA:NM_080792:exon3:c.C
300A:p.N100K 
104 0.18 
chr1 16946292 16946292 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.A2170G:p.M724V 36 0.17 
chr20 1915338 1915338 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C319A:p.R107S,SI
RPA:NM_001040022:exo
n3:c.C319A:p.R107S,SIR
PA:NM_080792:exon3:c.C
319A:p.R107S 
109 0.17 
chr3 49360951 49360951 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A524G:p.Y175C 25 0.16 
163 
 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.387_389del:p.129_1
30del,SIRPA:NM_001040
022:exon3:c.387_389del:p
.129_130del,SIRPA:NM_0
80792:exon3:c.387_389de
l:p.129_130del 
81 0.15 
chr20 1915344 1915344 G A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.G325A:p.G109S,SI
RPA:NM_001040022:exo
n3:c.G325A:p.G109S,SIR
PA:NM_080792:exon3:c.
G325A:p.G109S 
104 0.14 
chr1 16945580 16945580 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
15:c.G2110A:p.A704T 30 0.13 
chrX 77681846 77681846 C A ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G3296T:p.R1099I,ATRX
:NM_000489:exon9:c.G34
10T:p.R1137I 
93 0.12 
 
Table S2.21: All Cancer Associated SNVs Called for Case 16. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
111 1.00 
chr4 105275794 105275794 A G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.A5284G:p.I1762V 35 1.00 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 32 1.00 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
20 0.90 
chr7 138917686 138917686 G C KIAA1549 
Non-
synonymous 
SNV 
KIAA1549:NM_00116466
5:exon2:c.C1940G:p.S647
C,KIAA1549:NM_020910:
exon2:c.C1940G:p.S647C 
14 0.64 
chr13 28049450 28049450 C T FLT3 
Non-
synonymous 
SNV 
FLT3:NM_004119:exon8:c
.G970A:p.D324N 19 0.63 
165 
 
chr17 43071077 43071077 T C BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
14:c.A4696G:p.S1566G,B
RCA1:NM_007298:exon1
4:c.A1525G:p.S509G,BR
CA1:NM_007294:exon15:
c.A4837G:p.S1613G,BRC
A1:NM_007299:exon15:c.
A1525G:p.S509G,BRCA1:
NM_007300:exon16:c.A49
00G:p.S1634G 
16 0.63 
chr6 41936060 41936060 C A CCND3 
Non-
synonymous 
SNV 
CCND3:NM_001136125:e
xon4:c.G543T:p.E181D,C
CND3:NM_001136126:ex
on4:c.G171T:p.E57D,CCN
D3:NM_001136017:exon5
:c.G516T:p.E172D,CCND
3:NM_001287427:exon5:c
.G609T:p.E203D,CCND3:
NM_001287434:exon5:c.
G171T:p.E57D,CCND3:N
M_001760:exon5:c.G759T
:p.E253D 
233 0.61 
chr9 21970986 21970986 C G CDKN2A 
Non-
synonymous 
SNV 
CDKN2A:NM_000077:exo
n2:c.G373C:p.D125H,CD
KN2A:NM_001195132:ex
on2:c.G373C:p.D125H 
117 0.57 
chr18 44952641 44952641 G A SETBP1 
Non-
synonymous 
SNV 
SETBP1:NM_015559:exo
n4:c.G3301A:p.V1101I 16 0.56 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c
.C731T:p.T244I 176 0.56 
chr2 25799408 25799408 T C ASXL2 
Non-
synonymous 
SNV 
ASXL2:NM_018263:exon4
:c.A380G:p.K127R 196 0.55 
chr16 72787445 72787445 G A ZFHX3 
Non-
synonymous 
SNV 
ZFHX3:NM_001164766:e
xon9:c.C8089T:p.H2697Y,
ZFHX3:NM_006885:exon
10:c.C10831T:p.H3611Y 
21 0.52 
166 
 
chr17 43092919 43092919 G A BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
9:c.C2471T:p.P824L,BRC
A1:NM_007294:exon10:c.
C2612T:p.P871L,BRCA1:
NM_007300:exon10:c.C2
612T:p.P871L 
21 0.52 
chr4 55113391 55113391 C T KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon7:c
.G889A:p.V297I 270 0.52 
chr12 49038030 49038030 G T KMT2D 
Non-
synonymous 
SNV 
KMT2D:NM_003482:exon
34:c.C9326A:p.P3109H 112 0.52 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 104 0.51 
chr9 5126343 5126343 G A JAK2 
Non-
synonymous 
SNV 
JAK2:NM_004972:exon24
:c.G3188A:p.R1063H 285 0.51 
chr17 43092418 43092418 T C BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
9:c.A2972G:p.E991G,BR
CA1:NM_007294:exon10:
c.A3113G:p.E1038G,BRC
A1:NM_007300:exon10:c.
A3113G:p.E1038G 
14 0.50 
chr8 11548067 11548067 G A BLK 
Non-
synonymous 
SNV 
BLK:NM_001715:exon4:c.
G211A:p.A71T 10 0.50 
chr1 245915549 245915549 C T SMYD3 
Non-
synonymous 
SNV 
SMYD3:NM_001167740:e
xon8:c.G794A:p.R265H,S
MYD3:NM_022743:exon8:
c.G617A:p.R206H 
496 0.48 
chr9 132911517 132911517 A G TSC1 
Non-
synonymous 
SNV 
TSC1:NM_001162427:exo
n9:c.T812C:p.M271T,TSC
1:NM_000368:exon10:c.T
965C:p.M322T,TSC1:NM_
001162426:exon10:c.T96
5C:p.M322T 
44 0.48 
167 
 
chr1 179143010 179143010 C G ABL2 
Non-
synonymous 
SNV 
ABL2:NM_001136000:exo
n1:c.G35C:p.S12T,ABL2:
NM_001168239:exon1:c.
G35C:p.S12T,ABL2:NM_0
05158:exon1:c.G35C:p.S1
2T 
94 0.47 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 271 0.45 
chr4 55106807 55106807 T A KDR 
Non-
synonymous 
SNV 
KDR:NM_002253:exon11:
c.A1416T:p.Q472H 195 0.45 
chr11 3702551 3702551 G C NUP98 
Non-
synonymous 
SNV 
NUP98:NM_016320:exon
23:c.C3424G:p.Q1142E,N
UP98:NM_139132:exon23
:c.C3424G:p.Q1142E 
173 0.43 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 299 0.43 
chr1 169613079 169613079 C T SELP 
Non-
synonymous 
SNV 
SELP:NM_003005:exon5:
c.G625A:p.V209M 23 0.39 
chr9 131163898 131163898 A G NUP214 
Non-
synonymous 
SNV 
NUP214:NM_005085:exo
n20:c.A2752G:p.N918D 46 0.39 
chr6_GL000253
v2_alt 
3528887 3528895 
AGCAGCA
GC 
- NOTCH4 
Non-
frameshift 
deletion 
NOTCH4:NM_004557:exo
n1:c.36_44del:p.12_15del 42 0.38 
chr7 152144741 152144741 T C KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
55:c.A14315G:p.N4772S 113 0.38 
chr13 32332592 32332592 A C BRCA2 
Non-
synonymous 
SNV 
BRCA2:NM_000059:exon
10:c.A1114C:p.N372H 26 0.31 
chr17 43091983 43091983 T C BRCA1 
Non-
synonymous 
SNV 
BRCA1:NM_007297:exon
9:c.A3407G:p.K1136R,BR
CA1:NM_007294:exon10:
c.A3548G:p.K1183R,BRC
A1:NM_007300:exon10:c.
A3548G:p.K1183R 
18 0.28 
168 
 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G2671C:p.E891Q,ATRX
:NM_000489:exon9:c.G27
85C:p.E929Q 
133 0.26 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 1416 0.22 
chr11 118505199 118505199 - A KMT2A 
frameshift 
insertion 
KMT2A:NM_001197104:e
xon27:c.9308dupA:p.Q31
03fs,KMT2A:NM_005933:
exon27:c.9299dupA:p.Q3
100fs 
48 0.21 
chr7 152177062 152177062 - T KMT2C 
frameshift 
insertion 
KMT2C:NM_170606:exon
38:c.8390dupA:p.K2797fs 85 0.20 
chr3 49360951 49360951 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A524G:p.Y175C 26 0.19 
chr1 16938425 16938425 C T CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
11:c.C1316T:p.A439V 21 0.19 
chrX 77681846 77681846 C A ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G3296T:p.R1099I,ATRX
:NM_000489:exon9:c.G34
10T:p.R1137I 
104 0.16 
chr15 41762197 41762197 - A MGA 
frameshift 
insertion 
MGA:NM_001080541:exo
n21:c.6953dupA:p.Q2318f
s,MGA:NM_001164273:ex
on22:c.7580dupA:p.Q252
7fs 
77 0.16 
chr10 63214489 63214489 - T JMJD1C 
frameshift 
insertion 
JMJD1C:NM_001282948:
exon7:c.1131dupA:p.D378
fs,JMJD1C:NM_032776:e
xon8:c.1677dupA:p.D560f
s 
116 0.16 
chr19 10151462 10151462 - T DNMT1 
frameshift 
insertion 
DNMT1:NM_001379:exon
23:c.2152dupA:p.M718fs,
DNMT1:NM_001130823:e
xon24:c.2200dupA:p.M73
4fs 
148 0.15 
169 
 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon
6:c.1224dupA:p.Q409fs 470 0.14 
chrX 77684181 77684181 - T ATRX 
frameshift 
insertion 
ATRX:NM_138270:exon8:
c.960dupA:p.L321fs,ATRX
:NM_000489:exon9:c.107
4dupA:p.L359fs 
181 0.12 
chr11 119274893 119274893 - T CBL 
frameshift 
insertion 
CBL:NM_005188:exon5:c.
810dupT:p.A270fs 157 0.11 
 
Table S2.22: All Cancer Associated SNVs Called for Case 65. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column l ists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 60 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 19 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 16 1.00 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 18 1.00 
chr5 180630293 180630293 T C FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon4:c
.A445G:p.N149D,FLT4:N
M_182925:exon4:c.A445
G:p.N149D 
27 0.70 
chr6_GL000253
v2_alt 
3528887 3528895 
AGCAGCA
GC 
- NOTCH4 
Non-
frameshift 
deletion 
NOTCH4:NM_004557:exo
n1:c.36_44del:p.12_15del 13 0.69 
chr5 180612606 180612606 C T FLT4 
Non-
synonymous 
SNV 
FLT4:NM_002020:exon26
:c.G3437A:p.R1146H,FLT
4:NM_182925:exon26:c.G
3437A:p.R1146H 
68 0.68 
chr6 43771215 43771215 G A VEGFA 
Non-
synonymous 
SNV 
VEGFA:NM_001025366:e
xon1:c.G509A:p.S170N,V
EGFA:NM_001025367:ex
on1:c.G509A:p.S170N,VE
GFA:NM_001025368:exo
n1:c.G509A:p.S170N,VEG
FA:NM_001025369:exon1
:c.G509A:p.S170N,VEGF
A:NM_001025370:exon1:c
.G509A:p.S170N,VEGFA:
NM_001033756:exon1:c.
G509A:p.S170N,VEGFA:
NM_001171622:exon1:c.
G509A:p.S170N,VEGFA:
35 0.66 
171 
 
NM_001204385:exon1:c.
G509A:p.S170N,VEGFA:
NM_003376:exon1:c.G50
9A:p.S170N 
chr4 105275843 105275843 A G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.A5333G:p.H1778R 13 0.54 
chr5 38923171 38923171 G A OSMR 
Non-
synonymous 
SNV 
OSMR:NM_003999:exon1
3:c.G1787A:p.R596Q 223 0.54 
chr5 180603313 180603313 C A FLT4 
Non-
synonymous 
SNV 
FLT4:NM_182925:exon30
:c.G3971T:p.R1324L 71 0.51 
chr5 35874473 35874473 C T IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon6:c
.C731T:p.T244I 14 0.50 
chr7 106882147 106882147 A G PIK3CG 
Non-
synonymous 
SNV 
PIK3CG:NM_001282426:
exon7:c.A2569G:p.T857A,
PIK3CG:NM_001282427:
exon7:c.A2569G:p.T857A,
PIK3CG:NM_002649:exon
7:c.A2569G:p.T857A 
18 0.50 
chr17 16086391 16086391 C T NCOR1 
Non-
synonymous 
SNV 
NCOR1:NM_001190440:e
xon22:c.G3116A:p.R1039
Q,NCOR1:NM_006311:ex
on23:c.G3068A:p.R1023Q 
36 0.47 
chr9 21816759 21816759 G A MTAP 
Non-
synonymous 
SNV 
MTAP:NM_002451:exon3:
c.G166A:p.V56I 72 0.47 
172 
 
chr16 72794794 72794794 C T ZFHX3 
Non-
synonymous 
SNV 
ZFHX3:NM_001164766:e
xon8:c.G5146A:p.D1716N
,ZFHX3:NM_006885:exon
9:c.G7888A:p.D2630N 
12 0.42 
chr4 105236541 105236541 T C TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n3:c.T2599C:p.Y867H,TE
T2:NM_017628:exon3:c.T
2599C:p.Y867H 
12 0.42 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
17 0.41 
chr3 128486108 128486108 C T GATA2 
Non-
synonymous 
SNV 
GATA2:NM_001145662:e
xon3:c.G490A:p.A164T,G
ATA2:NM_032638:exon3:
c.G490A:p.A164T,GATA2:
NM_001145661:exon4:c.
G490A:p.A164T 
17 0.41 
chr11 3702551 3702551 G C NUP98 
Non-
synonymous 
SNV 
NUP98:NM_016320:exon
23:c.C3424G:p.Q1142E,N
UP98:NM_139132:exon23
:c.C3424G:p.Q1142E 
66 0.41 
chr7 116771869 116771869 C T MET 
Non-
synonymous 
SNV 
MET:NM_000245:exon14:
c.C2908T:p.R970C,MET:
NM_001127500:exon14:c.
C2962T:p.R988C 
35 0.37 
chr7 148828812 148828812 C G EZH2 
Non-
synonymous 
SNV 
EZH2:NM_152998:exon5:
c.G436C:p.D146H,EZH2:
NM_001203247:exon6:c.
G553C:p.D185H,EZH2:N
M_001203248:exon6:c.G5
26C:p.D176H,EZH2:NM_0
01203249:exon6:c.G526C
:p.D176H,EZH2:NM_0044
56:exon6:c.G553C:p.D185
H 
17 0.35 
173 
 
chr22 22893809 22893809 A T IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A316T:p.T106S 112 0.35 
chr2 46145188 46145188 C T PRKCE 
Non-
synonymous 
SNV 
PRKCE:NM_005400:exon
12:c.C1688T:p.T563M 13 0.31 
chr11 108304735 108304735 G A ATM 
Non-
synonymous 
SNV 
ATM:NM_000051:exon37:
c.G5557A:p.D1853N 11 0.27 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:e
xon7:c.636dupA:p.V213fs,
NCOR1:NM_001190440:e
xon9:c.963dupA:p.V322fs,
NCOR1:NM_006311:exon
10:c.963dupA:p.V322fs 
35 0.26 
chr16 2058786 2058786 - T TSC2 
frameshift 
insertion 
TSC2:NM_000548:exon10
:c.889dupT:p.V296fs,TSC
2:NM_001077183:exon10:
c.889dupT:p.V296fs,TSC2
:NM_001114382:exon10:c
.889dupT:p.V296fs 
21 0.24 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 2957 0.22 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:ex
on3:c.396_398del:p.132_1
33del,CHD4:NM_001273:
exon4:c.417_419del:p.139
_140del 
64 0.20 
chr22 22893804 22893804 A C IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on2:c.A311C:p.K104T 105 0.19 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon
6:c.1224dupA:p.Q409fs 215 0.12 
 
Table S2.23: All Cancer Associated SNVs Called for Case 66. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column lists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
21 1.00 
chr2 29193500 29193500 G C ALK 
Non-
synonymous 
SNV 
ALK:NM_004304:exon29:
c.C4587G:p.D1529E 36 1.00 
chr4 849720 849720 C T GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exo
n25:c.G3595A:p.D1199N,
GAK:NM_005255:exon28:
c.G3889A:p.D1297N 
210 1.00 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 179 1.00 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 151 1.00 
chr3 89472514 89472514 G A EPHA3 
Non-
synonymous 
SNV 
EPHA3:NM_005233:exon
16:c.G2741A:p.R914H 10 0.80 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 14 0.64 
chr4 105275794 105275794 A G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.A5284G:p.I1762V 15 0.60 
175 
 
chr20 56370253 56370253 T C AURKA 
Non-
synonymous 
SNV 
AURKA:NM_003600:exon
9:c.A1117G:p.M373V,AU
RKA:NM_198435:exon9:c.
A1117G:p.M373V,AURKA
:NM_198437:exon9:c.A11
17G:p.M373V,AURKA:NM
_198434:exon10:c.A1117
G:p.M373V,AURKA:NM_1
98436:exon10:c.A1117G:
p.M373V,AURKA:NM_198
433:exon11:c.A1117G:p.
M373V 
24 0.58 
chr7 152162598 152162598 G A KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
43:c.C10979T:p.S3660L 31 0.58 
chr1 81990901 81990901 G A ADGRL2 
Non-
synonymous 
SNV 
ADGRL2:NM_012302:exo
n20:c.G3968A:p.R1323K,
ADGRL2:NM_001297704:
exon21:c.G3968A:p.R132
3K 
79 0.56 
chr3 47083895 47083895 G A SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
12:c.C5885T:p.P1962L 53 0.55 
chr20 53581599 53581599 T C ZNF217 
Non-
synonymous 
SNV 
ZNF217:NM_006526:exon
1:c.A1228G:p.M410V 11 0.55 
chr18 12817349 12817349 G T PTPN2 
Non-
synonymous 
SNV 
PTPN2:NM_001308287:e
xon5:c.C425A:p.T142K,P
TPN2:NM_002828:exon6:
c.C512A:p.T171K,PTPN2:
NM_080422:exon6:c.C51
2A:p.T171K,PTPN2:NM_0
80423:exon6:c.C512A:p.T
171K,PTPN2:NM_001207
013:exon7:c.C581A:p.T19
4K 
177 0.51 
176 
 
chr7 148828812 148828812 C G EZH2 
Non-
synonymous 
SNV 
EZH2:NM_152998:exon5:
c.G436C:p.D146H,EZH2:
NM_001203247:exon6:c.
G553C:p.D185H,EZH2:N
M_001203248:exon6:c.G5
26C:p.D176H,EZH2:NM_0
01203249:exon6:c.G526C
:p.D176H,EZH2:NM_0044
56:exon6:c.G553C:p.D185
H 
41 0.51 
chr19 34466925 34466925 C T UBA2 
Non-
synonymous 
SNV 
UBA2:NM_005499:exon1
6:c.C1652T:p.P551L 144 0.51 
chr1 9717541 9717541 C G PIK3CD 
Non-
synonymous 
SNV 
PIK3CD:NM_005026:exon
8:c.C935G:p.S312C 13 0.46 
chr17 50188134 50188134 C T COL1A1 
Non-
synonymous 
SNV 
COL1A1:NM_000088:exo
n44:c.G3223A:p.A1075T 1591 0.45 
chr5 180603322 180603322 C T FLT4 
Non-
synonymous 
SNV 
FLT4:NM_182925:exon30
:c.G3962A:p.R1321Q 68 0.43 
chr1 16969820 16969820 G C CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
33:c.G5337C:p.E1779D 40 0.43 
chr16 67636779 67636779 C T CTCF 
Non-
synonymous 
SNV 
CTCF:NM_001191022:ex
on9:c.C943T:p.P315S,CT
CF:NM_006565:exon11:c.
C1927T:p.P643S 
40 0.43 
chr21 38383690 38383690 G A ERG 
Non-
synonymous 
SNV 
ERG:NM_001136155:exo
n9:c.C877T:p.R293C,ERG
:NM_001243429:exon9:c.
C805T:p.R269C,ERG:NM
_182918:exon10:c.C1153
T:p.R385C,ERG:NM_004
449:exon11:c.C1102T:p.R
368C,ERG:NM_00113615
4:exon12:c.C1174T:p.R39
2C,ERG:NM_001243428:
exon12:c.C1174T:p.R392
17 0.41 
177 
 
C 
chr12 111447491 111447491 G A SH2B3 
Non-
synonymous 
SNV 
SH2B3:NM_001291424:e
xon5:c.G577A:p.E193K,S
H2B3:NM_005475:exon6:
c.G1183A:p.E395K 
44 0.41 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
22 0.41 
chrX 154400814 154400814 G A RPL10 
Non-
synonymous 
SNV 
RPL10:NM_001256577:ex
on6:c.G442A:p.V148I,RPL
10:NM_001256580:exon6:
c.G497A:p.S166N,RPL10:
NM_001303624:exon6:c.
G605A:p.S202N,RPL10:N
M_001303625:exon7:c.G6
05A:p.S202N,RPL10:NM_
006013:exon7:c.G605A:p.
S202N 
2283 0.40 
178 
 
chr3 49360990 49360990 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A485G:p.K162R 25 0.40 
chr7 152180875 152180875 C T KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
36:c.G6985A:p.G2329R 30 0.40 
chr20 53576098 53576098 T C ZNF217 
Non-
synonymous 
SNV 
ZNF217:NM_006526:exon
3:c.A2666G:p.D889G 28 0.39 
chr11 118505199 118505199 - A KMT2A 
frameshift 
insertion 
KMT2A:NM_001197104:e
xon27:c.9308dupA:p.Q31
03fs,KMT2A:NM_005933:
exon27:c.9299dupA:p.Q3
100fs 
25 0.28 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 2036 0.22 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A526G:p.R176G 14 0.21 
chr9 37357252 37357252 - A ZCCHC7 
frameshift 
insertion 
ZCCHC7:NM_001289119:
exon9:c.1617dupA:p.R539
fs,ZCCHC7:NM_0012891
20:exon9:c.1617dupA:p.R
539fs,ZCCHC7:NM_0012
89121:exon9:c.1617dupA:
p.R539fs,ZCCHC7:NM_03
2226:exon9:c.1617dupA:p
.R539fs 
38 0.21 
chr17 16146494 16146494 - T NCOR1 
frameshift 
insertion 
NCOR1:NM_001190438:e
xon7:c.636dupA:p.V213fs,
NCOR1:NM_001190440:e
xon9:c.963dupA:p.V322fs,
NCOR1:NM_006311:exon
10:c.963dupA:p.V322fs 
53 0.17 
chr16 2058786 2058786 - T TSC2 
frameshift 
insertion 
TSC2:NM_000548:exon10
:c.889dupT:p.V296fs,TSC
2:NM_001077183:exon10:
c.889dupT:p.V296fs,TSC2
:NM_001114382:exon10:c
30 0.17 
179 
 
.889dupT:p.V296fs 
chrX 77682737 77682737 - T ATRX 
frameshift 
insertion 
ATRX:NM_138270:exon8:
c.2404dupA:p.R802fs,AT
RX:NM_000489:exon9:c.2
518dupA:p.R840fs 
54 0.17 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon
6:c.1224dupA:p.Q409fs 104 0.13 
 
Table S2.24: All Cancer Associated SNVs Called for Case 67. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column l ists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Chromosome Start End Reference Alteration Gene 
Exonic 
Function AA Change 
Read 
Depth 
VAF 
chr12 6667904 6667906 TGC - ZNF384 
Non-
frameshift 
deletion 
ZNF384:NM_001039920:e
xon9:c.1194_1196del:p.39
8_399del,ZNF384:NM_13
3476:exon10:c.1359_1361
del:p.453_454del,ZNF384:
NM_001135734:exon11:c.
1542_1544del:p.514_515
del 
17 1.00 
chr20 1915303 1915303 - GT SIRPA 
frameshift 
insertion 
SIRPA:NM_001040023:ex
on2:c.284_285insGT:p.D9
5fs,SIRPA:NM_00104002
2:exon3:c.284_285insGT:
p.D95fs,SIRPA:NM_0807
92:exon3:c.284_285insGT
:p.D95fs 
54 1.00 
chr20 1915305 1915306 CT - SIRPA 
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.286_287del:p.L96fs,
SIRPA:NM_001040022:ex
on3:c.286_287del:p.L96fs,
SIRPA:NM_080792:exon3
:c.286_287del:p.L96fs 
54 1.00 
chr20 1915319 1915319 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C300A:p.N100K,SI
RPA:NM_001040022:exo
n3:c.C300A:p.N100K,SIR
PA:NM_080792:exon3:c.C
300A:p.N100K 
50 1.00 
chr20 1915338 1915338 C A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.C319A:p.R107S,SI
RPA:NM_001040022:exo
n3:c.C319A:p.R107S,SIR
PA:NM_080792:exon3:c.C
319A:p.R107S 
42 1.00 
181 
 
chr20 1915344 1915344 G A SIRPA 
Non-
synonymous 
SNV 
SIRPA:NM_001040023:ex
on2:c.G325A:p.G109S,SI
RPA:NM_001040022:exo
n3:c.G325A:p.G109S,SIR
PA:NM_080792:exon3:c.
G325A:p.G109S 
37 1.00 
chr20 1915406 1915408 CGA - SIRPA 
Non-
frameshift 
deletion 
SIRPA:NM_001040023:ex
on2:c.387_389del:p.129_1
30del,SIRPA:NM_001040
022:exon3:c.387_389del:p
.129_130del,SIRPA:NM_0
80792:exon3:c.387_389de
l:p.129_130del 
32 1.00 
chrX 77682471 77682471 C G ATRX 
Non-
synonymous 
SNV 
ATRX:NM_138270:exon8:
c.G2671C:p.E891Q,ATRX
:NM_000489:exon9:c.G27
85C:p.E929Q 
33 1.00 
chr3 89472514 89472514 G A EPHA3 
Non-
synonymous 
SNV 
EPHA3:NM_005233:exon
16:c.G2741A:p.R914H 26 0.96 
chr7 152162598 152162598 G A KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
43:c.C10979T:p.S3660L 17 0.65 
chr15 41736622 41736622 A G MGA 
Non-
synonymous 
SNV 
MGA:NM_001080541:exo
n13:c.A4358G:p.Y1453C,
MGA:NM_001164273:exo
n13:c.A4358G:p.Y1453C 
11 0.64 
chr2 25750067 25750067 C T ASXL2 
Non-
synonymous 
SNV 
ASXL2:NM_018263:exon1
1:c.G1489A:p.A497T 11 0.64 
chr3 47121396 47121396 C T SETD2 
Non-
synonymous 
SNV 
SETD2:NM_014159:exon
3:c.G3240A:p.M1080I 31 0.61 
chr9 136523857 136523857 C T NOTCH1 
Non-
synonymous 
SNV 
NOTCH1:NM_017617:exo
n3:c.G263A:p.S88N 12 0.58 
chr16 72788746 72788746 G A ZFHX3 
Non-
synonymous 
SNV 
ZFHX3:NM_001164766:e
xon9:c.C6788T:p.S2263L,
ZFHX3:NM_006885:exon
10:c.C9530T:p.S3177L 
16 0.56 
182 
 
chr2 43225479 43225479 C T ZFP36L2 
Non-
synonymous 
SNV 
ZFP36L2:NM_006887:exo
n2:c.G325A:p.G109S 241 0.53 
chr3 66380453 66380453 G C LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon1
9:c.C3092G:p.P1031R 97 0.53 
chr3 66380763 66380763 C T LRIG1 
Non-
synonymous 
SNV 
LRIG1:NM_015541:exon1
8:c.G2869A:p.A957T 74 0.50 
chr22 22895680 22895680 A G IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001256296:ex
on2:c.A406G:p.T136A,IGL
L5:NM_001178126:exon3:
c.A631G:p.T211A 
763 0.50 
chr1 16130268 16130268 C T EPHA2 
Non-
synonymous 
SNV 
EPHA2:NM_004431:exon
15:c.G2627A:p.R876H 57 0.49 
chr4 849720 849720 C T GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exo
n25:c.G3595A:p.D1199N,
GAK:NM_005255:exon28:
c.G3889A:p.D1297N 
116 0.47 
chr9 132911517 132911517 A G TSC1 
Non-
synonymous 
SNV 
TSC1:NM_001162427:exo
n9:c.T812C:p.M271T,TSC
1:NM_000368:exon10:c.T
965C:p.M322T,TSC1:NM_
001162426:exon10:c.T96
5C:p.M322T 
43 0.47 
chr4 108048727 108048727 G A LEF1 
Non-
synonymous 
SNV 
LEF1:NM_001130714:exo
n10:c.C1106T:p.T369M 69 0.46 
chr11 3679646 3679646 C T NUP98 
Non-
synonymous 
SNV 
NUP98:NM_139132:exon
30:c.G4759A:p.E1587K,N
UP98:NM_016320:exon31
:c.G4981A:p.E1661K 
131 0.45 
chr17 16061887 16061887 G A NCOR1 
Non-
synonymous 
SNV 
NCOR1:NM_001190440:e
xon36:c.C5443T:p.P1815
S,NCOR1:NM_006311:ex
on37:c.C5395T:p.P1799S 
49 0.45 
chr19 15161407 15161407 G A NOTCH3 
Non-
synonymous 
SNV 
NOTCH3:NM_000435:exo
n33:c.C6221T:p.P2074L 29 0.45 
183 
 
chr4 849932 849932 T C GAK 
Non-
synonymous 
SNV 
GAK:NM_001286833:exo
n24:c.A3500G:p.K1167R,
GAK:NM_005255:exon27:
c.A3794G:p.K1265R 
136 0.44 
chr4 105275672 105275672 T G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n11:c.T5162G:p.L1721W 16 0.44 
chr5 35860966 35860966 T C IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon2:c
.T197C:p.I66T 277 0.42 
chr17 7676154 7676154 G C TP53 
Non-
synonymous 
SNV 
TP53:NM_001126118:exo
n3:c.C98G:p.P33R,TP53:
NM_000546:exon4:c.C21
5G:p.P72R,TP53:NM_001
126112:exon4:c.C215G:p.
P72R,TP53:NM_0011261
13:exon4:c.C215G:p.P72
R,TP53:NM_001126114:e
xon4:c.C215G:p.P72R,TP
53:NM_001276695:exon4:
c.C98G:p.P33R,TP53:NM
_001276696:exon4:c.C98
G:p.P33R,TP53:NM_0012
76760:exon4:c.C98G:p.P3
3R,TP53:NM_001276761:
exon4:c.C98G:p.P33R 
61 0.41 
chr19 41352971 41352971 C G TGFB1 
Non-
synonymous 
SNV 
TGFB1:NM_000660:exon
1:c.G74C:p.R25P 48 0.40 
chr7 152162938 152162938 A G KMT2C 
Non-
synonymous 
SNV 
KMT2C:NM_170606:exon
43:c.T10639C:p.S3547P 18 0.39 
chr1 16938425 16938425 C T CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
11:c.C1316T:p.A439V 16 0.38 
184 
 
chr20 32795432 32795432 G A DNMT3B 
Non-
synonymous 
SNV 
DNMT3B:NM_001207056:
exon8:c.G862A:p.A288T,
DNMT3B:NM_001207055:
exon9:c.G964A:p.A322T,
DNMT3B:NM_175848:exo
n10:c.G1090A:p.A364T,D
NMT3B:NM_175849:exon
10:c.G1090A:p.A364T,DN
MT3B:NM_175850:exon1
0:c.G1126A:p.A376T,DN
MT3B:NM_006892:exon1
1:c.G1150A:p.A384T 
46 0.37 
chr22 22888120 22888120 C T IGLL5 
Non-
synonymous 
SNV 
IGLL5:NM_001178126:ex
on1:c.C67T:p.R23C 11 0.36 
chr11 118505199 118505199 - A KMT2A 
frameshift 
insertion 
KMT2A:NM_001197104:e
xon27:c.9308dupA:p.Q31
03fs,KMT2A:NM_005933:
exon27:c.9299dupA:p.Q3
100fs 
17 0.35 
chr5 35871088 35871088 G A IL7R 
Non-
synonymous 
SNV 
IL7R:NM_002185:exon4:c
.G412A:p.V138I 206 0.34 
chr1 26773690 26773690 - GCA ARID1A 
Non-
frameshift 
insertion 
ARID1A:NM_006015:exon
16:c.3977_3978insGCA:p.
P1326delinsPQ,ARID1A:N
M_139135:exon16:c.3977
_3978insGCA:p.P1326deli
nsPQ 
14 0.29 
chr7 148828812 148828812 C G EZH2 
Non-
synonymous 
SNV 
EZH2:NM_152998:exon5:
c.G436C:p.D146H,EZH2:
NM_001203247:exon6:c.
G553C:p.D185H,EZH2:N
M_001203248:exon6:c.G5
26C:p.D176H,EZH2:NM_0
01203249:exon6:c.G526C
:p.D176H,EZH2:NM_0044
56:exon6:c.G553C:p.D185
H 
14 0.29 
185 
 
chr1 16946274 16946274 G A CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.G2152A:p.V718M 11 0.27 
chr1 16946292 16946292 A G CROCC 
Non-
synonymous 
SNV 
CROCC:NM_014675:exon
16:c.A2170G:p.M724V 13 0.23 
chr11 108293436 108293436 - A ATM 
frameshift 
insertion 
ATM:NM_000051:exon31:
c.4736dupA:p.Q1579fs 26 0.23 
chr1 6197724 6197724 - T RPL22 
frameshift 
insertion 
RPL22:NM_000983:exon2
:c.44dupA:p.K15fs 2179 0.20 
chr4 105234028 105234028 C G TET2 
Non-
synonymous 
SNV 
TET2:NM_001127208:exo
n3:c.C86G:p.P29R,TET2:
NM_017628:exon3:c.C86
G:p.P29R 
16 0.19 
chr9 132595027 132595027 T C DDX31 
Non-
synonymous 
SNV 
DDX31:NM_022779:exon
20:c.A2395G:p.I799V 29 0.17 
chr3 49360949 49360949 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A526G:p.R176G 19 0.16 
chr3 49360951 49360951 T C RHOA 
Non-
synonymous 
SNV 
RHOA:NM_001313943:ex
on5:c.A524G:p.Y175C 19 0.16 
chr19 10151462 10151462 - T DNMT1 
frameshift 
insertion 
DNMT1:NM_001379:exon
23:c.2152dupA:p.M718fs,
DNMT1:NM_001130823:e
xon24:c.2200dupA:p.M73
4fs 
73 0.15 
chr4 24548878 24548878 - T DHX15 
frameshift 
insertion 
DHX15:NM_001358:exon
6:c.1224dupA:p.Q409fs 166 0.14 
chr11 3699158 3699158 - T NUP98 
frameshift 
insertion 
NUP98:NM_016320:exon
25:c.3932dupA:p.N1311fs,
NUP98:NM_139132:exon
25:c.3932dupA:p.N1311fs 
98 0.13 
chr12 6601979 6601981 TCC - CHD4 
Non-
frameshift 
deletion 
CHD4:NM_001297553:ex
on3:c.396_398del:p.132_1
33del,CHD4:NM_001273:
exon4:c.417_419del:p.139
51 0.12 
186 
 
_140del 
chr5 35867438 35867438 - A IL7R 
frameshift 
insertion 
IL7R:NM_002185:exon3:c
.355dupA:p.C118fs 238 0.11 
 
Table S2.25: All Cancer Associated SNVs Called for Case 69. Variants were filtered based on a list of 383 pre-defined cancer genes. The variants were maintained if they were 
exonic, had a damaging function, previously reported in COSMIC, and were considered pathogenic in the ClinVar Database. Variants were then excluded if they had a variant allele 
frequency below 0.05, depth below 10, a prevalence of greater than 10% in the 1000 Genomes Project, or if no annotations were present. SNVs are shaded dark orange if the 
variant allele frequency (VAF) =1, and lighter shades of orange for VAFs>=.5 and<1 and VAFs <.5 and>.4. The ‘AA Change’ column l ists the ref.seq. number, the base pair 
alteration, and the amino acid alteration.  
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Category Term Count P Value 
Fold 
Enrichment 
FDR 
Reactome 
VEGF ligand-receptor interactions (R-HSA-194313) 2 
9.36E-
05  > 100 
4.65E-
02 
Reactome 
VEGF binds to VEGFR leading to receptor dimerization (R-HSA-195399) 2 
9.36E-
05  > 100 
3.72E-
02 
Reactome 
PKMTs methylate histone lysines (R-HSA-3214841) 3 
2.74E-
05 55.04 
1.82E-
02 
Reactome 
Chromatin modifying enzymes (R-HSA-3247509) 5 
1.96E-
05 15.15 
3.90E-
02 
Reactome 
Chromatin organization (R-HSA-4839726) 5 
1.96E-
05 15.15 
1.95E-
02 
Molecular 
Function vascular endothelial growth factor-activated receptor activity (GO:0005021) 2 
7.49E-
05  > 100 
4.36E-
02 
Molecular 
Function histone-lysine N-methyltransferase activity (GO:0018024) 3 
5.39E-
05 43.33 
5.02E-
02 
Molecular 
Function helicase activity (GO:0004386) 4 
5.86E-
05 19.26 
4.54E-
02 
 
Table S2.26: Gene Ontology Terms for Commonly Shared SNVs. Panther Gene Ontology Term Enrichment analysis was performed on the set of 30 genes which harbored the 
most commonly shared SNVs amongst all 18 samples evaluated by RNAseq. The ‘category’ column references the type of test performed. The ‘count’ column displays the number 
of genes associated with the term that were in the set of 30 evaluated. Statistics are calculated based on the count and the expected count. 
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# Official Ab Name  
Ab Name Reported on 
Dataset 
Gene Name Company Catalog # Species 
Validation 
Status* 
RPPA 
Dilution 
1 14-3-3 beta 14-3-3-beta YWHAB Santa Cruz sc-628 Rabbit Valid 1:75 
2 14-3-3 zeta 14-3-3-zeta YWHAZ Santa Cruz sc-1019 Rabbit Valid 1:5000 
3 4E-BP1 4E-BP1 EIF4EBP1 CST 9452 Rabbit Valid 1:100 
4 4E-BP1 (phospho S65) 4E-BP1_pS65 EIF4EBP1 CST 9456 Rabbit Valid 1:250 
5 53BP1 53BP1 TP53BP1 CST 4937 Rabbit Valid 1:300 
6 Acetyl CoA Carboxylase (phospho S79) ACC_pS79 ACACA, ACACB CST 3661 Rabbit Valid 1:500 
7 Acetyl CoA Carboxylase 1 ACC1 ACACA Abcam ab45174 Rabbit 
Use with 
Caution 
1:20000 
8 ADAR1 ADAR1 ADAR Abcam ab88574 Mouse Valid 1:200 
9 Akt Akt AKT1,2,3 CST 4691 Rabbit Valid 1:10000 
10 Akt (phospho S473) Akt_pS473 AKT1,2,3 CST 9271 Rabbit Valid 1:150 
11 Akt (phospho T308) Akt_pT308 AKT1,2,3 CST 2965 Rabbit Valid 1:500 
12 AMPK alpha AMPKa PRKAA1 CST 2532 Rabbit 
Use with 
Caution 
1:200 
13 AMPK alpha (phospho T172) AMPKa_pT172 PRKAA1 CST 2535 Rabbit 
Use with 
Caution 
1:100 
14 AMPK alpha 2 (Phospho S345) AMPK-a2 _pS345 PRKAA2 Abcam ab129081 Rabbit Valid 1:500 
15 Androgen Receptor AR AR CST 5153 Rabbit Valid 1:250 
16 Annexin I Annexin-I ANXA1 BD Biosciences 610066 Mouse Valid 1:5000 
17 Annexin VII Annexin-VII ANXA7  BD Biosciences 610668 Mouse Valid 1:30 
18 A-Raf A-Raf ARAF CST 4432 Rabbit Valid 1:150 
19 ARID1A ARID1A ARID1A Sigma-Aldrich HPA005456 Rabbit 
Use with 
Caution 
1:1000 
20 Atg3 Atg3 ATG3 CST 3415 Rabbit Valid 1:750 
21 Atg7 Atg7 ATG7 CST 8558 Rabbit Valid 1:1000 
22 ATM ATM ATM CST 2873 Rabbit Valid 1:250 
23 ATM(phospho S1981) ATM_pS1981 ATM CST 5883 Rabbit Valid 1:25 
24 
ATR (Phospho S428) ATR_pS428 ATR Abcam ab178407 Rabbit 
Use with 
Caution 1:1000 
25 Aurora B/AIM1 Aurora-B AIM1 CST 3094 Rabbit Valid 1:50 
26 Axl Axl AXL CST 8661 Rabbit Valid 1:1000 
27 
B7-H4 B7-H4 VTCN1 CST 14572 Rabbit 
Use with 
Caution 1:50 
28 Bad (phospho S112) Bad_pS112 BAD CST 9291 Rabbit Valid 1:50 
29 Bak Bak BAK1 Abcam ab32371 Rabbit 
Use with 
Caution 
1:30 
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30 BAP1 BAP1 BAP1 Santa Cruz sc-28383 Mouse Valid 1:125 
31 Bax Bax BAX CST 2772 Rabbit Valid 1:100 
32 Bcl2 Bcl2 BCL2 Dako M0887 Mouse Valid 1:50 
33 Bcl-xL Bcl-xL BCL2L1 CST 2762 Rabbit Valid 1:100 
34 Beclin Beclin BECN1 Santa Cruz sc-10086 Goat 
Use with 
Caution 
1:250 
35 beta Actin b-Actin ACTB CST 4970 Rabbit 
Use with 
Caution 
1:75 
36 beta Catenin b-Catenin CTNNB1 CST 9562 Rabbit Valid 1:1500 
37 beta Catenin (phospho T41/S45) b-Catenin _pT41_S45 CTNNB1 CST 9565 Rabbit Valid 1:30 
38 Bid Bid BID CST 2002 Rabbit 
Use with 
Caution 
1:1000 
39 Bim Bim BCL2L11 Abcam ab32158 Rabbit Valid 1:400 
40 
BiP/GRP78 BiP-GRP78 HSPA5 BD Biosciences 610978 Mouse 
Use with 
Caution 1:750 
41 B-Raf B-Raf BRAF CST 14814 Rabbit 
Use with 
Caution 
1:500 
42 
B-Raf  
(phospho S445) 
B-Raf_pS445 BRAF CST 2696 Rabbit Valid 1:1000 
43 BRD4 BRD4 BRD4 CST 13440 Rabbit Valid 1:200 
44 c-Abl c-Abl ABL CST 2862 Rabbit Valid 1:50 
45 c-IAP2 c-IAP2 BIRC3 CST 3130 Rabbit 
Use with 
Caution 
1:750 
46 Caspase-3 active Caspase-3 CASP3 Abcam ab32042 Rabbit 
Use with 
Caution 
1:250 
47 Caspase-7 (cleaved D198) Caspase-7-cleaved CASP7 CST 9491 Rabbit 
Use with 
Caution 
1:75 
48 Caspase-8 Caspase-8 CASP8 CST 9746 Mouse **Used for QC** 1:150 
49 Caveolin-1 Caveolin-1 CAV1 CST 3238 Rabbit Valid 1:5000 
50 CD4 CD4 CD4 Abcam ab133616 Rabbit Valid 1:500 
51 CD20 CD20 MS4A1 Abcam ab78237 Rabbit 
Use with 
Caution 
1:75 
52 CD29 CD29 ITGB1 BD Biosciences 610467 Mouse Valid 1:30 
53 CD31 CD31 PECAM1 Dako M0823 Mouse Valid 1:30 
54 CD44 CD44 CD44 CST 3570 Mouse 
Use with 
Caution 
1:50 
55 CD45 CD45 CD45 DAKO M070129-2 Mouse Valid 1:1000 
56 CD49b CD49b ITGA2 BD Biosciences 611016 Mouse Valid 1:50 
57 CD134/OX40 CD134 CD134 Abcam ab76000 Rabbit Valid 1:100 
58 
cdc2 (Phospho Y15) cdc2_pY15 CDK1 CST 4539 Rabbit 
Use with 
Caution 1:250 
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59 cdc25C cdc25C CDC25C CST 4688 Rabbit Valid 1:500 
60 CDK1 CDK1 CDK1 Abcam ab32384 Rabbit 
Use with 
Caution 
1:1000 
61 CDKN2A/p16INK4a p16INK4a CDKN2A Abcam ab81278 Rabbit Valid 1:500 
62 Chk1 Chk1 CHEK1 CST 2360 Mouse 
Use with 
Caution 
1:250 
63 Chk1 (phospho S296) Chk1_pS296 CHEK1 Abcam ab79758 Rabbit Valid 1:125 
64 Chk2 Chk2 CHEK2 CST 3440 Mouse Valid 1:50 
65 Chk2 (phospho T68) Chk2_pT68 CHEK2 CST 2197 Rabbit 
Use with 
Caution 
1:125 
66 c-Jun ( phospho S73) c-Jun_pS73 JUN CST 9164 Rabbit Valid 1:30 
67 c-Kit c-Kit KIT Abcam ab32363 Rabbit Valid 1:30 
68 Claudin 7 Claudin-7 CLDN7 Novus Biologicals NB100-91714 Rabbit Valid 1:300 
69 c-Met (phospho Y1234/Y1235) c-Met_ pY1234_Y1235 MET CST 3129 Rabbit Valid 1:100 
70 c-Myc c-Myc MYC Santa Cruz sc-764 Rabbit 
Use with 
Caution 
1:125 
71 COG3 COG3 COG3 ProteinTech 11130-1-AP Rabbit Valid 1:750 
72 COL6A1 Collagen-VI COL6A1 Santa Cruz sc-20649 Rabbit Valid 1:5000 
73 Connexin 43 Connexin-43 CNST43 CST 3512 Rabbit 
Use with 
Caution 
1:150 
74 Cox2 Cox2 PTGS2 CST 4842 Rabbit 
Use with 
Caution 
1:50 
75 Cox-IV Cox-IV PTGS3 CST 4850 Rabbit Valid 1:1000 
76 
C-Raf  
(phospho S338) 
C-Raf_pS338 RAF1 CST 9427 Rabbit Valid 1:100 
77 C-Raf/Raf-1 C-Raf RAF1 Millipore 04-739 Rabbit 
Use with 
Caution 
1:200 
78 
CREB CREB CREB1 CST 9197 Rabbit 
Use with 
Caution 1:1000 
79 Cyclin B1 Cyclin-B1 CCNB1 Epitomics 1495-1 Rabbit Valid 1:1500 
80 Cyclin D1 Cyclin-D1 CCND1 Santa Cruz sc-718 Rabbit Valid 1:200 
81 Cyclin D3 Cyclin-D3 CCND3 CST 2936 Mouse Valid 1:1000 
82 Cyclin E1 Cyclin-E1 CCNE1 Santa Cruz sc-247 Mouse Valid 1:30 
83 Cyclophilin F Cyclophilin-F PPIF Abcam ab110324 Mouse Valid 1:50000 
84 Detyrosinated alpha-Tubulin D-a-Tubulin TUBA1A Abcam ab48389 Rabbit Valid 1:500 
85 Dimethyl-Histone H3 (Lys4) DM-Histone-H3 HIST1H3A CST 9725 Rabbit Valid 1:100 
86 Dimethyl-K9 Histone H3 DM-K9-Histone-H3 H3K9ME2 Abcam ab32521 Rabbit 
Use with 
Caution 
1:250 
87 DUSP4/MKP2 DUSP4 DUSP4 CST 5149 Rabbit Valid 1:250 
88 E2F-1 E2F1 E2F1 Santa Cruz sc-251 Mouse Valid 1:30 
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89 E-Cadherin E-Cadherin CDH1 CST 3195 Rabbit Valid 1:300 
90 eEF2 eEF2 EEF2 CST 2332 Rabbit 
Use with 
Caution 
1:50 
91 eEF2K eEF2K EEF2K CST 3692 Rabbit Valid 1:50 
92 EGFR EGFR EGFR CST 2232 Rabbit Valid 1:100 
93 EGFR (phospho Y1173) EGFR_pY1173 EGFR Abcam ab32578 Rabbit Valid 1:50 
94 eIF4E eIF4E EIF4E CST 9742 Rabbit Valid 1:75 
95 eIF4E (Phospho S209) eIF4E_pS209 EIF4E Abcam ab76256 Rabbit Valid 1:500 
96 eIF4G eIF4G EIF4G1 CST 2498 Rabbit 
Use with 
Caution 
1:1000 
97 Elk1 (phospho S383) Elk1_pS383 ELK1 CST 9181 Rabbit 
Use with 
Caution 
1:50 
98 
ENY2 ENY2 ENY2 GeneTex GTX629542 Mouse 
Use with 
Caution 1:1000 
99 
Epithelial Membrane Antigen EMA EMA Dako M061329-2 Mouse 
Use with 
Caution 1:1000 
100 ErbB2/HER2 HER2 ERBB2 Lab Vision MS-325-P1 Mouse Valid 1:3000 
101 ErbB2/HER2 (phosphoY1248) HER2_pY1248 ERBB2 R&D Systems AF1768 Rabbit 
Use with 
Caution (likely 
sees pEGFR) 
1:1500 
102 ErbB3/HER3   HER3 ERBB3 Santa Cruz sc-285 Rabbit Valid 1:300 
103 ErbB3/HER3 (phosphoY1289) HER3_pY1289 ERBB3 CST 4791 Rabbit 
Use with 
Caution 
1:50 
104 ERCC1 ERCC1 ERCC1 Santa Cruz sc-17809 Mouse Valid 1:30 
105 ERCC5 ERCC5 ERCC5 ProteinTech 11331-1-AP Rabbit 
Use with 
Caution 
1:250 
106 ERRFI1/MIG6 MIG6 ERRFI1 Sigma-Aldrich 
WH0054206M
1 
Mouse Valid 1:50 
107 Estrogen Receptor ER ESR1 Lab Vision RM-9101 Rabbit Valid 1:40 
108 Estrogen Receptor alpha (Phospho S118) ER-a_pS118 ESR1 Abcam ab32396 Rabbit Valid 1:1000 
109 Ets-1 Ets-1 ETS1 Bethyl A303-501A Rabbit Valid 1:100 
110 FAK  FAK PTK2 Abcam ab40794 Rabbit 
Use with 
Caution 
1:1000 
111 FAK (phospho Y397) FAK_pY397 PTK2 CST 3283 Rabbit Valid 1:30 
112 Fatty Acid Synthase FASN FASN CST 3180 Rabbit Valid 1:1000 
113 Fibronectin Fibronectin FN1 Epitomics 1574-1 Rabbit Valid 1:10000 
114 FoxM1 FoxM1 FOXM1 CST 5436 Rabbit Valid 1:30 
115 FoxO3a FoxO3a FOXO3 CST 2497 Rabbit 
Use with 
Caution 
1:25 
116 FoxO3a (phospho S318/S321) FoxO3a _pS318_S321 FOXO3 CST 9465 Rabbit 
Use with 
Caution 
1:30 
117 G6PD G6PD G6PD CST 8866 Rabbit Valid 1:1000 
192 
 
118 Gab2 Gab2 GAB2 CST 3239 Rabbit Valid 1:300 
119 GAPDH GAPDH GAPDH Life Technologies AM4300 Mouse 
Use with 
Caution 
1:50000 
120 GATA3 GATA3 GATA3 BD Biosciences 558686 Mouse Valid 1:300 
121 GATA6 GATA6 GATA6 CST 4253 Rabbit 
Use with 
Caution 
1:500 
122 
GCLM GCLM GCLM Abcam ab124827 Rabbit 
Use with 
Caution 1:500 
123 GCN5L2 GCN5L2 KAT2A CST 3305 Rabbit Valid 1:30 
124 Glutamate Dehydrogenase1/2 Glutamate-D1-2 GLUD CST 12793 Rabbit 
Use with 
Caution 
1:500 
125 Glutaminase Glutaminase GLS Abcam ab156876 Rabbit 
Use with 
Caution 
1:250 
126 Glycogen Synthase Gys GYS1 CST 3886 Rabbit Valid 1:1500 
127 Glycogen Synthase (phospho S641) Gys_pS641 GYS1 CST 3891 Rabbit Valid 1:250 
128 Granzyme B Granzyme-B GZMB CST 4275 Rabbit Valid 1:500 
129 GSK-3alpha/beta GSK-3a-b GSK3A, GSK3B Santa Cruz sc-7291 Mouse Valid 1:750 
130 GSK-3alpha/beta (phospho S21/S9) GSK-3a-b _pS21_S9 GSK3A, GSK3B CST 9331 Rabbit Valid 1:200 
131 H2AX (phospho S140) H2AX_pS140 H2AX 
Pierce 
Biotechnology 
MA1-2022 Mouse 
Use with 
Caution 
1:400 
132 Heregulin Heregulin NRG1 CST 2573 Rabbit Valid 1:30 
133 HES1 HES1 HES1 CST 11988 Rabbit Valid 1:1000 
134 Hexokinase II Hexokinase-II HK2 CST 2106 Rabbit Valid 1:100 
135 Hif-1 alpha Hif-1-alpha HIF1A BD Biosciences 610958 Mouse 
Use with 
Caution 
1:50 
136 Histone H3 Histone-H3 H3F3A, H3F3B Abcam ab1791 Rabbit Valid 1:3000 
137 HLA-DR/DP/DQ/DX 
HLA- 
DR-DP-DQ-DX 
HLA Santa Cruz sc-53302 Mouse Valid 1:1000 
138 HSP27 HSP27 HSP27 CST 2402 Mouse 
Use with 
Caution 
1:100 
139 HSP27 (phospho S82) HSP27_pS82 HSBP1 CST 2401 Rabbit Valid 1:75 
140 HSP70 HSP70 HSP70 CST 4872 Rabbit 
Use with 
Caution 
1:150 
141 IGF1R (phospho Y1135/Y1136) IGF1R_pY1135_Y1136 IGF1R CST 3024 Rabbit Valid 1:30 
142 IGFBP2 IGFBP2 IGFBP2 CST 3922 Rabbit Valid 1:50 
143 IGFRb IGFRb INSR CST 3027 Rabbit 
Use with 
Caution 
1:250 
144 INPP4b INPP4b INPP4B CST 4039 Rabbit Valid 1:25 
145 
Insulin Receptor beta IR-b INSRB CST 3025 Rabbit 
Use with 
Caution 1:750 
146 IRF-1 IRF-1 IRF1 Santa Cruz sc-497 Rabbit 
Use with 
Caution 
1:200 
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147 IRS1 IRS1 IRS1 Millipore 06-248 Rabbit Valid 1:400 
148 Jagged1 Jagged1 JAG1 Abcam ab109536 Rabbit Valid 1:750 
149 Jak2 Jak2 JAK2 CST 3230 Rabbit Valid 1:750 
150 JNK/SAPK (phospho T183/Y185) JNK _pT183_Y185 MAPK8 CST 4668 Rabbit Valid 1:30 
151 JNK2 JNK2 MAPK9 CST 4672 Rabbit 
Use with 
Caution 
1:30 
152 
LC3A/B LC3A-B LC3AB CST 4108 Rabbit 
Use with 
Caution 1:500 
153 Lck Lck LCK CST 2752 Rabbit Valid 1:100 
154 LDHA LDHA LDHA CST 3582 Rabbit 
Use with 
Caution 
1:250 
155 LRP6 (phospho S1490) LRP6_pS1490 LRP6 CST 2568 Rabbit Valid 1:500 
156 MAPK (phospho T202/Y204) MAPK _pT202_Y204 MAPK1, MAPK3 CST 4377 Rabbit Valid 1:30 
157 Mcl 1 Mcl-1 MCL1 CST 5453 Rabbit Valid 1:100 
158 MDM2 (phospho S166) MDM2_pS166 MDM2 CST 3521 Rabbit Valid 1:50 
159 MEK1 MEK1 MAP2K1 Abcam ab32576 Rabbit Valid 1:1500 
160 MEK1 (phospho S217/S221) MEK1 _pS217_S221 MAP2K1 MAP2K2 CST 9154 Rabbit Valid 1:50 
161 MERIT40 (Phospho S29) MERIT40_pS29 BABAM1 CST 12110 Rabbit Valid 1:1000 
162 Merlin/NF2 Merlin NF2 Novus Biologicals 22710002 Rabbit 
Use with 
Caution 
1:250 
163 MIF MIF MIF Santa Cruz sc-20121 Rabbit 
Use with 
Caution 
1:300 
164 MMP2 MMP2 MMP2 CST 4022 Rabbit Valid 1:75 
165 Mnk1 Mnk1 MKNK1 CST 2195 Rabbit Valid 1:1000 
166 
Monocarboxylic Acid  
Transporter 4 
MCT4 SLC16A4 Millipore AB3314P Rabbit Valid 1:500 
167 MSH6 MSH6 MSH6 Novus Biologicals 22030002 Rabbit 
Use with 
Caution 
1:1000 
168 
MSI2 MSI2 MSI2 Abcam ab76148 Rabbit 
Use with 
Caution 1:4000 
169 mTOR mTOR MTOR CST 2983 Rabbit Valid 1:1000 
170 mTOR (phospho S2448) mTOR_pS2448 MTOR CST 2971 Rabbit 
Use with 
Caution 
1:50 
171 Myosin heavy chain 11 Myosin-11 MYH11 Novus Biologicals 21370002 Rabbit Valid 1:5000 
172 Myosin IIa (phospho S1943) Myosin-IIa _pS1943 MYH9 CST 5026 Rabbit Valid 1:1000 
173 
Myt1 Myt1 MYT1 CST 4282 Rabbit 
Use with 
Caution 1:2000 
174 NAPSIN A NAPSIN-A NAPSA Abcam ab129189 Rabbit 
Use with 
Caution 
1:150 
175 N-Cadherin N-Cadherin CDH2 CST 4061 Rabbit Valid 1:30 
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176 NDRG1 (phospho T346) NDRG1_pT346 NDRG1 CST 3217 Rabbit Valid 1:100 
177 NDUFB4 NDUFB4 NDUFB4 Abcam ab110243 Mouse Valid 1:30 
178 NF-kappaB p65 (phospho S536) NF-kB-p65_pS536 RELA CST 3033 Rabbit 
Use with 
Caution 
1:30 
179 Notch1 Notch1 NOTCH1 CST 3268 Rabbit Valid 1:30 
180 Notch3 Notch3 NOTCH3 Santa Cruz sc-5593 Rabbit 
Use with 
Caution 
1:300 
181 N-Ras N-Ras NRAS Santa Cruz sc-31 Mouse Valid 1:50 
182 
Oct-4 Oct-4 OCT4 CST 2750 Rabbit 
Use with 
Caution 1:200 
183 p21 p21 CDKN1A Santa Cruz sc-397 Rabbit Valid 1:150 
184 p27 KIP 1 p27-Kip-1 CDKN1B Abcam ab32034 Rabbit Valid 1:50 
185 p27/KIP 1 (phospho T198) p27_pT198 CDKN1B Abcam ab64949  Rabbit Valid 1:30 
186 p38 MAPK p38 MAPK14 CST 9212 Rabbit Valid 1:1500 
187 p38 MAPK (phosphorT180/Y182) p38 _pT180_Y182 MAPK14 CST 9211 Rabbit Valid 1:50 
188 p44/42 MAPK p44-42-MAPK MAPK3 CST 4695 Rabbit Valid 1:2000 
189 p53 p53 TP53   CST 9282 Rabbit 
Use with 
Caution 
1:2500 
190 p70 S6 Kinase (phospho T389) p70-S6K_pT389 RPS6KB1 CST 9205 Rabbit Valid 1:50 
191 p70/S6K1 p70-S6K1 RPS6KB1 Abcam ab32529 Rabbit Valid 1:300 
192 p90RSK (phospho T573) p90RSK_pT573 RPS6K CST 9346 Rabbit 
Use with 
Caution 
1:30 
193 PAI-1 PAI-1 SERPINE1 BD Biosciences 612024 Mouse Valid 1:100 
194 
PAICS PAICS PAICS Sigma-Aldrich HPA035895 Rabbit 
Use with 
Caution 1:250 
195 PAK1 PAK1 PAK1 CST 2602 Rabbit Valid 1:1000 
196 PAK4 PAK4 PAK4 CST 3242 Rabbit Valid 1:750 
197 PAR PAR PAR Trevigen 4336-BPC-100 Rabbit 
Use with 
Caution 
1:15000 
198 PARK7/DJ1 DJ1 PARK7 Abcam ab76008 Rabbit Valid 1:5000 
199 PARP PARP PARP1 CST 9532 Rabbit Valid 1:1000 
200 Paxillin Paxillin PXN CST 2542 Rabbit 
Use with 
Caution 
1:250 
201 P-Cadherin P-Cadherin CDH3 CST 2130 Rabbit 
Use with 
Caution 
1:50 
202 PCNA PCNA PCNA CST 2586 Mouse 
Use with 
Caution 
1:1000 
203 PD-1 PD-1 PD1 CST 43248 Rabbit Valid 1:500 
204 Pdcd4 Pdcd4 PDCD4 Rockland 600-401-965 Rabbit 
Use with 
Caution 
1:750 
205 PDGFR beta PDGFR-b PDGFRB CST 3169 Rabbit Valid 1:100 
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206 
PDHK1 PDHK1 PDHK1 CST 3820 Rabbit 
Use with 
Caution 1:500 
207 PDK1 PDK1 PDPK1 CST 3062 Rabbit Valid 1:50 
208 
PDK1  
(phospho S241) 
PDK1_pS241 PDPK1 CST 3061 Rabbit Valid 1:50 
209 
PD-L1 PD-L1 CD274 CST 13684 Rabbit 
Use with 
Caution 1:150 
210 PEA-15 PEA-15 PEA15 CST 2780 Rabbit Valid 1:100 
211 PED/PEA-15 (phospho S116) PEA-15_pS116 PEA15 Invitrogen 44-836G Rabbit Valid 1:1000 
212 PI3K p110 alpha PI3K-p110-a PIK3CA  CST 4255 Rabbit 
Use with 
Caution 
1:75 
213 PI3K p110 beta PI3K-p110-b PIK3CB Santa Cruz sc-376412 Mouse 
Use with 
Caution 
1:60 
214 PI3K p85 PI3K-p85 PIK3R1 Millipore 06-195 Rabbit Valid 1:15000 
215 PKA RI alpha PKA-a PRKAR1A CST 5675 Rabbit Valid 1:200 
216 PKCalpha PKCa PRKCA  CST 2056 Rabbit Valid 1:200 
217 PKC beta II (phospho S660) PKC-b-II_pS660 
PRKCA, PRKCB  
PRKCD, PRKCE   
PRKCH, PRKCQ 
CST 9371 Rabbit Valid 1:200 
218 PKC delta (phospho S664) PKC-delta_pS664 PRKCD Millipore 07-875 Rabbit Valid 1:100 
219 
PKM2 PKM2 PKM2 CST 4053 Rabbit 
Use with 
Caution 1:300 
220 PLC gamma2 (phospho Y759) PLC-gamma2 _pY759 PLCG2 CST 3874 Rabbit 
Use with 
Caution 
1:30 
221 PLK1 PLK1 PLK1 CST 4513 Rabbit 
Use with 
Caution 
1:125 
222 PMS2 PMS2 PMS2 Novus Biologicals 22510002 Rabbit Valid 1:1500 
223 PRAS40 PRAS40 AKT1S1 Invitrogen AHO1031 Mouse 
Use with 
Caution 
1:250 
224 PRAS40 (phospho T246) PRAS40_pT246 AKT1S1 Life Technologies 441100G Rabbit Valid 1:500 
225 PREX1 PREX1 PREX1 Abcam ab102739 Rabbit Valid 1:150 
226 Progesterone Receptor PR PGR Abcam ab32085 Rabbit Valid 1:50 
227 PTEN PTEN PTEN CST 9552 Rabbit Valid 1:500 
228 Rab11 Rab11 RAB11A,B CST 3539 Rabbit 
Use with 
Caution 
1:30 
229 Rab25 Rab25 RAB25 CST 4314 Rabbit Valid 1:30 
230 Rad50 Rad50 RAD50 CST 3427 Rabbit Valid 1:250 
231 Rad51 Rad51 RAD51 CST 8875 Rabbit Valid 1:30 
232 Raptor Raptor RPTOR CST 2280 Rabbit Valid 1:300 
233 Rb Rb RB1 CST 9309 Mouse **Used for QC** 1:100 
234 Rb (phospho S807/S811) Rb _pS807_S811 RB1 CST 9308 Rabbit Valid 1:500 
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235 RBM15 RBM15 RBM15 Novus Biologicals 21390002 Rabbit Valid 1:5000 
236 Rheb Rheb RHEB R&D Systems MAB3426 Mouse 
Use with 
Caution 
1:75 
237 Rictor Rictor RICTOR CST 2114 Rabbit 
Use with 
Caution 
1:100 
238 Rictor (phospho T1135) Rictor_pT1135 RICTOR CST 3806 Rabbit Valid 1:200 
239 
RIP RIP RIP CST 4926 Rabbit 
Use with 
Caution 1:250 
240 RPA32 RPA32 RPA32 CST 2208 Rat 
Use with 
Caution 
1:500 
241 
RPA32 (PhosphoS4/S8) RPA32_pS4_S8 RPA32 Bethyl A300-245A Rabbit 
Use with 
Caution 1:250 
242 RSK RSK 
RPS6KA1  RPS6KA2  
RPS6KA3 
CST 9347 Rabbit 
Use with 
Caution 
1:150 
243 S6 (phospho S235/S236) S6 _pS235_S236 RPS6 CST 2211 Rabbit Valid 1:2500 
244 S6 (phospho S240/S244) S6 _pS240_S244 RPS6 CST 2215 Rabbit Valid 1:1000 
245 S6 Ribosomal Protein S6 RPS6 CST 2317 Mouse Valid 1:1000 
246 SCD SCD SCD Santa Cruz sc-58420 Mouse Valid 1:30 
247 SDHA SDHA SDHA CST 11998 Rabbit Valid 1:250 
248 SF2/ASF SF2 SRSF1 Invitrogen 32-4500 Mouse Valid 1:150 
249 Shc (phospho Y317) Shc_pY317 SHC1 CST 2431 Rabbit Valid 1:30 
250 SHP-2 (phospho Y542) SHP-2_pY542 PTPN11 CST 3751 Rabbit 
Use with 
Caution 
1:75 
251 
SLC1A5 SLC1A5 SLC1A5 Sigma-Aldrich HPA035240 Rabbit 
Use with 
Caution 1:15000 
252 
Slfn11 Slfn11 SLFN11 Santa Cruz sc-136891 Goat 
Use with 
Caution 1:250 
253 Smac/Diablo Smac DIABLO CST 2954 Mouse **Used for QC** 1:150 
254 Smad1 Smad1 SMAD1 Abcam ab33902 Rabbit Valid 1:750 
255 Smad3 Smad3 SMAD3 Abcam ab40854 Rabbit Valid 1:150 
256 Smad4 Smad4 SMAD4 Santa Cruz sc-7966 Mouse Valid 1:30 
257 Snail Snail SNAI1 CST 3895 Mouse **Used for QC** 1:50 
258 SOD1 SOD1 SOD1 CST 4266 Mouse Valid 1:500 
259 SOD2 SOD2 SOD2 CST 13194 Rabbit Valid 1:200 
260 Sox2 Sox2 SOX2 CST 2748 Rabbit Valid 1:200 
261 Src Src SRC Millipore 05-184 Mouse Valid 1:200 
262 Src (phospho Y527) Src_pY527 
SRC, YES1, FYN  
FGR  
CST 2105 Rabbit Valid 1:30 
263 Src Family (phospho Y416) Src_pY416 
SRC, LYN, FYN  
LCK, YES1, HCK 
CST 2101 Rabbit Valid 1:500 
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264 Stat3 Stat3 STAT3 CST 4904 Rabbit 
Use with 
Caution 
1:3000 
265 Stat3 (phospho Y705) Stat3_pY705 STAT3 CST 9145 Rabbit Valid 1:100 
266 Stat5a Stat5a STAT5A Abcam ab32043 Rabbit Valid 1:250 
267 Stathmin 1 Stathmin-1 STMN1 Abcam ab52630 Rabbit Valid 1:75 
268 Sting STING STING CST 13647 Rabbit Valid 1:250 
269 Syk Syk SYK Santa Cruz sc-1240 Mouse Valid 1:3000 
270 Tau Tau TAU Millipore 05-348 Mouse 
Use with 
Caution 
1:100 
271 TAZ TAZ WWTR1 CST 4883 Rabbit Valid 1:300 
272 TFAM TFAM TFAM CST 7495 Rabbit Valid 1:300 
273 TIGAR TIGAR C12ORF5 Abcam ab137573 Rabbit Valid 1:100 
274 Transferrin Receptor TFRC TFRC Novus Biologicals 22500002 Rabbit Valid 1:15000 
275 Trans-glutaminase II Trans-glutaminase TGM2 Lab Vision MS-224-P1 Mouse Valid 1:150 
276 
TRIM25 TRIM25 TRIM25 Abcam ab167154 Rabbit 
Use with 
Caution 1:2000 
277 TSC1/Hamartin TSC1 TSC1 CST 4906 Rabbit 
Use with 
Caution 
1:200 
278 TSC2/Tuberin (phosphoT1462) Tuberin_pT1462 TSC2 CST 3617 Rabbit Valid 1:30 
279 TTF1** TTF1 NKX2-1 Abcam ab76013 Rabbit Valid 1:250 
280 Tuberin Tuberin TSC2 Abcam ab32554 Rabbit Valid 1:2500 
281 TUFM TUFM TUFM Abcam ab173300 Rabbit Valid 1:300 
282 Twist TWIST TWIST2 Santa Cruz sc-81417 Mouse 
Use with 
Caution 
1:30 
283 Tyro3 Tyro3 TYRO3 CST 5585 Rabbit Valid 1:30 
284 UBAC1 UBAC1 UBAC1 Sigma-Aldrich HPA005651 Rabbit Valid 1:250 
285 
Ubiquityl Histone H2B Ubq-Histone-H2B HIST1H2BB CST 5546 Rabbit 
Use with 
Caution 1:500 
286 UGT1A UGT1A UGT1A1 Santa Cruz sc-271268 Mouse Valid 1:75 
287 
ULK1 (phospho S757) ULK1_pS757 ULK1 CST 6888 Rabbit 
Use with 
Caution 1:1000 
288 VASP VASP VASP CST 3112 Rabbit Valid 1:250 
289 VDAC1/Porin Porin VDAC1 Abcam ab14734 Mouse Valid 1:300 
290 VEGF Receptor 2 VEGFR-2 KDR CST 2479 Rabbit Valid 1:12000 
291 VHL/EPPK1** VHL-EPPK1 EPPK1 BD Biosciences 556347 Mouse 
Use with 
Caution  
(Targets 
EPPK1) 
1:500 
292 Vimentin Vimentin VIM Dako M0725 Mouse 
Use with 
Caution 
1:250 
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293 
Wee1 Wee1 WEE1 CST 4936 Rabbit 
Use with 
Caution 1:2000 
294 
Wee1 (Phospho S642) Wee1_pS642 WEE1 CST 4910 Rabbit 
Use with 
Caution 1:75 
295 
WIPI1 WIPI1 WIPI1 CST 12124 Rabbit 
Use with 
Caution 1:1000 
296 
WIPI2 WIPI2 WIPI2 CST 8567 Rabbit 
Use with 
Caution 1:1000 
297 XBP1 XBP1 XBP1 Santa Cruz sc-32136 Goat 
Use with 
Caution 
1:200 
298 XPA XPA XPA Santa Cruz sc-56813 Mouse Valid 1:75 
299 XPF XPF XPF Abcam ab73720 Rabbit 
Use with 
Caution 
1:100 
300 XRCC1 XRCC1 XRCC1 CST 2735 Rabbit 
Use with 
Caution 
1:30 
301 YAP YAP YAP1 Santa Cruz sc-15407 Rabbit 
Use with 
Caution 
1:750 
302 YAP (phospho S127) YAP_pS127 YAP1 CST 4911 Rabbit Valid 1:250 
303 YB1 (phospho S102) YB1_pS102 YBX1 CST 2900 Rabbit Valid 1:50 
304 
ZAP-70 ZAP-70 ZAP70 CST 2705 Rabbit 
Use with 
Caution 1:1000 
 
Supplementary Table S3.1: MD Anderson RPPA Standard Antibody List. This table lists the antibodies used on the RPPA to detect total proteins and phospho-proteins. This 
table was adapted from the MD Anderson Cancer Center RPPA Core website: (https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-
core.html) 
 
*”Validation Status” column: Valid = RPPA and Western blot correlation > 0.7; Use with Caution = RPPA and Western blot correlation < 0.7; Under Evaluation = Antibody has given 
mixed results and/or evaluated by another lab; We are in the process of (re)validating; Used for QC = These antibodies are used for tissue sample quality control (QC); WILL NOT 
report to Datasets containing tissue samples, but WILL report to Datasets containing cell line samples.  
** VHL Antibody has been identified to recognize EPPK1 by MS, RNAi and correlation with RNA expression.  
Ab = antibody 
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Supplementary Figure S3.1. Expression of ALK fusion variants.  Lysates from the ALK variant 3T3 cell line clones selected for experiments were assessed for ALK expression 
by immunoblot. Lysates were run in triplicate. 
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Supplementary Figure S3.2. Active ALK variants change the protein expression profile of NIH3T3 cells. This heatmap is a depiction of the expression level for all 304 
interrogated proteins and/or phosphorylation sites for all cell lines and all replicates. This data was generated using a Reverse Phase Protein Array (RPPA). The experiment was run 
using biological replicates run in triplicate. Note that blue is representative of increased expression (from the mean), and red is decreased expression (from the mean). A hierarchical 
tree is depicted on the right to further distinguish delineation of the cell lines. The protein names and phosphorylation sites are represented at the bottom. This heatmap exhibits 
unsupervised clustering of all cell lines and replicates. 
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RANBP2-ALK 
 
TFG-ALK 
 Protein 
Fold 
Change 
(Log) 
Adjusted 
p Value  
Protein 
Fold 
Change 
(Log) 
Adjusted 
p Value 
 
 
GAPDH 4.87 8.45E-05 
 
GAPDH 7.79 3.24E-06 
Stat5a 4.64 8.99E-06 
 
Stat5a 3.37 1.45E-04 
Connexin-43 4.53 1.54E-06 
 
ACC pS79 2.78 6.11E-04 
Stat3 pY705 4.13 3.71E-03 
 
UGT1A 2.68 8.31E-05 
NDRG1 pT346 3.38 4.03E-04 
 
Stat3 2.63 3.60E-04 
ACC pS79 3.00 3.02E-04 
 
NDRG1 pT346 2.61 3.29E-03 
53BP1 2.32 4.89E-10 
 
Mcl-1 2.51 2.95E-09 
Notch1 2.31 1.70E-12 
 
Notch1 2.37 9.26E-13 
UGT1A 2.25 6.13E-04 
 
PKM2 2.28 8.08E-04 
Stat3 2.21 2.17E-03 
 
Connexin-43 2.12 3.19E-03 
MDM2 pS166 2.15 9.90E-04 
 
mTOR 2.12 6.99E-08 
Gys pS641 2.12 1.02E-04 
 
c-Jun pS73 1.88 4.31E-03 
PAK1 2.07 1.55E-08 
 
Transglutaminase 1.86 3.21E-08 
Gys 2.04 1.55E-05 
 
Akt 1.85 4.68E-07 
mTOR 1.89 8.25E-07 
 
Gab2 1.81 1.58E-07 
4E-BP1 1.85 7.82E-05 
 
4E-BP1 1.81 1.16E-04 
Shc pY317 1.84 1.13E-05 
 
MDM2 pS166 1.80 7.69E-03 
PKM2 1.83 8.99E-03 
 
53BP1 1.79 2.14E-07 
c-Jun pS73 1.82 6.16E-03 
 
Bim 1.75 3.53E-09 
PKC-b-II pS660 1.78 5.73E-03 
 
TSC1 1.70 3.61E-05 
Transglutaminase 1.75 1.59E-07 
 
14-3-3-zeta 1.67 9.79E-07 
PRAS40 pT246 1.69 4.23E-06 
 
Rictor 1.63 8.68E-09 
Akt 1.69 4.53E-06 
 
p44/42 MAPK 1.60 9.25E-07 
GSK-3a-b 
pS21/S9 1.68 2.09E-04 
 
Gys pS641 1.59 7.11E-03 
Rictor 1.68 3.26E-09 
 
Cyclin-D3 1.58 3.05E-06 
SHP-2 pY542 1.64 2.57E-03 
 
FAK 1.57 9.73E-08 
Mcl-1 1.62 4.01E-05 
 
PEA-15 1.52 6.95E-05 
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eIF4E 1.60 7.98E-07 
 
PRAS40 pT246 1.52 7.30E-05 
TSC1 1.59 1.68E-04 
 
Gys 1.52 3.50E-03 
ARID1A 1.57 1.05E-04 
 
PAR -8.78 1.69E-03 
PKA-a 1.56 5.02E-04 
 
IGF1R 
pY1135/Y1136 -5.55 3.19E-04 
Bim 1.53 2.75E-07 
 
FASN -5.37 1.52E-04 
Caveolin-1 1.52 2.80E-02 
 
Src pY527 -4.25 3.07E-04 
FAK 1.51 3.72E-07 
 
Chk1 -3.87 9.38E-04 
Chk1 -5.71 6.99E-05 
 
GSK-3a-b -3.18 5.29E-04 
FASN -4.41 5.43E-04 
 
S6 pS235/S236 -2.88 2.55E-04 
HES1 -3.35 3.04E-04 
 
Vimentin -2.85 2.05E-06 
b-Catenin -3.25 2.14E-04 
 
Rad50 -2.58 1.91E-04 
Annexin-I -2.97 7.38E-07 
 
ADAR1 -2.56 1.45E-04 
ADAR1 -2.82 4.73E-05 
 
CD171 -2.46 3.73E-07 
CD171 -2.77 5.34E-08 
 
Annexin-I -2.42 1.27E-05 
Rad50 -2.67 1.31E-04 
 
ULK1 pS757 -2.38 1.48E-06 
Porin -2.55 1.55E-04 
 
SOD1 -2.28 1.38E-05 
Vimentin -2.54 9.76E-06 
 
B-Raf -2.26 1.52E-07 
c-IAP2 -2.48 2.59E-05 
 
XPA -2.25 3.89E-04 
Smad4 -2.44 2.38E-05 
 
BAP1 -2.24 1.16E-04 
HER3 -2.42 5.28E-08 
 
E2F1 -2.21 4.71E-05 
YAP -2.35 3.57E-05 
 
Histone-H3 -2.19 5.86E-04 
G6PD -2.33 3.79E-08 
 
Porin -2.18 9.53E-04 
TRIM25 -2.32 8.24E-09 
 
Cyclin-E1 -2.17 4.49E-06 
SCD -2.27 1.64E-05 
 
c-IAP2 -2.15 1.83E-04 
ULK1 pS757 -2.25 3.62E-06 
 
Smad4 -2.15 1.41E-04 
TFRC -2.21 3.03E-04 
 
Syk -2.11 6.62E-05 
GATA3 -2.18 6.01E-05 
 
HER3 -2.10 7.18E-07 
GSK-3a-b -2.15 1.28E-02 
 
YAP -2.06 2.31E-04 
SF2 -2.14 6.39E-04 
 
NDUFB4 -2.03 3.32E-04 
BAP1 -2.14 2.12E-04 
 
N-Ras -2.02 6.28E-04 
N-Ras -2.13 3.14E-04 
 
CD31 -2.02 4.64E-03 
Smac -2.13 1.81E-07 
 
RPA32 -2.02 9.08E-04 
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PRAS40 -2.11 5.08E-04 
 
S6 pS240/S244 -2.01 9.94E-03 
Syk -2.10 7.11E-05 
 
SCD -2.00 1.16E-04 
RPA32 -2.02 8.66E-04 
 
G6PD -1.98 9.64E-07 
Bcl2 -2.02 4.85E-06 
 
Beclin -1.98 3.26E-04 
Cyclin-E1 -2.01 1.69E-05 
 
TRIM25 -1.96 2.96E-07 
cdc25C -2.01 8.76E-07 
 
VHL-EPPK1 -1.93 6.61E-04 
VHL-EPPK1 -2.01 3.84E-04 
 
HES1 -1.90 3.09E-02 
Src -1.99 2.77E-05 
 
TFRC -1.90 2.15E-03 
SOD1 -1.99 1.25E-04 
 
SLC1A5 -1.90 1.14E-05 
Notch3 -1.98 4.15E-06 
 
Src -1.84 1.15E-04 
S6 pS235/S236 -1.97 9.95E-03 
 
CD44 -1.83 6.22E-04 
RIP -1.97 3.41E-08 
 
Smac -1.81 5.41E-06 
Sox2 -1.95 6.16E-06 
 
Pdcd4 -1.81 3.57E-03 
PARP -1.90 1.79E-06 
 
Bcl2 -1.79 5.35E-05 
Cdc2 pY15 -1.88 1.44E-04 
 
Notch3 -1.78 3.53E-05 
ATM -1.87 2.56E-04 
 
PARP -1.75 1.08E-05 
E2F1 -1.82 9.06E-04 
 
HER2 -1.74 8.96E-04 
Hif1α -1.77 1.29E-05 
 
A-Raf -1.72 3.71E-07 
Granzyme-B -1.75 1.25E-06 
 
PRAS40 -1.71 7.36E-03 
Glutamate-D1-2 -1.75 9.20E-06 
 
Hif1α -1.71 2.85E-05 
HSP27 -1.74 2.02E-06 
 
RIP -1.68 1.86E-06 
MCT4 -1.72 8.19E-07 
 
Chk2 -1.67 1.21E-04 
CD31 -1.72 2.28E-02 
 
SHP-2 pY542 -1.67 1.84E-03 
PAI-1 -1.71 4.00E-06 
 
Caveolin-1 -1.66 9.48E-03 
Chk2 -1.70 8.72E-05 
 
PAI-1 -1.66 8.78E-06 
BRD4 -1.70 1.01E-05 
 
CD49b -1.64 1.08E-02 
B7-H4 -1.69 6.41E-05 
 
HSP27 -1.62 1.17E-05 
HSP27 pS82 -1.69 3.53E-05 
 
E-Cadherin -1.60 5.87E-06 
Histone-H3 -1.67 1.49E-02 
 
cdc25C -1.60 1.36E-04 
PAK4 -1.67 1.83E-06 
 
Sox2 -1.60 3.69E-04 
XPA -1.65 1.60E-02 
 
BRD4 -1.59 5.13E-05 
MIG6 -1.64 1.32E-02 
 
MCT4 -1.59 8.17E-06 
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HER2 -1.63 2.66E-03 
 
Granzyme-B -1.58 2.06E-05 
LRP6 pS1490 -1.62 1.23E-05 
 
PDGFR-b -1.58 2.22E-02 
Beclin -1.61 6.49E-03 
 
SF2 -1.55 3.01E-02 
MERIT40 pS29 -1.61 6.88E-06 
 
B7-H4 -1.55 4.56E-04 
E-Cadherin -1.60 5.99E-06 
 
HSP27 pS82 -1.52 4.12E-04 
p16INK4a -1.56 6.56E-05 
 
BiP-GRP78 -1.50 1.04E-05 
SLC1A5 -1.56 6.66E-04 
    
A-Raf -1.55 6.31E-06 
    
CD44 -1.55 7.88E-03 
    
MSI2 -1.55 6.28E-04 
    
PMS2 -1.54 7.32E-06 
    
CD49b -1.54 2.32E-02 
    
SDHA -1.54 7.70E-03 
    
Tau -1.53 3.43E-04 
    
Cox-IV -1.51 2.67E-05 
     
 
 
 
EML4-ALK V3 
 
KIF5B-ALK 
 
PRKAR1A-ALK 
Protein 
Fold 
Change 
(Log) 
Adj. p 
Value 
 
Protein 
Fold 
Change 
(Log) 
Adj. p 
Value 
 
Protein 
Fold 
Change 
(Log) 
Adj. p 
Value 
  
  
GAPDH 6.73 8.73E-06 
 
Connexin-43 4.52 1.58E-06 
 
ACC pS79 2.98 3.20E-04 
NDRG1 
pT346 3.04 9.60E-04 
 
c-Jun pS73 3.62 2.18E-06 
 
PKC-b-II 
pS660 2.31 2.26E-04 
ACC pS79 2.73 7.14E-04 
 
NDRG1 
pT346 3.48 3.17E-04 
 
GAPDH 2.25 2.04E-02 
Connexin-43 2.73 2.37E-04 
 
GAPDH 3.46 1.00E-03 
 
Stat5a 2.21 6.41E-03 
Stat3 pY705 2.63 3.67E-02 
 
PKM2 2.86 6.44E-05 
 
Notch1 2.14 9.23E-12 
PKM2 2.51 2.72E-04 
 
ACC pS79 2.81 5.57E-04 
 
Stat3 1.96 7.40E-03 
Gys pS641 2.06 1.53E-04 
 
PRAS40 2.40 9.72E-05 
 
UGT1A 1.95 3.37E-03 
UGT1A 2.04 1.92E-03 
 
Gys pS641 2.37 2.00E-05 
 
Connexin-43 1.93 8.19E-03 
Gys 1.84 9.97E-05 
 
MDM2 
pS166 2.11 1.24E-03 
 
PKM2 1.88 6.63E-03 
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Notch1 1.82 6.88E-10 
 
Gys 2.04 1.61E-05 
 
c-Jun pS73 1.66 1.76E-02 
PKC-b-II 
pS660 1.81 4.83E-03 
 
PKC-b-II 
pS660 2.02 1.21E-03 
 
TSC1 1.66 6.12E-05 
Stat5a 1.79 3.71E-02 
 
Cox2 2.00 2.90E-05 
 
MDM2 pS166 1.59 3.03E-02 
Shc pY317 1.71 5.56E-05 
 
Mcl-1 1.77 4.45E-06 
 
PRAS40 1.56 2.35E-02 
MDM2 pS166 1.68 1.63E-02 
 
Gab2 1.75 3.89E-07 
 
Akt 1.53 6.91E-05 
TSC1 1.60 1.35E-04 
 
PAK1 1.65 3.89E-06 
 
PAR -5.25 1.20E-02 
4E-BP1 1.60 1.18E-03 
 
Rictor 1.59 1.94E-08 
 
S6 
pS235/S236 -4.53 3.54E-06 
Rictor 1.58 2.42E-08 
 
Notch1 1.54 1.48E-07 
 
IGF1R 
pY1135/Y1136 -3.07 1.01E-02 
PDGFR-b -3.85 4.20E-07 
 
PAR -3.62 4.45E-02 
 
S6 
pS240/S244 -2.94 2.74E-04 
S6 
pS235/S236 -3.06 1.41E-04 
 
Vimentin -2.70 4.18E-06 
 
Vimentin -2.60 7.30E-06 
Vimentin -2.69 4.53E-06 
 
Caveolin-1 -2.43 6.95E-05 
 
Histone-H3 -2.51 1.18E-04 
Histone-H3 -2.32 2.96E-04 
 
S6 
pS235/S236 -2.26 2.75E-03 
 
HES1 -2.19 1.03E-02 
Src pY527 -2.31 2.05E-02 
 
Histone-H3 -2.17 6.63E-04 
 
VHL-EPPK1 -1.85 1.20E-03 
Pdcd4 -2.10 5.16E-04 
 
PDGFR-b -2.16 4.51E-04 
 
SOD1 -1.75 9.27E-04 
S6 
pS240/S244 -1.95 1.29E-02 
 
Fibronectin -2.07 5.31E-06 
 
Rad50 -1.68 2.12E-02 
Fibronectin -1.83 5.61E-05 
 
Pdcd4 -1.98 1.15E-03 
 
CD171 -1.67 4.22E-04 
Rad50 -1.61 3.40E-02 
 
S6 
pS240/S244 -1.72 3.93E-02 
 
TFRC -1.62 1.48E-02 
CD171 -1.59 1.09E-03 
 
CD171 -1.66 4.63E-04 
 
Syk -1.62 3.97E-03 
SLC1A5 -1.56 6.58E-04 
 
RPA32 -1.62 1.46E-02 
 
ULK1 pS757 -1.61 1.47E-03 
Syk -1.53 9.51E-03 
 
A-Raf -1.60 2.67E-06 
 
SLC1A5 -1.56 6.69E-04 
c-IAP2 -1.53 1.98E-02 
 
SCD -1.55 6.62E-03 
 
SF2 -1.55 3.14E-02 
HER2 -1.52 7.62E-03 
 
Syk -1.53 9.34E-03 
 
Beclin -1.54 1.21E-02 
SOD1 -1.52 8.92E-03 
 
HER3 -1.53 6.60E-04 
 
XPA -1.54 3.61E-02 
TFRC -1.51 3.35E-02 
 
VHL-EPPK1 -1.50 2.19E-02 
 
BAP1 -1.53 2.11E-02 
 
Supplementary Table S3.2: Proteins exhibiting most significantly different expression from the WT ALK cell line for each ALK fusion cell line. This table lists the proteins 
and phospho-proteins that exhibited significantly different expression for each ALK fusion cell line vs the WT ALK cell line along with the fold change and adjusted p-values. Proteins 
in blue are upregulated, and proteins in red are downregulated. 
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Supplementary Figure S3.3. ALK fusion variants exhibit differential response to ALK TKIs. NIH 3T3 cells expressing the 
indicated ALK variants were treated with increasing concentrations of ensartinib (A,E), alectinib (B,D), crizotinib (C), or 
lorlatinib (F) for 72 hours. Propidium iodide (PI) and Hoechst were added and allowed to incubate for 20 minutes before 
imaging on the ImageExpress. Dose response curves were generated by determining total live cells (# of Hoechst positive 
cells minus # of PI positive cells) at each dose of ALK TKI. A non-linear regression of for ensartinib and alectinib is 
represented in A and B. Experiments were performed with 6 replicates per drug concentration and repeated three times. One 
representative experiment is shown here. (G) NIH 3T3 cells expressing the indicated ALK variants were treated with 100 nM of 
crizotinib for 2 hours. Cell lysates were probed for pALK, ALK, and actin by infrared western blot. 
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ALK TKI Status# 
1st generation Crizotinib* FDA-approved, first-line 
2nd generation 
Alectinib* 
FDA approved, first-line  
FDA-approved, post crizotinib  
Ensartinib* Investigational 
Ceritinib 
FDA approved, first-line  
FDA-approved, post crizotinib 
Brigatinib FDA-approved, post crizotinib 
Entrectinib Investigational 
3rd generation Lorlatinib* FDA breakthrough therapy designation 
 
Supplementary Table S3.3: ALK TKIs in clinical use. This table depicts the ALK TKI in clinical use and the current approval status.
 #
Information obtained from 
https://www.fda.gov/. *Denotes ALK TKIs used in these studies.  
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ALK Variant 
ALK F1174L FN1-ALK KIF5B-ALK RANBP2-ALK TFG-ALK PRKAR1A-ALK 
EML4-ALK 
V1 
EML4-ALK 
V3 
Apoptosis pathway 
Fold Change 12.91 
NS NS 
5.68 7.60 
NS 
4.90 4.34 
P Value 6.28E-05 2.71E-03 7.12E-04 5.26E-03 9.00E-03 
Breast reactive 
pathway 
Fold Change -14.98 -8.67 -256.73 
NS 
-80.72 
NS 
-497.93 -57.75 
P Value 9.82E-03 3.39E-02 1.01E-05 1.62E-04 2.22E-06 3.69E-04 
Cell Cycle pathway 
Fold Change 6.50 8.26 
NS 
-3.53 
NS 
-5.63 
NS NS 
P Value 2.02E-03 7.01E-04 2.68E-02 3.78E-03 
Core reactive 
pathway 
Fold Change 
NS NS 
-27.22 63.08 
NS NS 
-16.27 
NS 
P Value 2.23E-03 2.79E-04 7.76E-03 
DNA damage 
response pathway 
Fold Change 
NS 
-6.07 
NS NS NS NS NS NS 
P Value 2.22E-02 
EMT pathway 
Fold Change 
NS NS 
-50.51 33.50 
NS NS NS NS 
P Value 2.52E-03 5.77E-03 
Hormone signaling 
(Breast) pathway 
Fold Change -11.34 -7.27 
NS 
-16.73 -3.69 
NS 
-7.30 
NS 
P Value 3.51E-04 2.20E-03 7.12E-05 3.17E-02 2.16E-03 
PI3K/AKT pathway 
Fold Change 8.64 
NS 
10.46 
NS NS NS NS NS 
P Value 2.93E-02 1.88E-02 
RAS/MAPK pathway 
Fold Change 79.05 18.75 564.08 26.95 
NS NS NS NS 
P Value 4.47E-03 4.41E-02 1.57E-04 2.55E-02 
RTK pathway 
Fold Change 
NS NS NS 
24.21 
NS NS 
33.94 
NS 
P Value 1.10E-03 4.28E-04 
TSC/mTOR pathway 
Fold Change 
NS NS NS NS NS 
-57.01 
NS 
-15.78 
P Value 3.43E-03 3.49E-02 
Kinase Activity  
Relative activity 1.9 3.5 4.5 5.2 2.6 3.0 3.4 1.3 
Standard Deviation 0.1 0.5 0.7 1.2 0.7 0.2 0.4 0.1 
Crizotinib Sensitivity 
IC50 79.5 153.3 405.1 220.7 87.4 461.8 165.8 122.5 
Lower 95% CI 67.3 127.0 283.9 180.1 68.9 291.4 134.9 96.0 
Upper 95% CI 94.0 185.2 580.0 270.5 110.9 743.2 204.0 156.6 
Alectinib Sensitivity 
IC50 83.9 273.1 84.1 163.9 36.0 406.7 48.2 136.7 
Lower 95% CI 70.3 219.7 65.8 138.1 32.3 327.7 39.0 112.7 
Upper 95% CI 100.1 341.1 107.9 194.6 40.0 507.0 59.7 166.0 
Ensartinib 
Sensitivity 
IC50 43.1 48.8 24.3 91.4 11.7 123.2 11.2 39.9 
Lower 95% CI 36.9 37.6 15.8 71.6 9.4 91.3 9.0 27.3 
Upper 95% CI 50.2 62.9 36.9 117.0 14.6 167.1 14.0 58.1 
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Lorlatinib Sensitivity 
IC50 23.8 35.2 89.1 171.6 7.8 328.5 7.7 6.1 
Lower 95% CI 19.7 28.4 56.4 128.7 6.3 262.7 6.1 5.4 
Upper 95% CI 28.8 43.6 145.0 232.4 9.6 418.8 9.7 6.9 
Focus Formation 
Foci 101.5 352.0 4.0 8.0 70.0 16.0 46.5 13.0 
Standard Deviation 24.7 4.9 1.7 2.0 24.3 5.7 9.2 12.7 
Colony Formation 
Mean Colony 
number 
11.3 228.7 23.0 55.0 30.7 13.3 27.3 13.3 
Lower 95% CI -5.2 105.2 -11.5 -94.9 -45.5 -14.9 -36.1 3.0 
Upper 95% CI 27.9 352.1 57.5 204.9 106.8 41.6 90.8 23.7 
Protein 
Stability/Turnover 
% ALK total protein 
at 16 hours 
80 50 2 43 168 70 49 147 
ALK 
autophosphorylation 
pALK/ALK ratio 0.93 0.56 0.79 0.59 0.15 0.26 0.2 0.17 
 
Supplementary Table S3.4: Compilation of all Phenotypic Data Measurements for ALK Fusion Variants and ALK F1174L. This table contains all data measurements 
presented in this manuscript. For the RPPA pathway analysis, each pathway listed was assessed for a statistical difference between the indicated ALK variant expressing cell line 
vs. the WT ALK expressing cell line. Numerical data is shown for pathways in which a statistical significant difference from the WT ALK cell line was found. NS = not significant. 
Protein stability/turnover is represented as the percent of ALK detected in cellular lysates by immunoblot 16 hours post cyclohexamide treatment. ALK autophosphorylation is 
represented as the ratio of pALK(Y1604) to total ALK detected in cellular lysates under normal culture conditions.  
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Supplementary Figure S3.4. Immunoprecipitated ALK fusion variants for kinase assays. ALK variants were immunoprecipitated from 3T3 cellular lysates using a polyclonal 
ALK antibody (Cell Signaling) and Sepharose A beads. An aliquot of the immunoprecipitate, equal to the amount used in each in vitro kinase assay, was assessed by immunoblot for 
total ALK.   
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Supplementary Figure S3.5. ALK fusion variants exhibit differences in protein turnover and sensitivity to ganetespib. 
(A) KIF5B-ALK or FN1-ALK expressing 3T3 cells were treated with 50μg/mL of cycloheximide over a short time course. 
Lysates were run on SDS-PAGE and probed with an antibody against total ALK. Collection time points are depicted above the 
respective lane for each variant. (B) Depicted is a spearman correlation analysis between kinase activity and protein stability 
at 16 hours post cycloheximide treatment. All fusion variants and the ALK F1174L positive control are included.  Error bars 
represent kinase activity standard deviations. (C) Depicted is a spearman correlation analysis between protein stability at 16 
hours post cycloheximide treatment and the respective IC50 values for crizotinib (Figure 2C). All fusion variants and the ALK 
F1174L positive control are included. Error bars represent IC50 95% confidence intervals. (D) NIH3T3 cell lines stably 
expressing ALK fusion variants were treated with increasing concentrations of ganetespib for 72 hours. Propidium iodide (PI) 
and Hoechst were added and allowed to incubate for 20 minutes before imaging on the ImageExpress. Dose response curves 
were generated by determining total live cells (# of Hoechst positive cells minus # of PI positive cells) at each concentration of 
ganetespib. IC50s with 95% confidence intervals were generated with the data from the dose response curves using 
GraphPad Prism and are depicted here. Experiments were performed with 6 replicates per drug concentration and repeated 
three times. One representative experiment is shown here. 
